Compositions comprising pharmaceutically acceptable salts and other derivatives of an amylin analog and uses thereof

Abstract

Provided herein are compounds comprising an ionic form of an amylin analog, such as cagrilintide, and a counterion thereof, other ester and prodrug derivatives of an amylin analog, and methods of use thereof.

Description

WSGR Docket No.: 56017-733.601 COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS AND OTHER DERIVATIVES OF AN AMYLIN ANALOG AND USES THEREOF CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No.63 / 558,866 filed on February 28, 2024, U.S. Provisional Application No. 63 / 658,314 filed on June 10, 2024, and U.S. Provisional Application No. 63 / 710,493 filed on October 22, 2024, the entirety of each is incorporated herein by reference. BACKGROUND

[0002] Human amylin, or islet amyloid polypeptide (IAPP), is a 37-residue polypeptide hormone. Amylin is co-secreted with insulin from pancreatic β-cells in the ratio of approximately 100:1 (insulin:amylin). Pro-islet amyloid polypeptide (i.e., pro-IAPP) is produced in the pancreatic β-cells as a 67 amino acid, 7404 Dalton pro-peptide that undergoes post-translational modifications including protease cleavage to produce the 37-residue amylin. Loss of β-cell function that occurs early in type 1 diabetics and can occur late in type 2 diabetics leads to deficiencies in the secretion of insulin and amylin.

[0003] Amylin functions as part of the endocrine pancreas, those cells within the pancreas that synthesize and secrete hormones. Amylin contributes to glycemic control; it is secreted from the pancreatic islets into the blood circulation and is cleared by peptidases in the kidney. Amylin's metabolic function is well-characterized as an inhibitor of the appearance of nutrients, such as glucose, in the plasma. It thus functions as a synergistic partner to insulin, a peptide that regulates blood glucose levels and coordinates the body's distribution and uptake of glucose.

[0004] Insulin's role in the body is, among other things, to prevent blood glucose levels from rising too high, particularly after a meal. Amylin is believed to play a role in glycemic regulation by slowing gastric emptying and promoting satiety (i.e., feeling of fullness), thereby preventing post-prandial (i.e., after-meal) spikes in blood glucose levels. The overall effect is to slow the rate of appearance of glucose in the blood after eating. Amylin also lowers the secretion of glucagon by the pancreas. Glucagon's role in the body is, among other things, to prevent blood glucose levels dropping too low. This is significant because certain type 1 diabetics, for example, are prone to secrete excess amounts of the blood glucose-raising glucagon just after meals.

[0005] For numerous reasons, human amylin, having a half-life in serum of about 13 minutes, is not amenable for use as a therapeutic agent. Rather, pramlintide (Symlin®, developed by Amylin Pharmaceuticals, Inc., San Diego, Calif., USA and marketed by AstraZeneca plc, Cambridge, UK) was developed as a synthetic analogue of human amylin for the treatment ofWSGR Docket No.: 56017-733.601 patients with types 1 or 2 diabetes, who use meal-time insulin but cannot achieve desired glycemic control despite optimal insulin therapy. Pramlintide differs from human amylin in 3 of its 37 amino acids. These modifications provide pramlintide a longer half-life of approximately 48 minutes in humans and reduce its propensity to aggregate, a characteristic found of human amylin.

[0006] For treatment of type 1 diabetics, pramlintide is administered up to four times per day, via subcutaneous injection before meals, as an adjunct to insulin therapy administered after meals. Pramlintide cannot be mixed with insulin; separate syringes are used. Reported side effects of pramlintide include nausea and vomiting. Adverse reactions can include severe hypoglycemia, particularly for type 1 diabetics. Consequently, dosage of meal-time insulin is reduced for patients who initiate administration of pramlintide.

[0007] For treatment of type 2 diabetics, pramlintide is administered before each meal via subcutaneous injection at a recommended starting dose that is gradually increased to a target maintenance dose.

[0008] Cagrilintide is a long acting human amylin analog, specifically a dual amylin & calcitonin receptor agonist (DACRA), under clinical development by Novo Nordisk A / S headquartered in Copenhagen Denmark. Cagrilintide is administered via once-weekly injections and has shown promising results for weight loss, both as a monotherapy and in combination with the glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide (CagriSema).

[0009] Human amylin analogs, such as cagrilintide, are used for the treatment of various diseases or conditions, such as metabolic diseases, and for weight management. However, there are limitations to currently available compositions or formulations containing cagrilintide and other amylin analogs, such as poor solubility in an aqueous environment and lower stability, which could lead to limited efficacy and high dosing. Thus, there is a need for better compositions or formulations containing amylin analogs, such as cagrilintide. SUMMARY

[0010] In an aspect, provided herein is, inter alia, a compound comprising the structure of Formula I: Formula I, wherein:anion of cagrilintide; andWSGR Docket No.: 56017-733.601 is a cationic component.

[0011] In another aspect, provided herein is, inter alia, a compound comprising the structure of Formula I: Formula I, wherein: is an anion of cagrilintide; and is a cationic component,wherein does not have the structure of , wherein R8, R9, and R10are independently C1-C5 alkyl, and R11is C2-C5 alkyl that is unsubstituted or substituted with 1 or more hydroxyl.

[0012] In some embodiments, provided herein is a compound consisting, or consisting essentially, of the structure of Formula I.

[0013] In some embodiments, the anion of cagrilintide derives from the structure of the compound in Table 2.

[0014] In some embodiments, the cationic component is selected from the group consisting of alkali metal, alkaline earth metal, a metal ion such as aluminum, sodium, lithium, potassium, magnesium, calcium, and zinc, ammonium (NH4+), a protonated or positively (+) charged ion from an aliphatic primary amine, secondary amine or tertiary amine such as 2-aminoethanol, tromethamine, dimethylamine, diethylamine, N-ethyl-glucamine, hydrabamine, trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, (2,2′,2″-nitrilotris(ethanol)), 2-diethylaminoethanol, procaine or substituted procaine (e.g., chloroprocaine), meglumine, carnitine, ethylenediamine, choline, acetylcholine, aralkyl amine such as Ν,Ν-dibenzylethylenediamine, benzathine, benethamine; heterocyclic aromatic amine such as pyridine, pyrimidine, picoline, quinoline or isoquinoline, quaternary ammonium (e.g., NH4+) such as betaine, nontoxic quaternary ammonium (e.g., NMe4+, N+(C1–4alkyl)4,), tetramethylammonium, tetraethylammonium, benzyltrimethylammonium, benzyltriethylammonium, benzyltributylammonium, methyltrioctylammonium or tetrabutylammonium; 1H-imidazole, substituted-imidazole (e.g., N-alkyl imidazole, N-methylWSGR Docket No.: 56017-733.601 imidazole), pyrrolidine, substituted pyrrolidine (e.g., 1-alkyl pyrrolidine, 1-methyl pyrrolidine, 1- (2-hydroxy-ethyl)-pyrrolidine), piperidine or substituted piperidine (e.g., 1-alkyl piperidine, 1- methyl piperidine), piperazine or substituted piperazine (e.g., 1-alkyl piperazine, 1-methyl piperazine, 1,4-dialkyl piperazine, 1,4-dimethyl piperazine), morpholine, substituted morpholine (e.g., N-substituted morpholine, N-methyl morpholine or 4-(2-hydroxyethyl)-morpholine), basic amino acid such as arginine, lysine, or histidine. aminoguanidine, guanidine derivatives and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate. In some embodiments, the cationic component is not choline.

[0015] In some embodiments, the cationic component is selected from the group consisting of alkali metal, alkaline earth metal, a metal ion, ammonium (NH4+), a protonated or positively (+) charged ion from an aliphatic primary amine, secondary amine or tertiary amine , aralkyl amine, benzathine, benethamine; heterocyclic aromatic amine, quaternary ammonium, nontoxic quaternary ammonium, 1H-imidazole, substituted-imidazole, pyrrolidine, substituted pyrrolidine, piperidine or substituted piperidine, piperazine or substituted piperazine, morpholine, substituted morpholine, basic amino acid, aminoguanidine, guanidine derivatives, and an amine cation formed using a counterion.

[0016] In some embodiments, (i) a metal ion comprises aluminum, sodium, lithium, potassium, magnesium, calcium, or zinc; (ii) the aliphatic primary amine, secondary amine, or tertiary amine comprises 2-aminoethanol, tromethamine, dimethylamine, diethylamine, N-ethyl-glucamine, hydrabamine, trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, (2,2′,2″-nitrilotris(ethanol)), 2-diethylaminoethanol, procaine or substituted procaine, meglumine, carnitine, ethylenediamine, choline, or acetylcholine; (iii) aralkyl amine comprises Ν,Ν-dibenzylethylenediamine; (iv) heterocyclic aromatic amine comprises pyridine, pyrimidine, picoline, quinoline, or isoquinoline; (v) quaternary ammonium comprises NH4+or betaine; (vi) nontoxic quaternary ammonium comprises NMe4+, N+(C1–4alkyl)4,), tetramethylammonium, tetraethylammonium, benzyltrimethylammonium, benzyltriethylammonium, benzyltributylammonium, methyltrioctylammonium or tetrabutylammonium; (vii) substituted-imidazole comprises N-alkyl imidazole or N-methyl imidazole; (viii) substituted pyrrolidine comprises 1-alkyl pyrrolidine, 1-methyl pyrrolidine, or 1-(2- hydroxy-ethyl)-pyrrolidine); (ix) substituted piperidine comprises 1-alkyl piperidine or 1-methyl piperidine;WSGR Docket No.: 56017-733.601 (x) substituted piperazine comprises 1-alkyl piperazine, 1-methyl piperazine, 1,4-dialkyl piperazine, or 1,4-dimethyl piperazine; (xi) substituted morpholine comprises N-substituted morpholine, N-methyl morpholine ,or 4-(2- hydroxyethyl)-morpholine); (xii) basic amino acid comprises arginine, lysine, or histidine; (xiii) the amine cation is formed using a counterion selected from the group consisting of halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate; or (xiv) any combination thereof.

[0017] In some embodiments, the substituted procaine comprises chloroprocaine.

[0018] In some embodiments, the cationic component is betaine.

[0019] In some embodiments, the cationic component comprises the structure of:.

[0020] In some embodiments, the cationic component is selected from the group consisting of those in Table 3.

[0021] In some embodiments, any of the cationic components of Table 3 is provided in any of the molar ratios and weight ratios of Table 3 relative to one or more anions of cagrilintide.

[0022] In some embodiments, the cationic component and anion of cagrilintide are provided in a molar ratio of anion of cagrilintide to cationic component that is selected from the group consisting of about 1:1, 1:2 and 1:3, or any ratio between any two of these values. In some embodiments, the cationic component and anion of cagrilintide are provided in a molar ratio of anion of cagrilintide to cationic component that is from about 1:1 to about 1:3. In some embodiments, the cationic component and anion of cagrilintide are provided in a molar ratio of anion of cagrilintide to cationic component that is from about 1:2 to about 1:3. In some embodiments, the cationic component and anion of cagrilintide are provided in a molar ratio of anion of cagrilintide to cationic component that is selected from the group consisting of about 1:2 and about 1:3. In some embodiments, the cationic component and anion of cagrilintide are provided in a molar ratio of anion of cagrilintide to cationic component that is about 1:3. In some embodiments, the cationic component is selected from the group of cationic components described herein or listed in the preceding paragraphs, further provided in a molar ratio of anion of cagrilintide to cationic component that is selected from the group consisting of about 1:1, 1:2 and 1:3, or any ratio between any two of these values. In some embodiments, the cationic component is selected from the group of cationic components described herein or listed in the preceding paragraphs, further provided in a molar ratio of anion of cagrilintide to cationic component that isWSGR Docket No.: 56017-733.601 from about 1:1 to about 1:3. In some embodiments, the cationic component is selected from the group of cationic components described herein or listed in the preceding paragraphs, further provided in a molar ratio of anion of cagrilintide to cationic component that is from about 1:2 to about 1:3. In some embodiments, the cationic component is selected from the group of cationic components described herein or listed in the preceding paragraphs, further provided in a molar ratio of anion of cagrilintide to cationic component that is selected from the group consisting of about 1:2 and about 1:3. In some embodiments, the cationic component is selected from the group of cationic components described herein or listed in the preceding paragraphs, further provided in a molar ratio of anion of cagrilintide to cationic component that is about 1:3. In some embodiments, the cationic component is selected from the group of cationic components listed in Table 3. In some embodiments, the cationic component is selected from the group of cationic components listed in Table 3, further provided in a molar ratio of anion of cagrilintide to cationic component that is selected from the group consisting of about 1:1, 1:2 and 1:3, or any ratio between any two of these values. In some embodiments, the cationic component is selected from the group of cationic components listed in Table 3, further provided in a molar ratio of anion of cagrilintide to cationic component that is from about 1:1 to about 1:3. In some embodiments, the cationic component is selected from the group of cationic components listed in Table 3, further provided in a molar ratio of anion of cagrilintide to cationic component that is from about 1:2 to about 1:3. In some embodiments, the cationic component is selected from the group of cationic components listed in Table 3, further provided in a molar ratio of anion of cagrilintide to cationic component that is selected from the group consisting of about 1:2 and about 1:3. In some embodiments, the cationic component is selected from the group of cationic components listed in Table 3, further provided in a molar ratio of anion of cagrilintide to cationic component that is about 1:3. In some embodiments, the cationic component is selected from the group of cationic components listed in Table 3, further provided in a weight % (wt. %) ratio relative to the anion of cagrilintide as listed in Table 3.

[0023] In some embodiments, a molar ratio of : is selected from the group consistingof about 1:1, 1:2, and 1:3. In some embodiments, a molar ratio of : is selected from thegroup consisting of from about 1:2 to about 1:3. In some embodiments, a molar ratio of : is selected from the group consisting of about 1:2 and about 1:3. In some embodiments, aWSGR Docket No.: 56017-733.601molar ratioabout 1:3.

[0024] In some embodiments, the quaternary ammonium has the structure of wherein: R8, R9, R10, and R11are each independently a substituted or unsubstituted group selected from C1-6 aliphatic, phenyl, cycloalkyl, 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0025] In some embodiments, the quaternary ammonium has the structure ofwherein: R8, R9, R10, and R11are each independently a substituted or unsubstituted C1-6aliphatic.

[0026] In some embodiments, the quaternary ammonium has the structure of wherein: (i) R8, R9, R10, and R11are independently C1-C6 alkyl; (ii) R8, R9, R10, and R11are independently C1-C4 alkyl; (iii) R8, R9, and R10are C2alkyl; and R11is C1alkyl; (iv) R8, R9, and R10are C4 alkyl; and R11is C1 alkyl; (v) all of R8, R9, R10, and R11are C1 alkyl; (vi) all of R8, R9, R10, and R11are C2alkyl; (vii) all of R8, R9, R10, and R11are C3alkyl; or (viii) all of R8, R9, R10, and R11are C4 alkyl.

[0027] In some embodiments, the cationic component is a quaternary ammonium, wherein the anion of cagrilintide and quaternary ammonium are provided in a molar ratio of anion of cagrilintide to quaternary ammonium that is selected from the group consisting of about 1:1, 1:2 and 1:3, or any ratio between any two of these values. In some embodiments, the cationicWSGR Docket No.: 56017-733.601 component is a quaternary ammonium having the structure of , wherein the anion of cagrilintide and quaternary ammonium are provided in a molar ratio of anion of cagrilintide to quaternary ammonium that is selected from the group consisting of about 1:1, 1:2 and 1:3, or any ratio between any two of these values.

[0028] In some embodiments, the quaternary ammonium has the structure of or.

[0029] In some embodiments, the quaternary ammonium has the structure of.

[0030] In some embodiments, the cationic component is a quaternary ammonium having the structure, ,, , wherein the anion of cagrilintide and quaternary ammonium are provided in a molar ratio of anion of cagrilintide to quaternary ammonium that is selected from the group consisting of about 1:1, 1:2 and 1:3 or any ratio between any two of these values.

[0031] In some embodiments, provided is a hydrate of the compound of the structure of Formula I. The term “hydrate”, as used herein, means a solid or a semi-solid form of a chemical compound containing water in a molecular complex. The water is generally in a stoichiometric amount with respect to the chemical compound. Exemplary hydrates include (compound of Formula I • ZH2O), wherein Z is from 1 to 50 equivalents of H2O.

[0032] In another aspect, provided herein is a compound comprising the structure of Formula IIa, Formula IIb, Formula IIc, or any combination thereof: Formula IIa,WSGR Docket No.: 56017-733.601Formula IIb,Formula IIc,wherein, , , any combination thereof is one or more cations ofcagrilintide; andanionic component.

[0033] In some embodiments, provided herein is a compound consisting, or consisting essentially, of the structure of Formula IIa, Formula IIb, Formula IIc, or any combination thereof.

[0034] In some embodiments, the one or more cations of cagrilintide derive from the structure of the compound in Table 2.

[0035] In some embodiments, the anionic component is selected from the group consisting of besylate, mesylate, tosylate, sulfonate, sulfate, methylsulfate, camsylate, isethionate, edisylate, 1- hydroxy-2-naphthoate, 2,2-dichloroacetate, 2-hydroxyethanesulfonate, 2-oxoglutarate, 4- acetamidobenzoate, 4-aminosalicylate, acetate, adipate, ascorbate, aspartate, benzenesulfonate, benzoate, bromide, chloride, camphorate, camphor-10-sulfonate, caprate (decanoate), caproate (hexanoate), caprylate (octanoate), carbonate, cinnamate, citrate, cyclamate, dodecylsulfate, dodecylsulfurate, ethanesulfonate, ethane-1,2-disulfonate, ethanesulfonate, formate, fumarate, galactarate, gentisate, glucoheptonate, gluconate, glutantate, glucuronate, glutamate, glutarate, glycerophosphorate, glycine, glycolate, hippurate, hydrobromate, hydroiodide, hydrochlorate, isobutyrate, lactate, lactobionate, laurate, lysine, maleate, malate, malonate, mandelate, methanesulfonate , naphthalene-1,5-disulfonate, naphthalene-2-sulfonate, nicotinate, nitrate, oleate, orotate, oxalate, palmitate, pamoate, phosphorate, proprionate, pyroglutamate, salicylate, sebacate, stearate, succinate, sulfurate, tannate, tartarate, thiocyanate, toluenesulfonate, undecylenate, α-lipoate, 12-hydroxystearate, 2-(4-isobutylphenyl)propionate, 2-(4,4-dimethyl-2-WSGR Docket No.: 56017-733.601 pentanyl)-5,7,7-trimethyloctanoate, 2-aminoethanesulfonate, 2-hexyldecanoate, 2- hydroxyhippurate, 3-(4-hydroxyphenyl)propionate, 3-methylcrotonate, 3,3-diphenylpropionate, 3,4-dihydroxbenzoate, ,5-dihydroxybenzoate, 4-acetamido-benzoate, 3,7-dimethyloctanoate, 4- hydroxybenzenesulfonate, 4-hydroxybenzoate, 4-methylhexanoate, 4-methyloctanoate, valerate salts including 4-methylvalerate, 5-norbornene-2-carboxylate, 8-[(2- hydroxybenzoyl)amino]octanoate, abietate, acetylcysteine, aconitate, arachidonate, behenate, caffeate, chenodeoxycholate, citronellate, crotonate, galactonate, deoxycholate, dihydrocaffeate, 2-phenylpropionate (hydratropate), tropate, eicosanedioate, eicosapentanoate (EPA), elaidate, ellagate, erucate, ethylenediaminetetraacetate (EDTA), geranate, heptanoate, hydrocinnamate (3- phenylpropionate), isovalerate, glutathione reduced, lactate, laurate, levulinate, linoleate, linolenate, lithocholate, mesaconate, nonanoate, oxalate, coumarate, palmitate, perillate, pimelate, 3–phenylpropionate, pivalate, propionate, pyruvate, ricinoleate, salicylate, 2-hydroxybenzoate, sinapinate (3,5-dimethoxy-4-hydroxycinnamate), sorbate, syringate, tiglate, 2-decenoate, 2- hexenoate, 2-octenoate, 3-octenoate, 7-octenoate, ferulate, undecanoate, valerate, vanillate, perchlorate, alginate, bisulfate, borate, butyrate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, glycerophosphate, hemisulfate, hydroiodide, lauryl sulfate, 2– naphthalenesulfonate, pectinate, persulfate, phosphate, tartrate, o-(4-hydroxybenzoyl)benzoate, 1,2,-ethanedisulfonate, chlorobenzenesulfonate, 4-methylbicyclo[2.2.2]oct-2-ene-carboxylate, 4.4’-methylenebis(3-hydroxy-2- ene-1-carboxylate), trimethylacetate, tertiary butylacetate, lauryl sulfurate, hydroxynaphthoate, muconate, α-ketoglutarate, p-toluenesulfonate, p-coumarate, and p- chlorobenzenesulfonate.

[0036] In some embodiments, the anionic component is selected from the group consisting of those in Table 4.

[0037] In some embodiments, any of the anionic components of Table 4 is provided in any of the molar ratios and weight ratios of Table 4 relative to one or more cations of cagrilintide.

[0038] In some embodiments, the anionic component is betaine. In some embodiments, theanionic component comprises the structure . In some embodiments, the anioniccomponent has the structure of: .

[0039] In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component of about 1:1, 1:2, 1:3 or 1:4, or any ratio between any two of these values. In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or moreWSGR Docket No.: 56017-733.601 cations of cagrilintide to anionic component of from about 1:1 to about 1:4. In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:2 to about 1:4. In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component that is about 1:3. In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component that is about 1:4. In some embodiments, the anionic component is selected from the group of anionic components described herein or listed in the preceding paragraphs, further provided in a molar ratio of one or more cations of cagrilintide to anionic component that is about 1:1, 1:2, 1:3 or 1:4, or any ratio between any two of these values. In some embodiments, the anionic component is selected from the group of anionic components described herein or listed in the preceding paragraphs, further provided in a molar ratio of one or more cations of cagrilintide to anionic component that is from about 1:1 to about 1:4. In some embodiments, the anionic component is selected from the group of anionic components described herein or listed in the preceding paragraphs, further provided in a molar ratio of one or more cations of cagrilintide to anionic component that is from about 1:2 to about 1:4. In some embodiments, the anionic component is selected from the group of anionic components described herein or listed in the preceding paragraphs, further provided in a molar ratio of one or more cations of cagrilintide to anionic component that is about 1:3. In some embodiments, the anionic component is selected from the group of anionic components described herein or listed in the preceding paragraphs, further provided in a molar ratio of one or more cations of cagrilintide to anionic component that is about 1:4. In some embodiments, the anionic component is selected from the group of cationic components listed in Table 4. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component that is about 1:1, 1:2, 1:3 or 1:4, or any ratio between any two of these values. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component that is from about 1:1 to about 1:4. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component that is from about 1:2 to about 1:4. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component that is about 1:3. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or moreWSGR Docket No.: 56017-733.601 cations of cagrilintide to anionic component that is about 1:4. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a weight % (wt. %) ratio relative to the one or more cations of cagrilintide as listed in Table 4.

[0040] In some embodiments, a molar ratio of , , , or anycombination thereof: is selected from the group consisting of about 1:1, 1:2, 1:3, and 1:4. Insome embodiments, a molar ratio of , , , or any combinationthereof: is selected from the group consisting of about 1:2, 1:3, and 1:4. In some embodiments,a molar ratio of,, , or any is about 1:4.In some embodiments, a molar ratio of , , , or any combinationthereof: is about 1:3.

[0041] In some embodiments, provided is a hydrate of the compound of the structure of Formula I. Exemplary hydrates include (compound of Formula IIa, Formula IIb, Formula IIc or any combination thereof • ZH2O), wherein Z is from 1 to 50.

[0042] In some embodiments, (i) a weight % (wt. %) ratio of : is from about 0.1 wt. %: 99.9 wt. % to about 20.0 wt. %: 80.0 wt. %; orWSGR Docket No.: 56017-733.601(ii) a weight % (wt. %) ratio of : , , , or any combination thereof is from about 0.1 wt. %: 99.9 wt. % to about 20.0 wt. %: 80.0 wt. %.

[0043] In some embodiments, (i) a molar ratio of : is from about 2:1 to about 10:1; or (ii) a molar ratio of, , , any combination thereof is from about 2:1 to about 10:1.

[0044] In some embodiments,(i) a molar ratio of : is from about 2:1 to about 7:1; or (ii) a molar ratio of, , , any combination thereof is from about 2:1 to about 7:1.

[0045] In some embodiments, (i) a molar ratio of : is from about 3:1 to about 7:1; or(ii) a molar ratio, , , any combination thereof is fromabout 3:1 to about 7:1.

[0046] In some embodiments, (i) a molar ratio of : is from about 4:1 to about 7:1; orWSGR Docket No.: 56017-733.601 (ii) a molar ratio of, , , any combination thereof is from about 4:1 to about 7:1.

[0047] In some embodiments, (i) a molar ratio of : is from about 3:1 to about 7:1; or(ii) a molar ratio of : , , , or any combination thereof is about 4:1.

[0048] In another aspect, provided herein is a compound comprising the structure of Formula I:Formula I, wherein: anion of cagrilintide; andis a cationic component, wherein the cationic component is betaine.

[0049] In some embodiments, the cationic component comprise the structure of .

[0050] In some embodiments, the compound has a molar ratio of anion of cagrilintide to betaine that is from about 1:1 to about 1:4 of anion of cagrilintide:betaine.

[0051] In some embodiments, the compound has a molar ratio of anion of cagrilintide to betaine that is from about 1:1 to about 1:3 of anion of cagrilintide:betaine.

[0052] In some embodiments, the compound has a molar ratio of anion of cagrilintide to betaine that is about 1:1 of anion of cagrilintide:betaine

[0053] In some embodiments, the compound has a molar ratio of anion of cagrilintide to betaine that is about 1:2 of anion of cagrilintide:betaine.WSGR Docket No.: 56017-733.601

[0054] In some embodiments, the compound has a molar ratio of anion of cagrilintide to betaine that is about 1:3 of anion of cagrilintide:betaine.

[0055] In some embodiments, the compound has a molar ratio of anion of cagrilintide to betaine that is about 1:4 of anion of cagrilintide:betaine.

[0056] In some embodiments, the compound has a molar ratiothat is fromabout 1:1 to about.

[0057] In some embodiments, the compound has a molar ratio of to that is fromabout 1:1 to about.

[0058] In some embodiments, the compound has a molar ratio of to that is about1:1 of anion.

[0059] In some embodiments, the compound has a molar ratio ofthat is about1:2 of anion.

[0060] In some embodiments, the compound has a molar ratio of to that is about1:3 of anion.

[0061] In some embodiments, the compound has a molar ratio of to that is about1:4 of anion.

[0062] In some embodiments, wherein the compound has a wt % of betaine of from about 1.0 wt % to about 12.0 wt %, relative to a wt % of anion of cagrilintide of from about 99.0 wt % to about 88.0 wt %.

[0063] In some embodiments, the compound has a wt % of betaine of from about 2.6 wt % to about 8.0 wt %, relative to a wt % of anion of cagrilintide of from about 97.4 wt % to about 92.0WSGR Docket No.: 56017-733.601 wt %.

[0064] In some embodiments, the compound has a wt % of betaine of about 8.0 wt %, relative to a wt % of anion of cagrilintide of about 92.0 wt %.

[0065] In another aspect, provided herein is a compound comprising the structure of Formula IIIa:Formula IIIa, or a pharmaceutically acceptable salt thereof, wherein: is a covalent derivative of one or more carboxyl groups of cagrilintide or a pharmaceutically acceptable salt thereof; and each R100is as defined herein.

[0066] In some embodiments, R100is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert- butyl, or pentyl, fluoromethyl, difluoromethyl, trifluoromethyl, CHCH3OC(O)OCH2CH, -CH3, - CH2CH3, -CH(CH3)2, CH2CH2CH2CH3, C(CH3)3, -CH2CH2N(CH3)3+,substituted C1-6 aliphatic, unsubstituted C1-6 aliphatic, substituted (C1-22)alkyl, unsubstituted (C1-22)alkyl, substituted (C1-22)alkenyl, unsubstituted (C1-22)alkenyl, substituted phenyl, unsubstituted phenyl, substituted - C(O)R, unsubstituted -C(O)R, substituted -C(O)OR, unsubstituted -C(O)OR, substituted - C(O)N(R)2, unsubstituted -C(O)N(R)2, (C2-C12)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N- (alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(C1-C2)alkylamino(C2-C3)alkyl (such as β- dimethylaminoethyl), carbamoyl-(C1-C2)alkyl, N,N-di(C1-C2)alkylcarbamoyl-(C1-C2)alkyl, piperidino-, pyrrolidino- or morpholino(C2-C3)alkyl, C1-6aliphatic, (C1-22)alkyl, (C1-22)alkenyl, - C(O)R, -C(O)OR, -C(O)N(R)2, phenyl, 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, andWSGR Docket No.: 56017-733.601 sulfur, an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and each occurrence of R is independently hydrogen or an optionally substituted group selected from C1-6aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0067] In some embodiments, the compound of Formula IIIa does not have the structure ofFormula II, wherein R8, R9, and R10are independently C1-C5alkyl.

[0068] In another aspect, provided herein is a compound comprising the structure of Formula IIIb: Formula IIIb or a pharmaceutically acceptable salt thereof, wherein:is a covalent derivative of one or more hydroxyl groups of cagrilintide, or a pharmaceutically acceptable salt thereof; and each R101is as defined herein.

[0069] In some embodiments, R101is selected from the group consisting of -CH2R, -C(O)R, - C(O)OR, -C(O)N(R)2, -OP(O)OROR, wherein each occurrence of R is independently hydrogen or an optionally substituted group selected from C1-6aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; orWSGR Docket No.: 56017-733.601 R101is -CH2OCH2CH2OH, unsubstituted C(O)C1-6alkyl, substituted C(O)C1-6alkyl, substituted C(O)phenyl or unsubstituted C(O)phenyl, -(C1-C6)alkanoyloxymethyl, -1-((C1- C6)alkanoyloxy)ethyl, -1-methyl-1-((C1-C6)alkanoyloxy)ethyl, -(C1- C6)alkoxycarbonyloxymethyl, -N-(C1-C6)alkoxycarbonylaminomethyl, -succinoyl, -(C1- C6)alkanoyl, -α-amino(C1-C4)alkanoyl, -arylacyl, -α-aminoacyl, or -α-aminoacyl-α-aminoacyl, optionally, wherein each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)2, -P(O)(O(C1-C6)alkyl)2 or glycosyl, and optionally, wherein the radical results from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate.

[0070] In some embodiments, R101is the unsubstituted C(O)C1-6alkyl comprising COCH3, COCH2CH3, or COCH(CH3)2), or R101is the substituted C(O)C1-6alkyl comprising COCF3, COCHCF2, or -COCH2CF.

[0071] In some embodiments, R101is -C(O)R selected from the group consisting of -C(O)CH3 and -C(O)H, -C(O)OR that is -C(O)OH2), -C(O)N(R)2 selected from the group consisting of - C(O)NH2 and -C(O)N(CH3)2), or -OP(O)OROR that is -OP(O)OHOH.

[0072] In some embodiments, R101is -CHCH3OC(O)OCH2CH3.

[0073] In another aspect, provided herein is a compound comprising the structure of Formula IIIc and / or Formula IIId:, Formula IIIc Formula IIId or a pharmaceutically acceptable salt of each thereof; wherein:and / or is each a covalent derivative of one or more amino or imidazole groups of cagrilintide, or a pharmaceutically acceptable salt thereof; and each of R102and R103is as defined herein.WSGR Docket No.: 56017-733.601

[0074] In some embodiments, each of R102and R103is independently selected from the group consisting of -CH2R, -C(O)R, -C(O)OR, -C(O)N(R)2, -OP(O)OROR, wherein each occurrence of R is independently hydrogen or an optionally substituted group selected from C1-6aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each R102and R103is independently C(O)R, C(O)OR, C(O)R’, or C(O)NR’R”, where R’ and R” are each independently (C1-C10)alkyl, (C3-C7)cycloalkyl, benzyl; or each R102and R103is a natural α-aminoacyl or natural α-aminoacyl-natural α-aminoacyl, - C(OH)C(O)OY1, wherein Y1is H, (C1-C6)alkyl or benzyl, -C(OY2)Y3, wherein Y2is (C1-C4) alkyl and Y3is (C1-C6)alkyl, carboxy(C1-C6)alkyl, amino(C1-C4)alkyl or mono-N-or di-N,N-(C1- C6)alkylaminoalkyl, -C(Y4)Y5, wherein Y4is H or methyl and Y5is mono-N- or di-N,N-( C1- C6)alkylamino, morpholino, piperidin-1-yl or pyrrolidin-1-yl.

[0075] In some embodiments, each R102and R103is independently -CH2OCH2CH2OH or unsubstituted C(O)C1-6alkyl.

[0076] In some embodiments, R102is substituted C(O)C1-6alkyl comprising COCF3, COCHCF2, or -COCH2CF.

[0077] In some embodiments, R102is substituted C(O)phenyl or unsubstituted C(O)phenyl.

[0078] In some embodiments, R102is CHCH3OC(O)OCH2CH3. ‘

[0079] In another aspect, provided herein is a compound comprising the structure of Formula IIIe:Formula IIIe, or a pharmaceutically acceptable salt thereof; wherein:covalent derivative of one or more thiol groups of cagrilintide, or a pharmaceutically acceptable salt thereof; each R104is as defined herein.

[0080] In some embodiments, R104is -CH2OCH2CH2OH, unsubstituted C(O)C1-6alkyl,WSGR Docket No.: 56017-733.601 substituted C(O)C1-6alkyl, substituted C(O)phenyl or unsubstituted C(O)phenyl, -(C1- C6)alkanoyloxymethyl, -1-((C1-C6)alkanoyloxy)ethyl, -1-methyl-1-((C1-C6)alkanoyloxy)ethyl, - (C1-C6)alkoxycarbonyloxymethyl, -N-(C1-C6)alkoxycarbonylaminomethyl, -succinoyl, -(C1- C6)alkanoyl, -α-amino(C1-C4)alkanoyl, -arylacyl and -α-aminoacyl, or -α-aminoacyl-α- aminoacyl, wherein each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)2, -P(O)(O(C1-C6)alkyl)2or glycosyl, wherein the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate; R104is selected from an optionally substituted group consisting of -CH2R; or R104is C(O)R, -C(O)OR, -C(O)N(R)2, or -OP(O)OROR, wherein each occurrence of R is independently hydrogen or an optionally substituted group selected from C1-6aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0081] In some embodiments, R104is -C(O)R comprising -C(O)CH3 or -C(O)H), -C(O)OR comprising -C(O)OH2), -C(O)N(R)2comprising -C(O)NH2or -C(O)N(CH3)2), -OP(O)OROR comprising -OP(O)OHOH), or C(O)C1-6alkyl comprising COCH3, COCH2CH3, or COCH(CH3)2).

[0082] In some embodiments, R104is substituted C(O)C1-6alkyl comprising COCF3, COCHCF2, or -COCH2CF).

[0083] In some embodiments, R104is CHCH3OC(O)OCH2CH3.

[0084] In some embodiments, the compound of Formula IIIe is formed from the side chain thiol moiety of one or more of the Cys residues of cagrilintide.

[0085] In some embodiments, the compound of Formula IIIe is formed from the side chain thiol moiety of one of the Cys residues of cagrilintide.

[0086] In some embodiments, the compound of Formula IIIe is formed from the side chain thiol moiety of one of the Cys residues of cagrilintide.

[0087] As used herein, the term “pharmaceutically acceptable salt” refers to any of the cationic components or anionic components described herein.

[0088] In another aspect, provided herein is a pharmaceutical composition comprising the compound as provided herein, and a pharmaceutically acceptable excipient.

[0089] In some embodiments, the pharmaceutical composition is formulated for parenteralWSGR Docket No.: 56017-733.601 administration, oral administration, or implantable administration.

[0090] In some embodiments, the pharmaceutical composition is formulated for subcutaneous administration or intravenous administration.

[0091] In another aspect, provided herein is a drug delivery device comprising the compound as provided herein, or the pharmaceutical composition as provided herein.

[0092] In some embodiments, the drug delivery device is a syringe, a single-dose pen with an injection needle, or an autoinjector with an injection needle.

[0093] In some embodiments, the drug delivery device is an implantable osmotic drug delivery device.

[0094] In another aspect, provided herein is a kit comprising the compound as provided herein, the pharmaceutical composition as provided herein, or the drug delivery device as provided herein.

[0095] In some embodiments, the kit as provided herein further comprises an instruction for use.

[0096] In another aspect, provided herein is a method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound as provided herein, or the pharmaceutical composition as provided herein, wherein the administering is effective to treat the disease or disorder in the subject.

[0097] In another aspect, provided herein is the compound as provided herein or the pharmaceutical composition as provided herein for use in a method of treating a disease or disorder in a subject in need thereof by administering to the subject a therapeutically effective amount of the compound as provided herein, or the pharmaceutical composition as provided herein, wherein the administering is effective to treat the disease or disorder in the subject.

[0098] In another aspect, provided herein is use of the compound as provided herein or the pharmaceutical composition as provided herein in a method of treating a disease or disorder in a subject in need thereof by administering to the subject a therapeutically effective amount of the compound as provided herein, or the pharmaceutical composition as provided herein, wherein the administering is effective to treat the disease or disorder in the subject.

[0099] In some embodiments, the compound or the pharmaceutical composition is administered to the subject using the drug delivery device as provided herein.

[0100] In some embodiments, the disease or disorder is a metabolic disease or disorder, a cardiovascular disease or disorder, chronic kidney disease, or a neurological disease or disorder.

[0101] In some embodiments, the disease or disorder is selected from the group consisting of type 1 diabetes, type 2 diabetes, obesity, overweight, metabolic dysfunction–associated fatty liver disease (MAFLD), metabolic dysfunction-associated steatohepatitis (MASH), and nonalcoholic steatohepatitis (NASH).WSGR Docket No.: 56017-733.601

[0102] In some embodiments, the disease or disorder is selected from the group consisting of arrhythmia, coronary artery disease, heart failure, valve disease, aortic disease, congenital heart disease, heart attack, angina, cardiomyopathy, peripheral arterial disease, atherosclerosis, cardiac dysrhythmias, pericarditis, pulmonary hypertension, stroke, cerebrovascular disease, rheumatic heart disease, atrial fibrillation, Brugada syndrome, aortic stenosis, bradycardia, endocarditis, high cholesterol, and long QT syndrome.

[0103] In some embodiments, the disease or disorder is Parkinson’s disease or Alzheimer disease.

[0104] In some embodiments, the subject is human.

[0105] In some embodiments, the compound or the pharmaceutical composition is administered to the subject via parenteral administration, oral administration, or implantable administration.

[0106] In some embodiments, the compound or the pharmaceutical composition is administered to the subject via subcutaneous administration or intravenous administration.

[0107] In another aspect, provided herein is a method of reducing weight in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound as provided herein or the pharmaceutical composition as provided herein, wherein the administering is effective to reduce weight in the subject.

[0108] In another aspect, provided herein is the compound as provided herein or the pharmaceutical composition as provided herein for use in a method of reducing weight in a subject in need thereof by administering to the subject a therapeutically effective amount of the compound as provided herein or the pharmaceutical composition as provided herein, wherein the administering is effective to reduce weight in the subject.

[0109] In another aspect, provided herein is use of the compound as provided herein or the pharmaceutical composition as provided herein in a method of reducing weight in a subject in need thereof by administering to the subject a therapeutically effective amount of the compound as provided herein, or the pharmaceutical composition as provided herein, wherein the administering is effective to reduce weight in the subject.

[0110] In some embodiments, the compound or the pharmaceutical composition is administered to the subject using the drug delivery device as provided herein.

[0111] In some embodiments, the subject is human.

[0112] In some embodiments, the subject has obesity or is overweight.

[0113] In some embodiments, the compound or the pharmaceutical composition is administered to the subject via parenteral administration, oral administration, or implantable administration.

[0114] In some embodiments, the compound or the pharmaceutical composition is administered to the subject via subcutaneous administration or intravenous administration.WSGR Docket No.: 56017-733.601 BRIEF DESCRIPTION OF THE DRAWINGS

[0115] FIG.1 shows the chemical structure of an exemplary amylin analog, cagrilintide. The squares depict the ionizable carboxylates, and the circles depict the ionizable basic amino groups of cagrilintide.

[0116] FIG.2 shows a photograph of the clear solution of the choline-cagrilintide salt, and the cloudy aqueous solutions of cagrilintide free acid (i.e., base form) and the cagrilintide-acetate salt having visible precipitation as obtained from Example 9.

[0117] FIG.3 shows the solubility of various exemplary salts of cagrilintide as obtained from Example 9. The choline-cagrilintide salt exhibited 100% solubility at the concentration of 50 mg / mL, whereas the cagrilintide-acetate salt and cagrilintide free acid (i.e., base form) exhibited lower solubility, i.e., approximately 96% and 92% solubility, respectively.

[0118] FIG. 4 shows that the average particle sizes of the cagrilintide-acetate salt and cagrilintide free acid (i.e., base form) as measured by Dynamic light scattering were much larger compared with the average particle size of the choline-cagrilintide salt as measured by dynamic light scattering, as shown in Example 10.

[0119] FIG.5 shows 1H proton nuclear magnetic resonance (NMR) spectra of cagrilintide free acid (top) and the betaine salt of cagrilintide (bottom) having a 1:3 molar ratio of cagrilintide:betaine. Preparation of the betaine salt of cagrilintide is described in Example 12. DETAILED DESCRIPTION

[0120] Provided herein is a compound comprising an ionic form (i.e., salt form) of a therapeutic agent, particularly an amylin analog, such as cagrilintide, and a counterion thereof. In some embodiments, cagrilintide is in a cationic form and the counterion is an anion. In some embodiments, cagrilintide is in an anionic form and the counterion is a cation. In some embodiments, the compound is a salt composed of an ionic form of cagrilintide and a counterion thereof. In some embodiments, cagrilintide is a cationic component of the salt and the counterion is an anionic component of the salt. In some embodiments, cagrilintide is an anionic component of the salt and the counterion is a cationic component of the salt.

[0121] Cagrilintide has an amino acid sequence similar to human amylin, augmented by several improvements in chemical structure that render cagrilintide a far superior therapeutic and more “drug-like” than endogenous human amylin. Cagrilintide is further modified at the lysine of position 1 by covalent attachment of a long C20 lipophilic side chain ending with a carboxylate group that increases cagrilintide’s binding affinity to blood protein (albumin), which significantly prolongs the presence of this peptide in blood circulation. Consequently, cagrilintide's elimination half-life (t1 / 2) from blood is about seven to eight days (159-195 hours) which renders cagrilintide amenable to weekly subcutaneous injection.WSGR Docket No.: 56017-733.601

[0122] Applicant has discovered that cagrilintide, despite being optimized for “drug-likeness” with respect to its amino acid sequence and chemical structure, is nonetheless unoptimized for drug-likeness with respect to potential ionic salt forms, esters and / or prodrug of this peptide. Not only is the choice of salt, ester and / or prodrug form, among numerous possibilities, critical to enhancement of certain drug like properties of cagrilintide, but so too is the stoichiometry of salt, ester and / or prodrug form employed, where either the weight / weight ratio (i.e., wt. % or % w / w) of any given salt to cagrilintide peptide, generally ranging from 0.1 wt. % to 50.0 wt. % salt relative to 99.9 wt. % to 50.0 wt. % cagrilintide, or molar ratio of any given salt, ester and / or prodrug to cagrilintide peptide, generally ranging from 1:1 to 100:1, can be used to further “tune” certain desired drug like properties of this peptide relative to those, for example, of the unoptimized free acid of cagrilintide.

[0123] From myriad potential permutations, Applicant conducted comparative experimentation and analyses of the resulting data to identify certain ionic salt forms, esters and / or prodrugs of cagrilintide, in certain wt. % ratios of salt to cagrilintide, generally ranging from 0.1 wt. % to 50.0 wt. % salt relative to 99.9 wt. % to 50.0 wt. % cagrilintide, or in certain molar ratios from 1:1 to 100:1 of salt, ester and / or prodrug to cagrilintide, that provide surprising advantages including enhanced stability and improved solubility in an aqueous environment relative to known injectable and oral administrations of, for example, the free acid of cagrilintide.

[0124] Accordingly, provided are improved pharmaceutical compositions comprising disclosed salt forms of cagrilintide, and in some embodiments having wt. % ratios of salt to cagrilintide from 0.1 wt. % to 50.0 wt. % salt relative to 99.9 wt. % to 50.0 wt. % cagrilintide, or molar ratios of salt, ester and / or prodrug to cagrilintide from 1:1 to 100:1, that have been formulated to selectively reduce the propensity for detrimental qualities, including poor solubility in an aqueous environment at any given dose relative to existing “free acid” formulation of cagrilintide. As such, improved pharmaceutical compositions comprising disclosed salt forms of cagrilintide of the present invention may permit lower dosing (and reduced cost of goods, i.e., COGs) as an additional means to achieve greater efficacy than existing “free acid” formulations of cagrilintide. Definitions

[0125] Certain specific details of this description are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the present disclosure may be practiced without these details. In other instances, well-known structures have not been shown or described in detail to avoid unnecessarily obscuring descriptions of the embodiments.WSGR Docket No.: 56017-733.601

[0126] Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising,” as used herein, are to be construed in an open, inclusive sense, that is, as “including, but not limited to.” Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed disclosure.

[0127] As used in this specification and the appended claims, the singular forms “a,” “an,” and “the,” as used herein, include plural referents unless the content clearly dictates otherwise. The use of the words “a” or “an,” as used herein, when used in conjunction with the term “comprising” herein may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”

[0128] It should also be noted that the term “or,” as used herein, is generally employed in its sense including “and / or” unless the content clearly dictates otherwise.

[0129] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below.

[0130] The term “about,” as used herein, when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20% or in some instances ±10%, or in some instances ±5%, or in some instances ±1%, or in some instances ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods. As used herein, “about” and “approximately” generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5% of a given range of values.

[0131] The terms “amylin analog,” “amylin receptor agonist” and “dual amylin & calcitonin receptor agonist (i.e., DACRA)” are used interchangeably herein.

[0132] The terms “polypeptide”, “peptide” and “protein” (if single chain) are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. The polypeptide can be isolated from natural sources, can be a produced by recombinant techniques from a eukaryotic or prokaryotic host, or can be a product of synthetic procedures.WSGR Docket No.: 56017-733.601

[0133] The terms “nucleic acid,” “nucleic acid sequence,” “nucleotide sequence,” or “polynucleotide sequence,” and “polynucleotide” are used interchangeably. As used herein, they refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. The polynucleotide may be either single-stranded or double- stranded, and if single-stranded may be the coding strand or non-coding (antisense) strand. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. The nucleic acid may be a recombinant polynucleotide, or a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which either does not occur in nature or is linked to another polynucleotide in a non-natural arrangement.

[0134] The compositions and methods as provided herein encompass polypeptides and nucleic acids having the sequences specified, or sequences substantially identical or similar thereto, e.g., sequences at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%. 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% identical or higher to the sequence specified. In the context of an amino acid sequence, the term “substantially identical” is used herein to refer to a first amino acid that contains a sufficient or minimum number of amino acid residues that are i) identical to, or ii) conservative substitutions of aligned amino acid residues in a second amino acid sequence such that the first and second amino acid sequences can have a common structural domain and / or common functional activity. For example, amino acid sequences that contain a common structural domain having at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%.97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100% sequence identity to a reference sequence, e.g., a sequence provided herein. In the context of nucleotide sequence, the term “substantially identical” is used herein to refer to a first nucleic acid sequence that contains a sufficient or minimum number of nucleotides that are identical to aligned nucleotides in a second nucleic acid sequence such that the first and second nucleotide sequences encode a polypeptide having common functional activity, or encode a common structural polypeptide domain or a common functional polypeptide activity. For example, nucleotide sequences having at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%. 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100% sequence identity to a reference sequence, e.g., a sequence provided herein.

[0135] Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows. To determine the percent identity of two aminoWSGR Docket No.: 56017-733.601 acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”).

[0136] The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453 ) algorithm which has been incorporated into the GAP program in the GCG software package (available at http: / / www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at http: / / www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that should be used unless otherwise specified) are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

[0137] The percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The nucleic acid and protein sequences described herein can be used as a “query sequence” to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a nucleic acid molecule .WSGR Docket No.: 56017-733.601 BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to protein molecules . To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

[0138] The term “agonist,” as used herein, refers to a molecule or an agent that activates a receptor to produce a biological response. In contrast, the term “antagonist,” as used herein, refers to a molecule or an agent that blocks the action of the agonist, and the term “inverse agonist,” as used herein, refers to a molecule or an agent that causes an action opposite to that of the agonist. In some embodiments, the agonist may be an endogenous agonist. In some embodiments, the agonist may be an exogenous agonist. In some embodiments, the agonist may be a polypeptide. In some embodiments, the agonist may be a polynucleotide, a nucleoside, an amino acid, a sugar, a carbohydrate, a lipid, or any combination thereof. In some embodiments, the agonist may be a chemical.

[0139] The term “variant,” as used herein, refers to a polypeptide that has a substantially identical amino acid sequence to a reference amino acid sequence, or is encoded by a substantially identical nucleotide sequence. In some embodiments, the variant is a functional variant. In some embodiments, an amylin analog variant can bind to the amylin receptor and activate the amylin receptor signaling.

[0140] The term “functional variant,” as used herein, refers to a polypeptide that has a substantially identical amino acid sequence to a reference amino acid sequence, or is encoded by a substantially identical nucleotide sequence, and is capable of having one or more activities of the reference amino acid sequence.

[0141] The term “functional fragment,” as used herein, refers to a polypeptide that has a partial amino acid sequence of a reference amino acid sequence, and is capable of having one or more activities of the reference amino acid sequence. In some embodiments, the functional fragment comprises at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% amino acid sequence of a reference amino acid sequence. In some embodiments, the functional fragment comprises an amino acid sequence that has at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acid deletion from the reference amino acid sequence. In some embodiments, the functional fragment comprises an amino acid sequence that has at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,WSGR Docket No.: 56017-733.601 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 350, 400, 450, or 500 amino acids of the reference amino acid sequence.

[0142] It is understood that the polypeptide as described herein may have additional conservative or non-essential amino acid substitutions, which do not have a substantial effect on their functions.

[0143] The term “amino acid,” as used herein, is intended to embrace all molecules, whether natural or synthetic, which include both an amino functionality and an acid functionality and capable of being included in a polymer of naturally-occurring amino acids. Exemplary amino acids include naturally-occurring amino acids; analogs, derivatives and congeners thereof; amino acid analogs having variant side chains; and all stereoisomers of any of any of the foregoing. As used herein the term “amino acid” includes both the D- or L- optical isomers and peptidomimetics.

[0144] A “conservative amino acid substitution,” as used herein, is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

[0145] As used herein, the term “molecule” as used in, e.g., agonist molecule, polypeptide molecule, or receptor molecule, includes full-length, naturally-occurring molecules, as well as variants, e.g., functional variants (e.g., truncations, fragments, mutated (e.g., substantially similar sequences) or derivatized form thereof), so long as at least one function and / or activity of the unmodified (e.g., naturally-occurring) molecule remains.

[0146] The term “salt” and “salt form” as used interchangeably herein, refer to a compound comprising an ionic assembly of positively charged cationic components (also known as positive ions and cations) and negatively charged anionic components (also known as negative ions and anions). In some embodiments, the salt is a neutral compound with no net electric charge. In some embodiments, the cationic components and the anionic components are held together by electrostatic forces termed ionic bonds.

[0147] The term “amylin analog,” as used herein, refers to an analog of human amylin, a 37- residue polypeptide hormone, is co-secreted with insulin from the pancreatic β-cells. Loss of β- cell function that occurs early in type 1 diabetics and can occur late in type 2 diabetics leads to deficiencies in the secretion of insulin and amylin. Amylin is believed to play a role in glycemicWSGR Docket No.: 56017-733.601 regulation by slowing gastric emptying and promoting satiety, thereby preventing post-prandial spikes in blood glucose levels. The overall effect is to slow the rate of appearance of glucose in the blood after eating. As referred to herein, an amylin analog includes any of the recombinant or naturally-occurring forms of human amylin or variants or homologs thereof that have or maintain the amylin receptor activity (e.g., at least 40% 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity). In some aspects, the variants or homologs have at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%.97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g., a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring human amylin.

[0148] Amylin's amino acid sequence is most closely related to that of calcitonin gene-related peptide (CGRP). CGRP also shares a similarly positioned disulfide bond and an amidated C- terminus. This is also the case for calcitonin, adrenomedullin, and adrenomedullin 2. Together, these peptides form a small family, united by these characteristic features. Consequently, there is a degree of overlap in binding the cognate receptors for each peptide and pharmacological activity. The table of FIG. 1 illustrates comparative sequence alignments for amylin and certain related reference polypeptides.

[0149] The peptides typically designated as calcitonin (CT) peptide family members include; calcitonin gene-related peptide (CGRP), calcitonin (CT), amylin (AMY), adrenomedullin 1, and adrenomedullin 2 / intermedin (ADM1, ADM2 respectively). Two G protein-coupled receptor proteins (calcitonin receptor; CTR, and calcitonin-receptor-like receptor; CALCRL) and three receptor activity-modifying proteins, (RAMP1, RAMP2, RAMP3) make up the pharmacologically distinct receptors for the entire peptide family (CTR, AMY1, AMY2, AMY3, CGRPR, AM1, AM2). There appear to be at least five distinct receptors to which amylin binds with significant affinity (AMY1, AMY2, AMY3, CTR, CGRPR). CTR dimerizes with RAMPs 1, 2, or 3 to reconstitute the AMY1, AMY2, or AMY3 receptors with pharmacology selective for amylin over calcitonin. In the absence of a RAMP, CTR pharmacology becomes calcitonin selective versus amylin. CALCRL dimerized with RAMP1 generates CGRPR with high affinity for CGRP and reduced affinities for all other peptide family members including amylin. CALCRL and RAMP2, or RAMP3, reconstitute the pharmacology of AM1, and AM2 respectively with very low to no affinity for amylin.

[0150] In some embodiments, the amylin analog may be an endogenous agonist. In some embodiments, the amylin analog may be an exogenous agonist. In some embodiments, the amylin analog may be a polypeptide. In some embodiments, the amylin analog may be a polynucleotide, a nucleoside, an amino acid, a sugar, a carbohydrate, a lipid, or any combination thereof. In someWSGR Docket No.: 56017-733.601 embodiments, the amylin analog may be a small molecule. Compounds and Salts

[0151] Compounds and salts of the present invention include those described generally herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March’s Advanced Organic Chemistry”, 5thEd., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.

[0152] The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as "carbocycle," “cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, “cycloaliphatic” (or “carbocycle” or “cycloalkyl”) refers to a monocyclic C3-C6hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

[0153] The term “lower alkyl” refers to a C1-4 straight or branched alkyl group. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.

[0154] The term “lower haloalkyl” refers to a C1-4straight or branched alkyl group that is substituted with one or more halogen atoms.

[0155] The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR+(as in N-substituted pyrrolidinyl)).WSGR Docket No.: 56017-733.601

[0156] The term "unsaturated," as used herein, means that a moiety has one or more units of unsaturation.

[0157] As used herein, the term “bivalent C1-8(or C1-6) saturated or unsaturated, straight or branched, hydrocarbon chain”, refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.

[0158] As used herein, the term “cyclopropylenyl” refers to a bivalent cyclopropyl group of thefollowing structure: .

[0159] The term “halogen” means F, Cl, Br, or I.

[0160] The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term “aryl” may be used interchangeably with the term “aryl ring.” In certain embodiments of the present invention, “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. Also included within the scope of the term “aryl,” as it is used herein, is a group in which an aromatic ring is fused to one or more non–aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.

[0161] The terms “heteroaryl” and “heteroar–,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 ^ electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms “heteroaryl” and “heteroar–”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H–quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3–b]–1,4–oxazin–3(4H)–one. A heteroaryl group may be mono– or bicyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that areWSGR Docket No.: 56017-733.601 optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.

[0162] As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5– to 7–membered monocyclic or 7–10–membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0–3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4– dihydro–2H–pyrrolyl), NH (as in pyrrolidinyl), or+NR (as in N–substituted pyrrolidinyl).

[0163] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms “heterocycle,” “heterocyclyl,” “heterocyclyl ring,” “heterocyclic group,” “heterocyclic moiety,” and “heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H–indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl. A heterocyclyl group may be mono– or bicyclic. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.

[0164] As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.

[0165] As described herein, compounds of the invention may contain “optionally substituted” moieties. In general, the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable,” as used herein, refers to compounds that areWSGR Docket No.: 56017-733.601 not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

[0166] Suitable monovalent substituents on a substitutable carbon atom of an “optionally substituted” group are independently halogen; –(CH2)0–4R^; –(CH2)0–4OR^; -O(CH2)0-4Ro, –O– (CH2)0–4C(O)OR°; –(CH2)0–4CH(OR^)2; –(CH2)0–4SR^; –(CH2)0–4Ph, which may be substituted with R°; –(CH2)0–4O(CH2)0–1Ph which may be substituted with R°; –CH=CHPh, which may be substituted with R°; –(CH2)0–4O(CH2)0–1-pyridyl which may be substituted with R°; –NO2; –CN; –N3; -(CH2)0–4N(R^)2; –(CH2)0–4N(R^)C(O)R^; –N(R^)C(S)R^; –(CH2)0–4N(R^)C(O)NR^2; -N(R^)C(S)NR^2; –(CH2)0–4N(R^)C(O)OR^; – N(R^)N(R^)C(O)R^; -N(R^)N(R^)C(O)NR^2; -N(R^)N(R^)C(O)OR^; –(CH2)0–4C(O)R^; – C(S)R^; –(CH2)0–4C(O)OR^; –(CH2)0–4C(O)SR^; -(CH2)0–4C(O)OSiR^3; –(CH2)0–4OC(O)R^; – OC(O)(CH2)0–4SR–, SC(S)SR°; –(CH2)0–4SC(O)R^; –(CH2)0–4C(O)NR^2; –C(S)NR^2; –C(S)SR°; –SC(S)SR°, -(CH2)0–4OC(O)NR^2; -C(O)N(OR^)R^; –C(O)C(O)R^; –C(O)CH2C(O)R^; – C(NOR^)R^; -(CH2)0–4SSR^; –(CH2)0–4S(O)2R^; –(CH2)0–4S(O)2OR^; –(CH2)0–4OS(O)2R^; – S(O)2NR^2; -(CH2)0–4S(O)R^; -N(R^)S(O)2NR^2; –N(R^)S(O)2R^; –N(OR^)R^; –C(NH)NR^2; – P(O)2R^; -P(O)R^2; -OP(O)R^2; –OP(O)(OR^)2; SiR^3; –(C1–4 straight or branched alkylene)O– N(R^)2; or –(C1–4 straight or branched alkylene)C(O)O–N(R^)2, wherein each R^ may be substituted as defined below and is independently hydrogen, C1–6 aliphatic, –CH2Ph, –O(CH2)0–1Ph, -CH2-(5-6 membered heteroaryl ring), or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R^, taken together with their intervening atom(s), form a 3–12–membered saturated, partially unsaturated, or aryl mono– or bicyclic ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.

[0167] Suitable monovalent substituents on R^ (or the ring formed by taking two independent occurrences of R^ together with their intervening atoms), are independently halogen, –(CH2)0– 2R^, –(haloR^), –(CH2)0–2OH, –(CH2)0–2OR^, –(CH2)0–2CH(OR^)2; -O(haloR^), –CN, –N3, – (CH2)0–2C(O)R^, –(CH2)0–2C(O)OH, –(CH2)0–2C(O)OR^, –(CH2)0–2SR^, –(CH2)0–2SH, –(CH2)0–2NH2, –(CH2)0–2NHR^, –(CH2)0–2NR^ 2, –NO2, –SiR^ 3, –OSiR^ 3, -C(O)SR^ , –(C1–4straight or branched alkylene)C(O)OR^, or –SSR^wherein each R^is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently selected from C1–4 aliphatic, –CH2Ph, –O(CH2)0–1Ph, or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalentWSGR Docket No.: 56017-733.601 substituents on a saturated carbon atom of R^ include =O and =S.

[0168] Suitable divalent substituents on a saturated carbon atom of an “optionally substituted” include the =O, =S, =NNR*2, =NNHC(O)R*, =NNHC(O)OR*, =NNHS(O)2R*,wherein each independent occurrence of R*is selected from hydrogen, C1–6 aliphatic which may be substituted as defined below, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an “optionally substituted” group include: –O(CR*2)2–3O–, wherein each independent occurrence of R*is selected from hydrogen, C1–6 aliphatic which may be substituted as defined below, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0169] Suitable substituents on the aliphatic group of R*include halogen, –R^, -(haloR^), -OH, –OR^, –O(haloR^), –CN, –C(O)OH, –C(O)OR^, –NH2, –NHR^, –NR^2, or –NO2, wherein each R^is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C1–4 aliphatic, –CH2Ph, –O(CH2)0–1Ph, or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0170] Suitable substituents on a substitutable nitrogen of an “optionally substituted” group include – C(O)wherein each R†is independently hydrogen, C1–6 aliphatic which may be substituted as defined below, unsubstituted –OPh, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R†, taken together with their intervening atom(s) form an unsubstituted 3–12–membered saturated, partially unsaturated, or aryl mono– or bicyclic ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0171] Suitable substituents on the aliphatic group of R†are independently halogen, – R^, -(haloR^), –OH, –OR^, –O(haloR^), –CN, –C(O)OH, –C(O)OR^, –NH2, –NHR^, –NR^2, or -NO2, wherein each R^is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C1–4 aliphatic, –CH2Ph, –O(CH2)0–1Ph, or a 5–6– membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.WSGR Docket No.: 56017-733.601 Compound Derivatives From Cagrilintide

[0172] Disclosed herein, in some embodiments, are compounds comprising certain ionic salt forms (i.e., pharmaceutically acceptable salts) of cagrilintide, having improved qualities, including enhanced stability and improved solubility in an aqueous environment, relative to the free acid form of cagrilintide. Also disclosed are other derivatives of cagrilintide.

[0173] As used herein, the terms “salt,” “salt form,” “ionic salt form” and “pharmaceutically acceptable salt,” as used herein, refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1–19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds as provided herein include those derived from suitable inorganic and organic acids and bases. Further pharmaceutically acceptable salts are discussed, for example, by P. Stahl et al., Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al., Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33201-217; Anderson et al., The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference.

[0174] In certain embodiments, the compound, or pharmaceutically acceptable salt thereof, is a prodrug. As used herein, the term "prodrug" refers to compounds that are transformed in vivo to yield a disclosed compound or a pharmaceutically acceptable form of the compound. A prodrug is converted in vivo to an active compound, for example, by hydrolysis (e.g., hydrolysis in blood). In certain cases, a prodrug has improved physical and / or delivery properties over the parent compound. Prodrugs are typically designed to enhance pharmaceutically and / or pharmacokinetically based properties associated with the parent compound. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam). A discussion of prodrugs is provided in Higuchi, T., et al., "Pro-drugs as Novel Delivery Systems," A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987. Exemplary advantages of a prodrug can include, but are not limited to, its physical properties, such as enhanced water solubility for parenteral administration at physiological pH compared to the parent compound, or it enhances absorption from the digestive tract, or it canWSGR Docket No.: 56017-733.601 enhance drug stability for long-term storage.

[0175] The term "prodrug" is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a subject. Prodrugs of an active compound, as described herein, can be prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound. Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of an alcohol or acetamide, formamide and benzamide derivatives of an amine functional group in the active compound and the like.

[0176] In an aspect, provided herein is, inter alia, a compound comprising the structure of Formula I: Formula I, wherein:anion of cagrilintide; and is a cationic component.

[0177] In another aspect, provided herein is, inter alia, a compound comprising an ionic salt form of cagrilintide having the structure of Formula I: wherein:anion of cagrilintide; and wherein one or more carboxyl groups of the C20 diacid, ^-Glu linker, Glu residues, and / or Asp residues of cagrilintide are in the form of ; and is a catanionic component.

[0178] As used herein, the term “C20 diacid” refers to fatty acid side chain of cagrilintide havingWSGR Docket No.: 56017-733.601 the structure –CO(CH2)18CO2. As used herein, the term “^-Glu linker” refers to the bivalent linker moiety of cagrilintide having the structure –CO(CH2)2CH(CO2)NH-.In some embodiments, does not have the structure of , wherein R8, R9, and R10are independently C1-C5alkyl, and R11is C2-C5alkyl that is unsubstituted or substituted with oneor more hydroxyl. In some embodiments, is not choline.

[0179] In some embodiments, provided herein is a compound consisting, or consisting essentially, of the structure of Formula I.

[0180] As used herein, “an anion of cagrilintide,” having the structure , is meant to encompass from one (1) to three (3) carboxylate anions of cagrilintide corresponding to at least one carboxylate anion and up to seven carboxylate anions, the total number of carboxylic acid moieties on the cagrilintide peptide. In some embodiments, the anion of cagrilintide, , has from one (1) to three (3) anions of cagrilintide, as represented by Formula Ia1:Formula Ia1.

[0181] In some embodiments, the anion of cagrilintide, is one anion of cagrilintide, as represented by Formula Ia1-1:Formula Ia1-1.

[0182] In some embodiments, the anion of cagrilintide, is two anions of cagrilintide, as represented by Formula Ia1-2:WSGR Docket No.: 56017-733.601 Formula Ia1-2.

[0183] In some embodiments, the anion of cagrilintide, is three anions of cagrilintide, as represented by Formula Ia1-3: Formula Ia1-3.

[0184] Accordingly, a “cationic component,” having the structure is meant to encompass from about one (1) to three (3) cations corresponding to at least one cation and up to three cations, provided as counterion(s) to the total potential number of carboxylate moieties on the cagrilintide peptide. In some embodiments, the cationic component has from about one (1) to three (3) cations. In some embodiments, the cationic component is one cation, corresponding to a molar ratio of cagrilintide anion to cationic component of about 1:1. In some embodiments, the cationic component is two cations, corresponding to a molar ratio of cagrilintide anion to cationic component of about 1:2. In some embodiments, the cationic component is three cations, corresponding to a molar ratio of cagrilintide anion to cationic component of about 1:3.

[0185] In an aspect, provided herein is a compound comprising the structure of Formula Ia2:Formula Ia2, wherein:is from one to three anions of cagrilintide; and is a cationic component.

[0186] In some embodiments, the compound of Formula 1a2 is a compound having the structure of:Formula Ia2-1.

[0187] In some embodiments, the compound of Formula 1a2 is a compound having the structureWSGR Docket No.: 56017-733.601 of:Formula Ia2-2.

[0188] In some embodiments, the compound of Formula 1a2 is a compound having the structure of:Formula Ia2-3.

[0189] In some embodiments, the cationic component of R2derives from appropriate bases and is selected from the group consisting of alkali metal, alkaline earth metal, a metal ion such as aluminum, sodium, lithium, potassium, magnesium, calcium, and zinc, ammonium (NH4+), a protonated or positively (+) charged ion from an aliphatic primary amine, secondary amine or tertiary amine such as 2-aminoethanol, tromethamine, dimethylamine, diethylamine, N-ethyl- glucamine, hydrabamine, trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, (2,2′,2″-nitrilotris(ethanol)), 2- diethylaminoethanol, procaine or substituted procaine (e.g., chloroprocaine), meglumine, carnitine, ethylenediamine, choline, acetylcholine, aralkyl amine such as Ν,Ν- dibenzylethylenediamine, benzathine, benethamine; heterocyclic aromatic amine such as pyridine, pyrimidine, picoline, quinoline or isoquinoline, quaternary ammonium (e.g., NH4+) such as betaine, nontoxic quaternary ammonium (e.g., NMe4+, N+(C1–4alkyl)4,), tetramethylammonium, tetraethylammonium, benzyltrimethylammonium, benzyltriethylammonium, benzyltributylammonium, methyltrioctylammonium or tetrabutylammonium; 1H-imidazole, substituted-imidazole (e.g., N-alkyl imidazole, N-methyl imidazole), pyrrolidine, substituted pyrrolidine (e.g., 1-alkyl pyrrolidine, 1-methyl pyrrolidine, 1- (2-hydroxy-ethyl)-pyrrolidine), piperidine or substituted piperidine (e.g., 1-alkyl piperidine, 1- methyl piperidine), piperazine or substituted piperazine (e.g., 1-alkyl piperazine, 1-methyl piperazine, 1,4-dialkyl piperazine, 1,4-dimethyl piperazine), morpholine, substituted morpholine (e.g., N-substituted morpholine, N-methyl morpholine or 4-(2-hydroxyethyl)-morpholine), basic amino acid such as arginine, lysine, or histidine. aminoguanidine, guanidine derivatives and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate. In some embodiments, the cationic component of R2is not choline. In some embodiments, the cationic component is betaine. In some embodiments,WSGR Docket No.: 56017-733.601 the cationic component comprises the structure of: . In some embodiments, thecationic component has the structure of: .

[0190] As used herein, the term “betaine” (alternatively known as “glycine betaine”) refers to a compound having a central methylene carbon (-CH2-) attached to an anionic carboxylate group - (CO2-) on one side and a positively charged cationic quaternary ammonium group -(N(CH3)3+) on the other, where the compound acts as a zwitterion having both positive and negative charges within the same molecule, as shown below.betaine

[0191] In some embodiments, the cationic component and anion of cagrilintide are provided in a molar ratio of anion of cagrilintide to cationic component that is selected from the group consisting of about 1:1, 1:2 and 1:3, or any ratio between any two of these values. In some embodiments, the cationic component and anion of cagrilintide are provided in a molar ratio of anion of cagrilintide to cationic component that is from about 1:1 to about 1:3, In some embodiments, the cationic component and anion of cagrilintide are provided in a molar ratio of anion of cagrilintide to cationic component that is from about 1:2 to about 1:3, In some embodiments, the cationic component is selected from the group of cationic components described herein or listed in the preceding paragraphs, further provided in a molar ratio of anion of cagrilintide to cationic component that is selected from the group consisting of about 1:1, 1:2 and 1:3, or any ratio between any two of these values. In some embodiments, the cationic component is selected from the group of cationic components described herein or listed in the preceding paragraphs, further provided in a molar ratio of anion of cagrilintide to cationic component that is from about 1:1 to about 1:3. In some embodiments, the cationic component is selected from the group of cationic components described herein or listed in the preceding paragraphs, further provided in a molar ratio of anion of cagrilintide to cationic component that is from about 1:2 to about 1:3. In some embodiments, the cationic component is selected from the group of cationic components listed in Table 3. In some embodiments, the cationic component is selected from the group of cationic components listed in Table 3, further provided in a molar ratio of anion of cagrilintide to cationic component that is selected from the group consisting of about 1:1, 1:2 and 1:3, or any ratio between any two of these values. In some embodiments, the cationic componentWSGR Docket No.: 56017-733.601 is selected from the group of cationic components listed in Table 3, further provided in a molar ratio of anion of cagrilintide to cationic component that is from about 1:1 to about 1:3. In some embodiments, the cationic component is selected from the group of cationic components listed in Table 3, further provided in a molar ratio of anion of cagrilintide to cationic component that is from about 1:2 to about 1:3. In some embodiments, the cationic component is selected from the group of cationic components listed in Table 3, further provided in a weight % (wt. %) ratio relative to the anion of cagrilintide as listed in Table 3.

[0192] In some embodiments, the cationic component and anion of cagrilintide are provided in a molar ratio of anion of cagrilintide to cationic component that is from about 1:1 to about 1:2. In some embodiments, the cationic component and anion of cagrilintide are provided in a molar ratio of anion of cagrilintide to cationic component that is about 1:1. In some embodiments, the cationic component and anion of cagrilintide are provided in a molar ratio of anion of cagrilintide to cationic component that is about 1:2. In some embodiments, the cationic component and anion of cagrilintide are provided in a molar ratio of anion of cagrilintide to cationic component that is about 1:3. In some embodiments, the cationic component is selected from the group of cationic components described herein or listed in the preceding paragraphs, further provided in a molar ratio of anion of cagrilintide to cationic component that is from about 1:1 to about 1:2. In some embodiments, the cationic component is selected from the group of cationic components described herein or listed in the preceding paragraphs, further provided in a molar ratio of anion of cagrilintide to cationic component that is about 1:1. In some embodiments, the cationic component is selected from the group of cationic components described herein or listed in the preceding paragraphs, further provided in a molar ratio of anion of cagrilintide to cationic component that is about 1:2. In some embodiments, the cationic component is selected from the group of cationic components described herein or listed in the preceding paragraphs, further provided in a molar ratio of anion of cagrilintide to cationic component that is about 1:3. In some embodiments, the cationic component is selected from the group of cationic components listed in Table 3, further provided in a molar ratio of anion of cagrilintide to cationic component that is from about 1:1 to about 1:2. In some embodiments, the cationic component is selected from the group of cationic components listed in Table 3, further provided in a molar ratio of anion of cagrilintide to cationic component that is about 1:1. In some embodiments, the cationic component is selected from the group of cationic components listed in Table 3, further provided in a molar ratio of anion of cagrilintide to cationic component that is about 1:2. In some embodiments, the cationic component is selected from the group of cationic components listed in Table 3, further provided in a molar ratio of anion of cagrilintide to cationic component that is about 1:3.

[0193] In some embodiments, anion of cagrilintide and betaine are provided in a molar ratio ofWSGR Docket No.: 56017-733.601 anion of cagrilintide to betaine that is from about 1:1 to about 1:2. In some embodiments, the anion of cagrilintide and betaine are provided in a molar ratio of anion of cagrilintide to betaine that is about 1:1. In some embodiments, the anion of cagrilintide and betaine are provided in a molar ratio of anion of cagrilintide to betaine that is about 1:2. In some embodiments, the anion of cagrilintide and betaine are provided in a molar ratio of anion of cagrilintide to betaine that is about 1:3.

[0194] In some embodiments, representative alkali or alkaline earth metal salts include, but are not limited to, aluminum, sodium, lithium, potassium, calcium, magnesium, zinc and the like.

[0195] In some embodiments, N(C1–4alkyl)4+), includes tetramethyl ammonium, tetraethyl ammonium, acetylcholine, tetrapropyl ammonium and tetrabutyl ammonium.

[0196] In some embodiments, the quaternary ammonium has the structure of wherein: R8, R9, R10, and R11are each independently a substituted or unsubstituted group selected from C1-6aliphatic, phenyl, cycloalkyl, 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0197] In some embodiments, the quaternary ammonium has the structure of wherein: three of R8, R9, R10, and R11are each independently a substituted or unsubstituted C1-6 aliphatic, and one of R8, R9, R10, and R11is substituted or unsubstituted phenyl, cycloalkyl, 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0198] In some embodiments, the quaternary ammonium has the structure of wherein: two of R8, R9, R10, and R11are each independently a substituted or unsubstituted C1-6 aliphatic, and two of R8, R9, R10, and R11is each independently substituted or unsubstituted phenyl, cycloalkyl, 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 memberedWSGR Docket No.: 56017-733.601 monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0199] In some embodiments, the quaternary ammonium has the structurewherein: one of R8, R9, R10, and R11is a substituted or unsubstituted C1-6 aliphatic, and three of R8, R9, R10, and R11is each independently substituted or unsubstituted phenyl, cycloalkyl, 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0200] In some embodiments, the quaternary ammonium has the structure of wherein: R8, R9, R10, and R11are each independently a substituted or unsubstituted C1-6aliphatic.

[0201] In some embodiments, the quaternary ammonium has the structure of wherein: (i) R8, R9, R10, and R1are independently substituted or unsubstituted C1-C6alkyl; (ii) R8, R9, R10, and R11are independently C1-C4alkyl (N(C1–4alkyl)4+); (iii) R8, R9, and R10are C2 alkyl , and R11is C1 alkyl; (iv) R8, R9, and R10are C4 alkyl, and R11is C1 alkyl; (v) all of R8, R9, R10, and R11are C1alkyl (NMe4+); (vi) all of R8, R9, R10, and R11are C2alkyl; (vii) all of R8, R9, R10, and R11are C3 alkyl; or (viii) all of R8, R9, R10, and R11are C4alkyl.

[0202] In some embodiments, the quaternary ammonium has the structure of , wherein R8, R9, R10, and R11are each independently substituted or unsubstituted C1-C20alkyl or an aryl.

[0203] In some embodiments, the cationic component is a quaternary ammonium, with theWSGR Docket No.: 56017-733.601 proviso that the cationic component does not have the structure of , wherein R8, R9, and R10are independently C1-C5 alkyl, and R11is C2-C5 alkyl that is unsubstituted or substituted with 1 or more hydroxyl. In some embodiments, the cationic component is a quaternary ammonium comprising substituted or unsubstituted C6-C20alkyl or an aryl.

[0204] In some embodiments, the cationic component is a quaternary ammonium, wherein the anion of cagrilintide and quaternary ammonium are provided in a molar ratio of anion of cagrilintide to quaternary ammonium that is selected from the group consisting of about 1:1, 1:2 and 1:3, or any ratio between any two of these values. In some embodiments, the cationic component is a quaternary ammonium having the structure, wherein the anion of cagrilintide and quaternary ammonium having the structure of are provided in a molar ratio of anion of cagrilintide to quaternary ammonium having the structure of that is selected from the group consisting of about 1:1, 1:2 and 1:3, or any ratio between any two of these values. In some embodiments, the cationic component is a quaternary ammonium having the structure of , wherein the anion of cagrilintide and quaternary ammonium havingthe structure of are provided in a molar ratio of anion of cagrilintide to quaternary ammonium having the structure of that is from about 1:1 to about 1:3. In some embodiments, the cationic component is a quaternary ammonium having the structure of , wherein the anion of cagrilintide and quaternary ammonium having the structure of are provided in a molar ratio of anion of cagrilintide to quaternary ammonium havingWSGR Docket No.: 56017-733.601 the structure of that is from about 1:1 to about 1:2. In some embodiments, the cationic component is a quaternary ammonium having the structure of , wherein the anion ofcagrilintide and quaternary ammonium having the structure of are provided in a molar ratio of anion of cagrilintide to quaternary ammonium having the structure of that is from about 1:2 to about 1:3. In some embodiments, the cationic component is a quaternaryammonium having the structure of , wherein the anion of cagrilintide and quaternary ammonium having the structure of are provided in a molar ratio of anion of cagrilintide to quaternary ammonium having the structure of that is about 1:1. Insome embodiments, the cationic component having the structure of is a quaternary ammonium having the structure of , wherein the anion of cagrilintide and quaternary ammonium having the structure of are provided in a molar ratio of anion of cagrilintide to quaternary ammonium having the structure of that is about 1:2. In some embodiments, the cationic component is a quaternary ammonium having the structure of , wherein the anion of cagrilintide and quaternary ammonium having the structure ofWSGR Docket No.: 56017-733.601 are provided in a molar ratio of anion of cagrilintide to quaternary ammonium having the structure of that is about 1:3.

[0205] In some embodiments, the quaternary ammonium has the structure of, wherein: R15, R16, R17are each independently a substituted or unsubstituted group selected from C1-6 aliphatic, phenyl, cycloalkyl, 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R18, R19, R20, and R21are each independently hydrogen, halogen, substituted or unsubstituted C1-6 aliphatic; and R22is hydrogen, or substituted or unsubstituted group selected from -C(O)-C1-6 aliphatic, C1-6 aliphatic, phenyl, cycloalkyl, 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0206] In some embodiments, R22is selected from the group consisting of -C(O)CH3, -C(O)CF3, -C(O)CH2F, -C(O)CHF2, -CH3, -CF3, -CH2F, -CHF2, -CH2CH3, and -CH2CH2CH3, and CH(CH3)2

[0207] In some embodiments, the quaternary ammonium has the structure of, wherein R15, R16, R17are each independently a substituted or unsubstituted group selected from C1-6 aliphatic, phenyl, cycloalkyl, 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;WSGR Docket No.: 56017-733.601 R18, R19, R20, and R21are each independently hydrogen, halogen, substituted or unsubstituted C1-6aliphatic; and R23is hydrogen, or substituted or unsubstituted group selected from C1-6aliphatic, phenyl, cycloalkyl, 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0208] In some embodiments, R23is selected from the group consisting of -CH3, -CF3, -CH2F, and -CHF2.

[0209] In some embodiments, the cationic component is a quaternary ammonium having the structure, wherein the anion of cagrilintideand quaternary ammonium having the structure of orare provided in a molar ratio of anion of cagrilintide to quaternary ammonium having the structurethat is selected from the group consisting of about 1:1, 1:2 and 1:3, or any ratio between any two of these values. In some embodiments, the cationic component is a quaternary ammonium having the structure, wherein the anion of cagrilintideand quaternary ammonium having the structure of or are provided in a molar ratio of anion of cagrilintide to quaternaryWSGR Docket No.: 56017-733.601 ammonium having the structurethat is from about 1:1 to about 1:3. In some embodiments, the cationic component is a quaternary ammonium having the structure, wherein the anion of cagrilintide and quaternary ammonium having the structure ofare provided in a molar ratio of anion of cagrilintide to quaternary ammonium having the structurethat is from about 1:1 to about 1:2. In some embodiments, the cationic component is a quaternary ammonium having the structure, wherein the anion of cagrilintide and quaternary ammonium having the structureprovided in a molar ratio of anion of cagrilintide to quaternary ammonium having the structurethat is from about 1:2 to about 1:3. In some embodiments, the cationic component is a quaternary ammoniumWSGR Docket No.: 56017-733.601 having the structure, wherein the anion of cagrilintide and quaternary ammonium having the structureare provided in a molar ratio of anion of cagrilintide to quaternary ammonium having the structurethat is about 1:1. In some embodiments, the cationic component is a quaternary ammonium having the structure, wherein the anion of cagrilintideand quaternary ammonium having the structure of orare provided in a molar ratio of anion of cagrilintide to quaternary ammonium having the structurethat is about 1:2. In some embodiments, the cationic component is a quaternary ammonium having the structure, wherein the anion of cagrilintideand quaternary ammonium having the structure of orWSGR Docket No.: 56017-733.601are provided in a molar ratio of anion of cagrilintide to quaternary ammonium having the structurethat is about 1:3.

[0210] In some embodiments, the quaternary ammonium has the structure selected from the ,.

[0211] In some embodiments, the quaternary ammonium has the structure of.

[0212] In some embodiments, the cationic component is a quaternary ammonium having the ,, and quaternary ammonium are provided in a molar ratio of anion of cagrilintide to quaternaryammonium having the structure of , ,, that is selected from the group consisting of about 1:1, 1:2 and 1:3, or any ratio between any two of these values. In some embodiments, In some embodiments, the cationic component is a quaternary ammonium having the structure, ,WSGR Docket No.: 56017-733.601, wherein the anion of cagrilintide and quaternary ammonium are provided in a molar ratio of anion of cagrilintide to quaternaryammonium having the structure of , ,, that is from about 1:1 to about 1:3. In some embodiments, the cationic component is a quaternary ammonium having the structure, , ,wherein the anion of cagrilintide and quaternary ammonium are provided in a molar ratio of anion of cagrilintide to quaternary ammonium having the structure of, , , orthat is from about 1:1 to about 1:2. In some embodiments, the cationic component is a quaternary ammonium having the structure of, , , orwherein the anion of cagrilintide and quaternary ammonium are provided in a molar ratio of anion of cagrilintide to quaternary ammonium having the structure of, , ,that is from about 1:2 to about 1:3. In some embodiments, the cationic component is a quaternary ammonium having the structure ofWSGR Docket No.: 56017-733.601, , ,wherein the anion of cagrilintide and quaternary ammonium are provided in a molar ratio of anion of cagrilintide to quaternary ammonium having the structure of, , , orthat is about 1:1. In some embodiments, the cationic component isa quaternary ammonium having the structure of ,, , wherein the anion of cagrilintide and quaternary ammonium are provided in a molar ratio of anionof cagrilintide to quaternary ammonium having the structure of ,, , that is about 1:2. In some embodiments, the cationic component is a quaternary ammonium having ,, and quaternary ammonium are provided in a molar ratio of anion of cagrilintide to quaternaryammonium having the structure of , ,, that is about 1:3.WSGR Docket No.: 56017-733.601 from about 1:1 to about 1:3. In some embodiments, the cationic component is a quaternaryammonium having the structure of , ,, cagrilintide and quaternary ammonium are provided in a molar ratio of anion of cagrilintide to quaternaryammonium having the structure of , ,, 1:2. In some embodiments, the cationic component is a quaternary ammonium having the structure, , ,wherein the anion of cagrilintide and quaternary ammonium are provided in a molar ratio of anion of cagrilintide to quaternary ammonium having the structure of, , , orthat is from about 1:2 to about 1:3. In some embodiments, the cationic component is a quaternary ammonium having the structure of, , , orwherein the anion of cagrilintide and quaternary ammonium are provided in a molar ratio of anion of cagrilintide to quaternary ammonium having the structure of, , , orWSGR Docket No.: 56017-733.601that is about 1:1. In some embodiments, the cationic component isa quaternary ammonium having the structure of ,, , wherein the anion of cagrilintide and quaternary ammonium are provided in a molar ratio of anionof cagrilintide to quaternary ammonium having the structure of ,, , that is about 1:2. In some embodiments, the cationic component is a quaternary ammonium having the structure of, ,, wherein the anion of cagrilintide and quaternary ammonium are provided in a molar ratio of anion of cagrilintide to quaternaryammonium having the structure of , ,,

[0213] In some embodiments, the cationic component is choline. In some embodiments, the cationic component is acetylcholine. In some embodiments, the cationic component is choline, wherein the anion of cagrilintide and choline are provided in a molar ratio of anion of cagrilintide to choline that is selected from the group consisting of about 1:1, 1:2 and 1:3 or any ratio between any two of these values. In some embodiments, the cationic component is choline, wherein the anion of cagrilintide and choline are provided in a molar ratio of anion of cagrilintide to choline that is from about 1:1 to about 1:3. In some embodiments, the cationic component is choline, wherein the anion of cagrilintide and choline are provided in a molar ratio of anion of cagrilintideWSGR Docket No.: 56017-733.601 to choline that is from about 1:1 to about 1:2. In some embodiments, the cationic component is choline, wherein the anion of cagrilintide and choline are provided in a molar ratio of anion of cagrilintide to choline that is from about 1:2 to about 1:3. In some embodiments, the cationic component is choline, wherein the anion of cagrilintide and choline are provided in a molar ratio of anion of cagrilintide to choline that is about 1:1. In some embodiments, the cationic component is choline, wherein the anion of cagrilintide and choline are provided in a molar ratio of anion of cagrilintide to choline that is about 1:2. In some embodiments, the cationic component is choline, wherein the anion of cagrilintide and choline are provided in a molar ratio of anion of cagrilintide to choline that is about 1:3. In some embodiments, the cationic component is acetylcholine, wherein the anion of cagrilintide and acetylcholine are provided in a molar ratio of anion of cagrilintide to acetylcholine that is selected from the group consisting of about 1:1, 1:2 and 1:3, or any ratio between any two of these values. In some embodiments, the cationic component is acetylcholine, wherein the anion of cagrilintide and acetylcholine are provided in a molar ratio of anion of cagrilintide to acetylcholine that is from about 1:1 to about 1:3. In some embodiments, the cationic component is acetylcholine, wherein the anion of cagrilintide and acetylcholine are provided in a molar ratio of anion of cagrilintide to acetylcholine that is from about 1:1 to about 1:2. In some embodiments, the cationic component is acetylcholine, wherein the anion of cagrilintide and acetylcholine are provided in a molar ratio of anion of cagrilintide to acetylcholine that is from about 1:2 to about 1:3. In some embodiments, the cationic component is acetylcholine, wherein the anion of cagrilintide and acetylcholine are provided in a molar ratio of anion of cagrilintide to acetylcholine that is about 1:1. In some embodiments, the cationic component is acetylcholine, wherein the anion of cagrilintide and acetylcholine are provided in a molar ratio of anion of cagrilintide to acetylcholine that is about 1:2. In some embodiments, the cationic component is acetylcholine, wherein the anion of cagrilintide and acetylcholine are provided in a molar ratio of anion of cagrilintide to acetylcholine that is about 1:3.

[0214] In some embodiments, the cationic component excludes choline. In some embodiments, the anion of cagrilintide and the cationic component that excludes choline are provided in a molar ratio of anion of cagrilintide to the cationic component that excludes choline that is selected from the group consisting of about 1:1, 1:2 and 1:3 or any ratio between any two of these values. In some embodiments, the anion of cagrilintide and the cationic component that excludes choline are provided in a molar ratio of anion of cagrilintide to the cationic component that excludes choline that is from about 1:1 to about 1:3. In some embodiments, the anion of cagrilintide and the cationic component that excludes choline are provided in a molar ratio of anion of cagrilintide to the cationic component that excludes choline that is from about 1:1 to about 1:2. In some embodiments, the anion of cagrilintide and the cationic component that excludes choline areWSGR Docket No.: 56017-733.601 provided in a molar ratio of anion of cagrilintide to the cationic component that excludes choline that is from about 1:2 to about 1:3. In some embodiments, the anion of cagrilintide and the cationic component that excludes choline are provided in a molar ratio of anion of cagrilintide to the cationic component that excludes choline that is about 1:1. In some embodiments, the anion of cagrilintide and the cationic component that excludes choline are provided in a molar ratio of anion of cagrilintide to the cationic component that excludes choline that is about 1:2. In some embodiments, the anion of cagrilintide and the cationic component that excludes choline are provided in a molar ratio of anion of cagrilintide to the cationic component that excludes choline that is about 1:3.

[0215] In some embodiments, provided is a hydrate of the compound of Formula I. The term “hydrate”, as used herein, means a solid or a semi-solid form of a chemical compound containing water in a molecular complex. The water is generally in a stoichiometric amount with respect to the chemical compound. Exemplary hydrates include (compound of Formula I • ZH2O), wherein Z is from 1 to 50 equivalents of H2O. In some embodiments, Z is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. In some embodiments, Z is between any two of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 and 50.

[0216] In some embodiments, the cationic component is a quaternary ammonium having the structure of , wherein R8, R9, and R10are independently C1-C5 alkyl, and R11is C2- C5alkyl that is unsubstituted or substituted with 1 or more hydroxyl.

[0217] In another aspect, provided herein is a compound comprising an ionic salt form of cagrilintide having the structure of Formula IIa, Formula IIb, Formula IIc, or any combination thereof: Formula IIa,Formula IIb,WSGR Docket No.: 56017-733.601Formula IIc,wherein , , , or any combination thereof is one or more cations of cagrilintide; andanionic component.

[0218] In some embodiments, provided herein is a compound consisting, or consisting essentially, of the structure of Formula IIa, Formula IIb, Formula IIc, or any combination thereof.

[0219] As used herein, “one or more cations of cagrilintide,” having the structure ,, , or any combination thereof, is meant to encompass from one (1) to four (4) cations of cagrilintide corresponding to at least one protonated amino moiety and up to four protonated amino moieties of cagrilintide, the total number of basic amino moieties on the cagrilintide peptide. In some embodiments, the one or more cations of cagrilintide, having the, , , any combination thereof, has from one (1) to four(4) cations of cagrilintide. In some embodiments, the one or more cations of cagrilintide is one cation of cagrilintide. In some embodiments, the one or more cations of cagrilintide is two cations of cagrilintide. In some embodiments, the one or more cations of cagrilintide is three cations of cagrilintide. In some embodiments, the one or more cations of cagrilintide is four cations of cagrilintide.

[0220] Accordingly, the “anionic component,” having the structure , is meant to encompassWSGR Docket No.: 56017-733.601 from about one (1) to four (4) anions corresponding to at least one anion and up to four anions, provided as counterion(s) to the total potential number of protonated basic amino moieties on the cagrilintide peptide. In some embodiments, the anionic component of cagrilintide has from about one (1) to four (4) anions of cagrilintide. In some embodiments, the anionic component is one anion, corresponding to a molar ratio of one or more cations of cagrilintide to anionic component of about 1:1. In some embodiments, the anionic component is two anions, corresponding to a molar ratio of one or more cations of cagrilintide to anionic component of about 1:2. In some embodiments, the anionic component is three anions, corresponding to a molar ratio of one or more cations of cagrilintide to anionic component of about 1:3. In some embodiments, the anionic component is four anions, corresponding to a molar ratio of one or more cations of cagrilintide to anionic component of about 1:4.

[0221] In some embodiments, the one or more cations of cagrilintide derive from the structure of the compound in Table 2.

[0222] In some embodiments, the anionic component of R7is selected from the group consisting of besylate, mesylate, tosylate, sulfonate, sulfate, methylsulfate, camsylate, isethionate, edisylate, 1-hydroxy-2-naphthoate, 2,2-dichloroacetate, 2-hydroxyethanesulfonate, 2-oxoglutarate, 4- acetamidobenzoate, 4-aminosalicylate, acetate, adipate, ascorbate, aspartate, benzenesulfonate, benzoate, bromide, chloride, camphorate, camphor-10-sulfonate, caprate (decanoate), caproate (hexanoate), caprylate (octanoate), carbonate, cinnamate, citrate, cyclamate, dodecylsulfate, dodecylsulfurate, ethanesulfonate, ethane-1,2-disulfonate, ethanesulfonate, formate, fumarate, galactarate, gentisate, glucoheptonate, gluconate, glutantate, glucuronate, glutamate, glutarate, glycerophosphorate, glycine, glycolate, hippurate, hydrobromate, hydroiodide, hydrochlorate, isobutyrate, lactate, lactobionate, laurate, lysine, maleate, malate, malonate, mandelate, methanesulfonate , naphthalene-1,5-disulfonate, naphthalene-2-sulfonate, nicotinate, nitrate, oleate, orotate, oxalate, palmitate, pamoate, phosphorate, proprionate, pyroglutamate, salicylate, sebacate, stearate, succinate, sulfurate, tannate, tartarate, thiocyanate, toluenesulfonate, undecylenate, α-lipoate, 12-hydroxystearate, 2-(4-isobutylphenyl)propionate, 2-(4,4-dimethyl-2- pentanyl)-5,7,7-trimethyloctanoate, 2-aminoethanesulfonate, 2-hexyldecanoate, 2- hydroxyhippurate, 3-(4-hydroxyphenyl)propionate, 3-methylcrotonate, 3,3-diphenylpropionate, 3,4-dihydroxbenzoate, ,5-dihydroxybenzoate, 4-acetamido-benzoate, 3,7-dimethyloctanoate, 4- hydroxybenzenesulfonate, 4-hydroxybenzoate, 4-methylhexanoate, 4-methyloctanoate, valerate salts including 4-methylvalerate, 5-norbornene-2-carboxylate, 8-[(2- hydroxybenzoyl)amino]octanoate, abietate, acetylcysteine, aconitate, arachidonate, behenate, caffeate, chenodeoxycholate, citronellate, crotonate, galactonate, deoxycholate, dihydrocaffeate, 2-phenylpropionate (hydratropate), tropate, eicosanedioate, eicosapentanoate (EPA), elaidate,WSGR Docket No.: 56017-733.601 ellagate, erucate, ethylenediaminetetraacetate (EDTA), geranate, heptanoate, hydrocinnamate (3- phenylpropionate), isovalerate, glutathione reduced, lactate, laurate, levulinate, linoleate, linolenate, lithocholate, mesaconate, nonanoate, oxalate, coumarate, palmitate, perillate, pimelate, 3–phenylpropionate, pivalate, propionate, pyruvate, ricinoleate, salicylate, 2-hydroxybenzoate, sinapinate (3,5-dimethoxy-4-hydroxycinnamate), sorbate, syringate, tiglate, 2-decenoate, 2- hexenoate, 2-octenoate, 3-octenoate, 7-octenoate, ferulate, undecanoate, valerate, vanillate, perchlorate, alginate, bisulfate, borate, butyrate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, glycerophosphate, hemisulfate, hydroiodide, lauryl sulfate, 2– naphthalenesulfonate, pectinate, persulfate, phosphate, tartrate, o-(4-hydroxybenzoyl)benzoate, 1,2,-ethanedisulfonate, chlorobenzenesulfonate, 4-methylbicyclo[2.2.2]oct-2-ene-carboxylate, 4.4’-methylenebis(3-hydroxy-2- ene-1-carboxylate), trimethylacetate, tertiary butylacetate, lauryl sulfurate, hydroxynaphthoate, muconate, α-ketoglutarate, p-toluenesulfonate, p-coumarate, and p-chlorobenzenesulfonate. In some embodiments, the anionic component ( ) is betaine. In someembodiments, the anionic component ( ) comprises the structure of:.In someembodiments, the anionic component (.

[0223] In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component of about 1:1, 1:2, 1:3 or 1:4, or any ratio between any two of these values. In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:1 to about 1:4. In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:2 to about 1:4. In some embodiments, the anionic component is selected from the group of anionic components described herein, further provided in a molar ratio of one or more cations of cagrilintide to anionic component that is about 1:1, 1:2, 1:3 or 1:4, or any ratio between any two of these values. In some embodiments, the anionic component is selected from the group of anionic components described herein, further provided in a molar ratio of one or more cations of cagrilintide to anionic component that is from about 1:1 to about 1:4. In some embodiments, the anionic component is selected from the group of anionic components described herein, further provided in a molar ratio of one or more cations of cagrilintide to anionic component that is from about 1:2 to about 1:4. In some embodiments, the anionic component is selected from the group of cationic componentsWSGR Docket No.: 56017-733.601 listed in Table 4. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component that is about 1:1, 1:2, 1:3 or 1:4, or any ratio between any two of these values. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component that is from about 1:1 to about 1:4. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component that is from about 1:2 to about 1:4. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a weight % (wt. %) ratio relative to the one or more cations of cagrilintide as listed in Table 4.

[0224] In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:1 to about 1:4. In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:2 to about 1:4. In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:3 to about 1:4. In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:1 to about 1:3. In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:1 to about 1:2. In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:2 to about 1:4. In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:2 to about 1:3.In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:3 to about 1:4. In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component of about 1:1. In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component of about 1:2. In some embodiments, the one or more cations of cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component of about 1:3. In some embodiments, the one or more cations ofWSGR Docket No.: 56017-733.601 cagrilintide and anionic component are provided in a molar ratio of one or more cations of cagrilintide to anionic component of about 1:4.

[0225] In some embodiments, the anionic component is selected from the group of anionic components described herein, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:1 to about 1:4. In some embodiments, the anionic component is selected from the group of anionic components described herein, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:2 to about 1:4. In some embodiments, the anionic component is selected from the group of anionic components described herein, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:3 to about 1:4. In some embodiments, the anionic component is selected from the group of anionic components described herein, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:1 to about 1:3. In some embodiments, the anionic component is selected from the group of anionic components described herein, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:1 to about 1:2. In some embodiments, the anionic component is selected from the group of anionic components described herein, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:2 to about 1:4. In some embodiments, the anionic component is selected from the group of anionic components described herein, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:2 to about 1:3.In some embodiments, the anionic component is selected from the group of anionic components described herein, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:3 to about 1:4. In some embodiments, the anionic component is selected from the group of anionic components described herein, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of about 1:1. In some embodiments, the anionic component is selected from the group of anionic components described herein, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of about 1:2. In some embodiments, the anionic component is selected from the group of anionic components described herein, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of about 1:3. In some embodiments, the anionic component is selected from the group of anionic components described herein, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of about 1:4.

[0226] In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:1 to about 1:4. In some embodiments, theWSGR Docket No.: 56017-733.601 anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:2 to about 1:4. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:3 to about 1:4. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:1 to about 1:3. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:1 to about 1:2. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:2 to about 1:4. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:2 to about 1:3.In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of from about 1:3 to about 1:4. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of about 1:1. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of about 1:2. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of about 1:3. In some embodiments, the anionic component is selected from the group of anionic components listed in Table 4, further provided in a molar ratio of one or more cations of cagrilintide to anionic component of about 1:4.

[0227] In some embodiments, the one or more cations of cagrilintide and betaine are provided in a molar ratio of one or more cations of cagrilintide to betaine of from about 1:1 to about 1:4. In some embodiments, the one or more cations of cagrilintide and betaine are provided in a molar ratio of one or more cations of cagrilintide to betaine of from about 1:2 to about 1:4. In some embodiments, the one or more cations of cagrilintide and betaine are provided in a molar ratio of one or more cations of cagrilintide to betaine of from about 1:3 to about 1:4. In some embodiments, the one or more cations of cagrilintide and betaine are provided in a molar ratio of one or more cations of cagrilintide to betaine of from about 1:1 to about 1:3. In some embodiments, the one orWSGR Docket No.: 56017-733.601 more cations of cagrilintide and betaine are provided in a molar ratio of one or more cations of cagrilintide to betaine of from about 1:1 to about 1:2. In some embodiments, the one or more cations of cagrilintide and betaine are provided in a molar ratio of one or more cations of cagrilintide to betaine of from about 1:2 to about 1:4. In some embodiments, the one or more cations of cagrilintide and betaine are provided in a molar ratio of one or more cations of cagrilintide to betaine of from about 1:2 to about 1:3.In some embodiments, the one or more cations of cagrilintide and betaine are provided in a molar ratio of one or more cations of cagrilintide to betaine of from about 1:3 to about 1:4. In some embodiments, the one or more cations of cagrilintide and betaine are provided in a molar ratio of one or more cations of cagrilintide to betaine of about 1:1. In some embodiments, the one or more cations of cagrilintide and betaine are provided in a molar ratio of one or more cations of cagrilintide to betaine of about 1:2. In some embodiments, the one or more cations of cagrilintide and betaine are provided in a molar ratio of one or more cations of cagrilintide to betaine of about 1:3. In some embodiments, the one or more cations of cagrilintide and betaine are provided in a molar ratio of one or more cations of cagrilintide to betaine of about 1:4.

[0228] In some embodiments, provided is a hydrate of the compound of Formula IIa, Formula IIb, Formula IIc, or any combination thereof. Exemplary hydrates include (compound of Formula IIa, Formula IIb or Formula IIc, or any combination thereof • ZH2O), wherein Z is from 1 to 50. In some embodiments, Z is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. In some embodiments, Z is between any two of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 and 50.

[0229] In an aspect, provided herein is, inter alia, a compound comprising the structure of Formula IIIa:Formula IIIa or a pharmaceutically acceptable salt thereof; wherein:is a covalent derivative of one or more carboxyl groups of cagrilintide, or a pharmaceutically acceptable salt thereof, wherein the covalent derivative of one or more carboxyl groups are of the C20 diacid, ^-Glu linker,WSGR Docket No.: 56017-733.601 / or Asp residue of cagrilintide; and each R100is independently selected from an optionally substituted group consisting of C1-6aliphatic, (C1-22)alkyl, (C1-22)alkenyl, -C(O)R, -C(O)OR, -C(O)N(R)2, phenyl, 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and each occurrence of R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0230] In some embodiments, the compound of Formula IIIa does not have the structure ofFormula II, wherein R8, R9, and R10are independently C1-C5 alkyl.

[0231] In some embodiments, R100is substituted C1-6aliphatic, unsubstituted C1-6aliphatic, substituted (C1-22)alkyl, unsubstituted (C1-22)alkyl, substituted (C1-22)alkenyl, unsubstituted (C1- 22)alkenyl, substituted phenyl, unsubstituted phenyl, substituted -C(O)R, unsubstituted -C(O)R, substituted -C(O)OR, unsubstituted -C(O)OR, substituted -C(O)N(R)2, or unsubstituted - C(O)N(R)2.

[0232] In some embodiments, R100is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert- butyl, or pentyl. In some embodiments, R100is fluoromethyl, difluoromethyl, or trifluoromethyl. In some embodiments, R100is CHCH3OC(O)OCH2CH3.

[0233] In some embodiments, R100is -CH3, -CH2CH3, -CH(CH3)2, CH2CH2CH2CH3, C(CH3)3, -CH2CH2N(CH3)3+.

[0234] In some embodiments, R100is (C2-C12)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms,WSGR Docket No.: 56017-733.601 alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N- (alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(C1-C2)alkylamino(C2-C3)alkyl (such as β- dimethylaminoethyl), carbamoyl-(C1-C2)alkyl, N,N-di(C1-C2)alkylcarbamoyl-(C1-C2)alkyl and piperidino-, pyrrolidino- or morpholino(C2-C3)alkyl.

[0235] In some embodiments, the compound of Formula IIIa is formed from the terminal carboxyl moiety of the –CO(CH2)16CO2diacid moiety, the (^Glu) linker, and / or the side chain carboxyl moiety of one or more aspartic acid or glutamic acid residues of cagrilintide.

[0236] In some embodiments, the compound of Formula IIIa is formed from the carboxyl of the –CO(CH2)18CO2 diacid moiety of cagrilintide.

[0237] In some embodiments, the compound of Formula IIIa is formed from the carboxyl of the (^Glu) linker of cagrilintide.

[0238] In some embodiments, the compound of Formula IIIa is formed from the side chain carboxyl of one or more aspartic acid or glutamic acid residues of cagrilintide.

[0239] In some embodiments, provided herein is a compound comprising the structure of Formula IIIa1:Formula IIIa1 or a pharmaceutically acceptable salt thereof.

[0240] In some embodiments, provided herein is a compound comprising the structure of Formula III a1-1:Formula IIIa1-1 or a pharmaceutically acceptable salt thereof.

[0241] In some embodiments, provided herein is a compound comprising the structure of Formula III a1-1:WSGR Docket No.: 56017-733.601Formula IIIa1-1 or a pharmaceutically acceptable salt thereof, wherein R100is -CH3, -CH2CH3, -CH(CH3)2, CH2CH2CH2CH3, C(CH3)3, or -CH2CH2N(CH3)3+.

[0242] In some embodiments, provided herein is a compound comprising the structure of Formula IIIa1-1:Formula IIIa1-1 or a pharmaceutically acceptable salt thereof, wherein R100is -CH3, -CH2CH3, -CH(CH3)2, CH2CH2CH2CH3, C(CH3)3, or -CH2CH2N(CH3)3+, and the compound of Formula IIIa1-1- is formed from the terminal carboxyl moiety of the –CO(CH2)16CO2diacid moiety of cagrilintide.

[0243] In some embodiments, provided herein is a compound comprising the structure of Formula IIIa1-2:Formula IIIa1-2 or a pharmaceutically acceptable salt thereof.

[0244] In some embodiments, provided herein is a compound comprising the structure of Formula IIIa1-3:Formula IIIa1-3 or a pharmaceutically acceptable salt thereof.

[0245] In some embodiments, provided is a hydrate of the compound of Formula IIIa. Exemplary hydrates include (compound of Formula IIIa • ZH2O), wherein Z is from 1 to 50. In some embodiments, Z is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. In some embodiments, Z is between any two of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,, 39,WSGR Docket No.: 56017-733.601 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 and 50.

[0246] In an aspect, provided herein is, inter alia, a compound comprising the structure of Formula IIIb:Formula IIIb or a pharmaceutically acceptable salt thereof; wherein:is a covalent derivative of one or more hydroxyl groups of cagrilintide, or a pharmaceutically acceptable salt thereof; wherein one or more hydroxyl groups of the Ser residues, Thr residues, and / or Tyr residues of cagrilintide are in the form of ; and each R101is independently selected from an optionally substituted group consisting of -CH2R, - C(O)R (such as -C(O)CH3 or -C(O)H), -C(O)OR (such as -C(O)OH2), -C(O)N(R)2 (such as - C(O)NH2or -C(O)N(CH3)2), -OP(O)OROR (such as -OP(O)OHOH); and each occurrence of R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0247] In some embodiments, R101is -CH2OCH2CH2OH, unsubstituted C(O)C1-6alkyl such as COCH3, COCH2CH3, or COCH(CH3)2). In some embodiments, R101is substituted C(O)C1-6alkyl such as COCF3, COCHCF2, or -COCH2CF. In some embodiments, R101is substituted C(O)phenyl or unsubstituted C(O)phenyl. In some embodiments, R101is -(C1-C6)alkanoyloxymethyl, -1-((C1- C6)alkanoyloxy)ethyl, -1-methyl-1-((C1-C6)alkanoyloxy)ethyl, -(C1- C6)alkoxycarbonyloxymethyl, -N-(C1-C6)alkoxycarbonylaminomethyl, -succinoyl, -(C1- C6)alkanoyl, -α-amino(C1-C4)alkanoyl, -arylacyl and -α-aminoacyl, or -α-aminoacyl-α- aminoacyl, where each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)2, -P(O)(O(C1-C6)alkyl)2or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate). In some embodiments,WSGR Docket No.: 56017-733.601 R101is CHCH3OC(O)OCH2CH3.

[0248] In some embodiments, the compound of Formula IIIb is formed from the side chain hydroxyl moiety of one or more serine residues of cagrilintide.

[0249] In some embodiments, the compound of Formula IIIb is formed from the side chain hydroxyl moiety of one or more threonine residues of cagrilintide.

[0250] In some embodiments, provided herein is a compound comprising the structure of Formula IIIb1:Formula IIIb1 or a pharmaceutically acceptable salt thereof.

[0251] In some embodiments, provided herein is a compound comprising the structure of Formula IIIb1-1:Formula IIIb1-1 or a pharmaceutically acceptable salt thereof.

[0252] In some embodiments, provided herein is a compound comprising the structure of Formula IIIb1-2:Formula IIIb1-2 or a pharmaceutically acceptable salt thereof.

[0253] In some embodiments, provided herein is a compound comprising the structure of Formula IIIb1-3:Formula IIIb1-3 or a pharmaceutically acceptable salt thereof.

[0254] In some embodiments, provided herein is a compound comprising the structure of Formula IIIb1-4:WSGR Docket No.: 56017-733.601Formula IIIb1-4 or a pharmaceutically acceptable salt thereof.

[0255] In some embodiments, provided herein is a compound comprising the structure of Formula IIIb1-5:Formula IIIb1-5 or a pharmaceutically acceptable salt thereof.

[0256] In some embodiments, provided herein is a compound comprising the structure of Formula IIIb1-6:Formula IIIb1-6 or a pharmaceutically acceptable salt thereof.

[0257] In some embodiments, provided herein is a compound comprising the structure of Formula IIIb1-7:Formula IIIb1-7 or a pharmaceutically acceptable salt thereof.

[0258] In some embodiments, provided is a hydrate of the compound of the structure of Formula IIIb. Exemplary hydrates include (compound of Formula IIIb • ZH2O), wherein Z is from 1 to 50. In some embodiments, Z is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. In some embodiments, Z is between any two of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 and 50.

[0259] In an aspect, provided herein is, inter alia, a compound comprising the structure of Formula IIIc and / or Formula IIId:WSGR Docket No.: 56017-733.601,Formula IIIc Formula IIId or a pharmaceutically acceptable salt or each thereof; wherein: is a covalent derivative of one or more amino groups of cagrilintide, or a pharmaceutically acceptable salt thereof; wherein the one or more amino groups of the Arg residues and / or terminal amino group of cagrilintide are in the form;is a covalent derivative of the imidazole group of cagrilintide, or a pharmaceutically acceptable salt thereof; wherein the imidazole group of the His residue of cagrilintide is in the form of; and each R102and R103is independently selected from an optionally substituted group consisting of - CH2R, -C(O)R (such as -C(O)CH3-C(O) CH2CH3or -C(O)H), -C(O)OR (such as -C(O)OH2), - C(O)N(R)2 (such as -C(O)NH2 or -C(O)NHR), -OP(O)OROR (such as -OP(O)OHOH); and each occurrence of R is independently hydrogen or an optionally substituted group selected from C1-WSGR Docket No.: 56017-733.601 6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0260] In some embodiments, each R102and R103is independently -CH2OCH2CH2OH, unsubstituted C(O)C1-6alkyl such as COCH3, COCH2CH3, or COCH(CH3)2). In some embodiments, R102is substituted C(O)C1-6alkyl such as COCF3, COCHCF2, or -COCH2CF. In some embodiments, R102is substituted C(O)phenyl or unsubstituted C(O)phenyl. In some embodiments, R102is CHCH3OC(O)OCH2CH3.

[0261] In some embodiments, each R102and R103is independently C(O)R, C(O)OR, C(O)NR’R”, where R’ and R” are each independently (C1-C10)alkyl, (C3-C7)cycloalkyl, benzyl, or C(O)R’ is a natural α-aminoacyl or natural α-aminoacyl-natural α-aminoacyl, - C(OH)C(O)OY1wherein Y1is H, (C1-C6)alkyl or benzyl, -C(OY2)Y3wherein Y2is (C1-C4) alkyl and Y3is (C1-C6)alkyl, carboxy(C1-C6)alkyl, amino(C1-C4)alkyl or mono-N-or di-N,N-(C1- C6)alkylaminoalkyl, -C(Y4)Y5wherein Y4is H or methyl and Y5is mono-N- or di-N,N-( C1- C6)alkylamino, morpholino, piperidin-1-yl or pyrrolidin-1-yl.

[0262] In some embodiments, provided herein is a compound comprising the structure of Formula IIIc1Formula IIIc1 or a pharmaceutically acceptable salt thereof.

[0263] In some embodiments, provided herein is a compound comprising the structure of Formula IIIc1-1:Formula IIIc1-1 or a pharmaceutically acceptable salt thereof.

[0264] In some embodiments, provided herein is a compound comprising the structure ofWSGR Docket No.: 56017-733.601 Formula IIIc1-2:Formula IIIc1-2 or a pharmaceutically acceptable salt thereof.

[0265] In some embodiments, provided herein is a compound comprising the structure of Formula IIIc1-3:Formula IIIc1-3 or a pharmaceutically acceptable salt thereof.

[0266] In some embodiments, provided herein is a compound comprising the structure of Formula IIId:Formula IIId or a pharmaceutically acceptable salt thereof.

[0267] In some embodiments, provided is a hydrate of the compound of Formula IIIc and / or Formula IIId. Exemplary hydrates include (compound of Formula IIIc and / or Formula IIId • ZH2O), wherein Z is from 1 to 50. In some embodiments, Z is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. In some embodiments, Z is between any two of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 and 50.

[0268] In an aspect, provided herein is, inter alia, a compound comprising the structure of Formula IIIe:WSGR Docket No.: 56017-733.601 Formula IIIe, or a pharmaceutically acceptable salt thereof; wherein: iscovalent derivative of one or more thiol groups of cagrilintide, or a pharmaceutically acceptable salt thereof; wherein one or more thiol groups of the Cys residues of cagrilintide are in the form ofeach R104is independently selected from an optionally substituted group consisting of -CH2R, - C(O)R (such as -C(O)CH3 or -C(O)H), -C(O)OR (such as -C(O)OH2), -C(O)N(R)2 (such as - C(O)NH2or -C(O)N(CH3)2), -OP(O)OROR (such as -OP(O)OHOH); and each occurrence of R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0269] In some embodiments, the compound of Formula IIIe is formed from the side chain thiol moiety of one of the Cys residues of cagrilintide.

[0270] In some embodiments, the compound of Formula IIIe is formed from the side chain thiol moiety of both of the Cys residues of cagrilintide.

[0271] In some embodiments, R104is -CH2OCH2CH2OH, unsubstituted C(O)C1-6alkyl such as COCH3, COCH2CH3, or COCH(CH3)2). In some embodiments, R104is substituted C(O)C1-6alkyl such as COCF3, COCHCF2, or -COCH2CF. In some embodiments, R104is substituted C(O)phenyl or unsubstituted C(O)phenyl. In some embodiments, R104is -(C1-C6)alkanoyloxymethyl, -1-((C1- C6)alkanoyloxy)ethyl, -1-methyl-1-((C1-C6)alkanoyloxy)ethyl, -(C1- C6)alkoxycarbonyloxymethyl, -N-(C1-C6)alkoxycarbonylaminomethyl, -succinoyl, -(C1- C6)alkanoyl, -α-amino(C1-C4)alkanoyl, -arylacyl and -α-aminoacyl, or -α-aminoacyl-α- aminoacyl, where each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)2, -P(O)(O(C1-C6)alkyl)2or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate). In some embodiments, R104is CHCH3OC(O)OCH2CH3.WSGR Docket No.: 56017-733.601

[0272] In some embodiments, provided herein is a compound comprising the structure of Formula III e1Formula IIIe1 or a pharmaceutically acceptable salt thereof.

[0273] In some embodiments, provided herein is a compound comprising the structure of Formula IIIe1-1:Formula IIIe1-1 or a pharmaceutically acceptable salt thereof.

[0274] In some embodiments, provided herein is a compound comprising the structure of Formula IIIe1-2:Formula IIIe1-2 or a pharmaceutically acceptable salt thereof.

[0275] In some embodiments, provided is a hydrate of the compound of the structure of Formula IIIe. Exemplary hydrates include (compound of Formula IIIe • ZH2O), wherein Z is from 1 to 50. In some embodiments, Z is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. In some embodiments, Z is between any two of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 and 50. Ratios of Counterion(s) to Ionic Salt Form of Cagrilintide

[0276] In some embodiments,(i) a weight % (wt. %) ratio of : is from about 0.1 wt. %: 99.9 wt. % to about 20.0 wt. %: 80.0 wt. %; orWSGR Docket No.: 56017-733.601(ii) a weight % (wt. %) ratio of : , , , or any combination thereof is from about 0.1 wt. %: 99.9 wt. % to about 20.0 wt. %: 80.0 wt. %.

[0277] In some embodiments, (i) a molar ratio of : is from about 2:1 to about 10:1; or (ii) a molar ratio of, , , any combination thereof is from about 2:1 to about 10:1.

[0278] In some embodiments,(i) a molar ratio of : is from about 2:1 to about 7:1; or(ii) a molar ratio, , , any combination thereof is fromabout 2:1 to about 7:1.

[0279] In some embodiments, (i) a molar ratio of : is from about 3:1 to about 7:1; or(ii) a molar ratio, , , any combination thereof is fromabout 3:1 to about 7:1.

[0280] In some embodiments, (i) a molar ratio of : is from about 4:1 to about 7:1; orWSGR Docket No.: 56017-733.601 (ii) a molar ratio of, , , any combination thereof is from about 4:1 to about 7:1.

[0281] In some embodiments, (i) a molar ratio of : is from about 3:1 to about 7:1; orRatios of Counterion to Ionic Salt Form of Cagrilintide

[0282] In some embodiments, a weight % (wt. %) ratio of : is from about 0.1 wt. %: 99.9 wt. % to about 20.0 wt. %: 80.0 wt. %.

[0283] In some embodiments, a weight % (wt. %) ratio of : is from about 0.2 wt. %: 99.8 wt. %, from about 0.3 wt. %: 99.7 wt. %, from about 0.4 wt. %: 99.6 wt. %, from about 0.5 wt. %: 99.5 wt. %, from about 0.6 wt. %: 99.4 wt. %, from about 0.7 wt. %: 99.3 wt. %, from about 0.8 wt. %: 99.2 wt. %, from about 0.9 wt. %: 99.1 wt. %, from about 1.0 wt. %: 99.0 wt. %, from about 1.1 wt. %: 98.9 wt. %, from about 1.2 wt. %: 98.8 wt. %, from about 1.3 wt. %: 98.7 wt. %, from about 1.4 wt. %: 98.6 wt. %, from about 1.5 wt. %: 98.5 wt. %, from about 1.6 wt. %: 98.4 wt. %, from about 1.7 wt. %: 98.3 wt. %, from about 1.8 wt. %: 98.2 wt. %, from about 1.9 wt. %: 98.1 wt. %, from about 2.0 wt. %: 98.0 wt. %, from about 3.0 wt. %: 97.0 wt. %, from about 4.0 wt. %: 96.0 wt. %, from about 5.0 wt. %: 95.0 wt. %, from about 6.0 wt. %: 94.0 wt. %, from about 7.0 wt. %: 93.0 wt. %, from about 8.0 wt. %: 92.0 wt. %, from about 9.0 wt. %: 91.0 wt. %, from about 10 wt. %: 90 wt. %, from about 11 wt. %: 89 wt. %, from about 12 wt. %: 88 wt. %, from about 13 wt. %: 87 wt. %, from about 14 wt. %: 86 wt. %, from about 15 wt. %: 85 wt. %, from about 16 wt. %: 84 wt. %, from about 17 wt. %: 83 wt. %, from about 18 wt. %: 82 wt. %, from about 19 wt. %: 81 wt. %, from about 20 wt. %: 80 wt. %, from about 21 wt. %: 79 wt. %, from about 22 wt. %: 78 wt. %, from about 23 wt. %: 77 wt. %, from about 24 wt. %: 76WSGR Docket No.: 56017-733.601 wt. %, from about 25 wt. %: 75 wt. %, from about 26 wt. %: 74 wt. %, from about 27 wt. %: 73 wt. %, from about 28 wt. %: 72 wt. %, from about 29 wt. %: 71 wt. %, from about 30 wt. %: 70 wt. %, from about 35 wt. %: 65 wt. %, from about 40 wt. %: 60 wt. %, from about 45 wt. %: 55 wt. %, from about 50 wt. %: 50 wt. %, from about 55 wt. %: 45 wt. %, from about 60 wt. %: 40 wt. %, from about 65 wt. %: 35 wt. %, from about 70 wt. %: 30 wt. %, from about 75 wt. %: 25 wt. %, from about 80 wt. %: 20 wt. %, from about 85 wt. %: 15 wt. %, from about 90 wt. %: 10 wt. %, or from about 95 wt. %: 5 wt. %.

[0284] In some embodiments, a weight % (wt. %) ratio of : is to about 20.0 wt. %: 80.0 wt. %. In some embodiments, a weight % (wt. %) ratio of : is to about 0.2 wt. %: 99.8 wt. %, to about 0.3 wt. %: 99.7 wt. %, to about 0.4 wt. %: 99.6 wt. %, to about 0.5 wt. %: 99.5 wt. %, to about 0.6 wt. %: 99.4 wt. %, to about 0.7 wt. %: 99.3 wt. %, to about 0.8 wt. %: 99.2 wt. %, to about 0.9 wt. %: 99.1 wt. %, to about 1.0 wt. %: 99.0 wt. %, to about 1.1 wt. %: 98.9 wt. %, to about 1.2 wt. %: 98.8 wt. %, to about 1.3 wt. %: 98.7 wt. %, to about 1.4 wt. %: 98.6 wt. %, to about 1.5 wt. %: 98.5 wt. %, to about 1.6 wt. %: 98.4 wt. %, to about 1.7 wt. %: 98.3 wt. %, to about 1.8 wt. %: 98.2 wt. %, to about 1.9 wt. %: 98.1 wt. %, to about 2.0 wt. %: 98.0 wt. %, to about 3.0 wt. %: 97.0 wt. %, to about 4.0 wt. %: 96.0 wt. %, to about 5.0 wt. %: 95.0 wt. %, to about 6.0 wt. %: 94.0 wt. %, to about 7.0 wt. %: 93.0 wt. %, to about 8.0 wt. %: 92.0 wt. %, to about 9.0 wt. %: 91.0 wt. %, to about 10 wt. %: 90 wt. %, to about 11 wt. %: 89 wt. %, to about 12 wt. %: 88 wt. %, to about 13 wt. %: 87 wt. %, to about 14 wt. %: 86 wt. %, to about 15 wt. %: 85 wt. %, to about 16 wt. %: 84 wt. %, to about 17 wt. %: 83 wt. %, to about 18 wt. %: 82 wt. %, to about 19 wt. %: 81 wt. %, to about 20 wt. %: 80 wt. %, to about 21 wt. %: 79 wt. %, to about 22 wt. %: 78 wt. %, to about 23 wt. %: 77 wt. %, to about 24 wt. %: 76 wt. %, to about 25 wt. %: 75 wt. %, to about 26 wt. %: 74 wt. %, to about 27 wt. %: 73 wt. %, to about 28 wt. %: 72 wt. %, to about 29 wt. %: 71 wt. %, to about 30 wt. %: 70 wt. %, to about 35 wt. %: 65 wt. %, to about 40 wt. %: 60 wt. %, to about 45 wt. %: 55 wt. %, to about 50 wt. %: 50 wt. %, to about 55 wt. %: 45 wt. %, to about 60 wt. %: 40 wt. %, to about 65 wt. %: 35 wt. %, to about 70 wt. %: 30 wt. %, to about 75 wt. %: 25 wt. %, to about 80 wt. %: 20 wt. %, to about 85 wt. %: 15 wt. %, to about 90 wt. %: 10 wt. %, or to about 95 wt. %: 5 wt. %.

[0285] In some embodiments, a weight % (wt. %) ratio of : is from about 0.2 wt. %: 99.8 wt. % to about 95 wt. %: 5 wt. % , from about 0.3 wt. %: 99.7 wt. % to about 95 wt. %: 5 wt. %, from about 0.4 wt. %: 99.6 wt. % to about 95 wt. %: 5 wt. %, from about 0.5 wt. %: 99.5 wt.WSGR Docket No.: 56017-733.601 % to about 95 wt. %: 5 wt. %, from about 0.6 wt. %: 99.4 wt. % to about 95 wt. %: 5 wt. %, from about 0.7 wt. %: 99.3 wt. % to about 95 wt. %: 5 wt. %, from about 0.8 wt. %: 99.2 wt. % to about 95 wt. %: 5 wt. %, from about 0.9 wt. %: 99.1 wt. % to about 95 wt. %: 5 wt. %, from about 1.0 wt. %: 99.0 wt. % to about 95 wt. %: 5 wt. %, from about 1.1 wt. %: 98.9 wt. % to about 95 wt. %: 5 wt. %, from about 1.2 wt. %: 98.8 wt. % to about 95 wt. %: 5 wt. %, from about 1.3 wt. %: 98.7 wt. % to about 95 wt. %: 5 wt. %, from about 1.4 wt. %: 98.6 wt. % to about 95 wt. %: 5 wt. %, from about 1.5 wt. %: 98.5 wt. % to about 95 wt. %: 5 wt. %, from about 1.6 wt. %: 98.4 wt. % to about 95 wt. %: 5 wt. %, from about 1.7 wt. %: 98.3 wt. % to about 95 wt. %: 5 wt. %, from about 1.8 wt. %: 98.2 wt. % to about 95 wt. %: 5 wt. %, from about 1.9 wt. %: 98.1 wt. % to about 95 wt. %: 5 wt. %, from about 2.0 wt. %: 98.0 wt. % to about 95 wt. %: 5 wt. %, from about 3.0 wt. %: 97.0 wt. % to about 95 wt. %: 5 wt. %, from about 4.0 wt. %: 96.0 wt. % to about 95 wt. %: 5 wt. %, from about 5.0 wt. %: 95.0 wt. % to about 95 wt. %: 5 wt. %, from about 6.0 wt. %: 94.0 wt. % to about 95 wt. %: 5 wt. %, from about 7.0 wt. %: 93.0 wt. % to about 95 wt. %: 5 wt. %, from about 8.0 wt. %: 92.0 wt. % to about 95 wt. %: 5 wt. %, from about 9.0 wt. %: 91.0 wt. % to about 95 wt. %: 5 wt. %, from about 10 wt. %: 90 wt. % to about 95 wt. %: 5 wt. %, from about 11 wt. %: 89 wt. % to about 95 wt. %: 5 wt. %, from about 12 wt. %: 88 wt. % to about 95 wt. %: 5 wt. %, from about 13 wt. %: 87 wt. % to about 95 wt. %: 5 wt. %, from about 14 wt. %: 86 wt. % to about 95 wt. %: 5 wt. %, from about 15 wt. %: 85 wt. % to about 95 wt. %: 5 wt. %, from about 16 wt. %: 84 wt. % to about 95 wt. %: 5 wt. %, from about 17 wt. %: 83 wt. % to about 95 wt. %: 5 wt. %, from about 18 wt. %: 82 wt. % to about 95 wt. %: 5 wt. %, from about 19 wt. %: 81 wt. % to about 95 wt. %: 5 wt. %, from about 20 wt. %: 80 wt. % to about 95 wt. %: 5 wt. %, from about 21 wt. %: 79 wt. % to about 95 wt. %: 5 wt. %, from about 22 wt. %: 78 wt. % to about 95 wt. %: 5 wt. %, from about 23 wt. %: 77 wt. % to about 95 wt. %: 5 wt. %, from about 24 wt. %: 76 wt. % to about 95 wt. %: 5 wt. %, from about 25 wt. %: 75 wt. % to about 95 wt. %: 5 wt. %, from about 26 wt. %: 74 wt. % to about 95 wt. %: 5 wt. %, from about 27 wt. %: 73 wt. % to about 95 wt. %: 5 wt. %, from about 28 wt. %: 72 wt. % to about 95 wt. %: 5 wt. %, from about 29 wt. %: 71 wt. % to about 95 wt. %: 5 wt. %, from about 30 wt. %: 70 wt. % to about 95 wt. %: 5 wt. %, from about 35 wt. %: 65 wt. % to about 95 wt. %: 5 wt. %, from about 40 wt. %: 60 wt. % to about 95 wt. %: 5 wt. %, from about 45 wt. %: 55 wt. % to about 95 wt. %: 5 wt. %, from about 50 wt. %: 50 wt. % to about 95 wt. %: 5 wt. %, from about 55 wt. %: 45 wt. % to about 95 wt. %: 5 wt. %, from about 60 wt. %: 40 wt. % to about 95 wt. %: 5 wt. %, from about 65 wt. %: 35 wt. % to about 95 wt. %: 5 wt. %, from about 70 wt. %: 30 wt. % to about 95 wt. %: 5 wt. %, from about 75 wt. %: 25 wt. % to about 95 wt. %: 5 wt. %, from about 80 wt. %: 20 wt. % to about 95 wt. %: 5 wt. %, from about 85 wt. %: 15 wt. % to about 95 wt. %: 5 wt. %, or from about 90 wt. %: 10 wt. % to about 95 wt. %: 5 wt. %.WSGR Docket No.: 56017-733.601

[0286] In some embodiments, a weight % (wt. %) ratio of : is from about 0.1 wt. %: 99.9 wt. % to about 0.2 wt. %: 99.8 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 0.3 wt. %: 99.7 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 0.4 wt. %: 99.6 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 0.5 wt. %: 99.5 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 0.6 wt. %: 99.4 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 0.7 wt. %: 99.3 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 0.8 wt. %: 99.2 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 0.9 wt. %: 99.1 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.0 wt. %: 99.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.1 wt. %: 98.9 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.2 wt. %: 98.8 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.3 wt. %: 98.7 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.4 wt. %: 98.6 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.5 wt. %: 98.5 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.6 wt. %: 98.4 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.7 wt. %: 98.3 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.8 wt. %: 98.2 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.9 wt. %: 98.1 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 2.0 wt. %: 98.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 3.0 wt. %: 97.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 4.0 wt. %: 96.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 5.0 wt. %: 95.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 6.0 wt. %: 94.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 7.0 wt. %: 93.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 8.0 wt. %: 92.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 9.0 wt. %: 91.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 10 wt. %: 90 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 11 wt. %: 89 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 12 wt. %: 88 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 13 wt. %: 87 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 14 wt. %: 86 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 15 wt. %: 85 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 16 wt. %: 84 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 17 wt. %: 83 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 18 wt. %: 82 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 19 wt. %: 81 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 20 wt. %: 80 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 21 wt. %: 79 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 22 wt. %: 78 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 23 wt. %: 77 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 24 wt. %: 76 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 25 wt. %: 75 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 26 wt. %: 74 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 27 wt. %: 73 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 28 wt. %: 72 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 29 wt. %: 71 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 30 wt. %: 70 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 35 wt. %: 65 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 40 wt. %: 60 wt. %, from about 0.1 wt. %: 99.9 wt. % toWSGR Docket No.: 56017-733.601 about 45 wt. %: 55 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 50 wt. %: 50 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 55 wt. %: 45 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 60 wt. %: 40 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 65 wt. %: 35 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 70 wt. %: 30 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 75 wt. %: 25 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 80 wt. %: 20 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 85 wt. %: 15 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 90 wt. %: 10 wt. %, or from about 0.1 wt. %: 99.9 wt. % to about 95 wt. %: 5 wt. %.

[0287] In some embodiments, a weight % (wt. %) ratio of : is from about 0.1 wt. %: 99.9 wt. % to about 95 wt. %: 5 wt. %, from about 0.2 wt. %: 99.8 wt. % to about 90 wt. %: 10 wt. %, from about 0.3 wt. %: 99.7 wt. % to about 85 wt. %: 15 wt. %, from about 0.4 wt. %: 99.6 wt. % to about 80 wt. %: 20 wt. %, from about 0.5 wt. %: 99.5 wt. % to about 75 wt. %: 25 wt. %, from about 0.6 wt. %: 99.4 wt. % to about 70 wt. %: 30 wt. %, from about 0.7 wt. %: 99.3 wt. % to about 65 wt. %: 35 wt. %, from about 0.8 wt. %: 99.2 wt. % to about 60 wt. %: 40 wt. %, from about 0.9 wt. %: 99.1 wt. % to about 55 wt. %: 45 wt. %, from about 1.0 wt. %: 99.0 wt. % to about 50 wt. %: 50 wt. %, from about 1.1 wt. %: 98.9 wt. % to about 45 wt. %: 55 wt. %, from about 1.2 wt. %: 98.8 wt. % to about 40 wt. %: 60 wt. %, from about 1.3 wt. %: 98.7 wt. % to about 35 wt. %: 65 wt. %, from about 1.4 wt. %: 98.6 wt. % to about 30 wt. %: 70 wt. %, from about 1.5 wt. %: 98.5 wt. % to about 29 wt. %: 71 wt. %, from about 1.6 wt. %: 98.4 wt. % to about 28 wt. %: 72 wt. %, from about 1.7 wt. %: 98.3 wt. % to about 27 wt. %: 73 wt. %, from about 1.8 wt. %: 98.2 wt. % to about 26 wt. %: 74 wt. %, from about 1.9 wt. %: 98.1 wt. % to about 25 wt. %: 75 wt. %, from about 2.0 wt. %: 98.0 wt. % to about 24 wt. %: 76 wt. %, from about 3.0 wt. %: 97.0 wt. % to about 23 wt. %: 77 wt. %, from about 4.0 wt. %: 96.0 wt. % to about 22 wt. %: 78 wt. %, from about 5.0 wt. %: 95.0 wt. % to about 21 wt. %: 79 wt. %, from about 6.0 wt. %: 94.0 wt. % to about 20 wt. %: 80 wt. %, from about 7.0 wt. %: 93.0 wt. % to about 19 wt. %: 81 wt. %, from about 8.0 wt. %: 92.0 wt. % to about 18 wt. %: 82 wt. %, from about 9.0 wt. %: 91.0 wt. % to about 17 wt. %: 83 wt. %, from about 10 wt. %: 90 wt. % to about 16 wt. %: 84 wt. %, from about 11 wt. %: 89 wt. % to about 15 wt. %: 85 wt. %, or from about 12 wt. %: 88 wt. % to about 14 wt. %: 86 wt. %.

[0288] In some embodiments, a weight % (wt. %) ratio of : is about 0.1 wt. %: 99.9 wt. %, about 0.2 wt. %: 99.8 wt. %, about 0.3 wt. %: 99.7 wt. %, about 0.4 wt. %: 99.6 wt. %, about 0.5 wt. %: 99.5 wt. %, about 0.6 wt. %: 99.4 wt. %, about 0.7 wt. %: 99.3 wt. %, about 0.8 wt. %: 99.2 wt. %, about 0.9 wt. %: 99.1 wt. %, about 1.0 wt. %: 99.0 wt. %, about 1.1 wt. %: 98.9 wt. %, about 1.2 wt. %: 98.8 wt. %, about 1.3 wt. %: 98.7 wt. %, about 1.4 wt. %: 98.6 wt.WSGR Docket No.: 56017-733.601 %, about 1.5 wt. %: 98.5 wt. %, about 1.6 wt. %: 98.4 wt. %, about 1.7 wt. %: 98.3 wt. %, about 1.8 wt. %: 98.2 wt. %, about 1.9 wt. %: 98.1 wt. %, about 2.0 wt. %: 98.0 wt. %, about 3.0 wt. %: 97.0 wt. %, about 4.0 wt. %: 96.0 wt. %, about 5.0 wt. %: 95.0 wt. %, about 6.0 wt. %: 94.0 wt. %, about 7.0 wt. %: 93.0 wt. %, about 8.0 wt. %: 92.0 wt. %, about 9.0 wt. %: 91.0 wt. %, about 10 wt. %: 90 wt. %, about 11 wt. %: 89 wt. %, about 12 wt. %: 88 wt. %, about 13 wt. %: 87 wt. %, about 14 wt. %: 86 wt. %, about 15 wt. %: 85 wt. %, about 16 wt. %: 84 wt. %, about 17 wt. %: 83 wt. %, about 18 wt. %: 82 wt. %, about 19 wt. %: 81 wt. %, about 20 wt. %: 80 wt. %, about 21 wt. %: 79 wt. %, about 22 wt. %: 78 wt. %, about 23 wt. %: 77 wt. %, about 24 wt. %: 76 wt. %, about 25 wt. %: 75 wt. %, about 26 wt. %: 74 wt. %, about 27 wt. %: 73 wt. %, about 28 wt. %: 72 wt. %, about 29 wt. %: 71 wt. %, about 30 wt. %: 70 wt. %, about 35 wt. %: 65 wt. %, about 40 wt. %: 60 wt. %, about 45 wt. %: 55 wt. %, about 50 wt. %: 50 wt. %, about 55 wt. %: 45 wt. %, about 60 wt. %: 40 wt. %, about 65 wt. %: 35 wt. %, about 70 wt. %: 30 wt. %, about 75 wt. %: 25 wt. %, about 80 wt. %: 20 wt. %, about 85 wt. %: 15 wt. %, about 90 wt. %: 10 wt. %, or about 95 wt. %: 5 wt. %.

[0289] In some embodiments, a weight % (wt. %) ratio of :,,, or any combination thereof is from about 0.1 wt. %: 99.9 wt. % to about 20.0 wt. %: 80.0 wt. %.

[0290] In some embodiments, a weight % (wt. %) ratio of:, ,any combination thereof is from about 0.2 wt. %: 99.8 wt. %, from about 0.3 wt. %: 99.7 wt. %, from about 0.4 wt. %: 99.6 wt. %, from about 0.5 wt. %: 99.5 wt. %, from about 0.6 wt. %: 99.4 wt. %, from about 0.7 wt. %: 99.3 wt. %, from about 0.8 wt. %: 99.2 wt. %, from about 0.9 wt. %: 99.1 wt. %, from about 1.0 wt. %: 99.0 wt. %, from about 1.1 wt. %: 98.9 wt. %, from about 1.2 wt. %: 98.8 wt. %, from about 1.3 wt. %: 98.7 wt. %, from about 1.4 wt. %: 98.6WSGR Docket No.: 56017-733.601 wt. %, from about 1.5 wt. %: 98.5 wt. %, from about 1.6 wt. %: 98.4 wt. %, from about 1.7 wt. %: 98.3 wt. %, from about 1.8 wt. %: 98.2 wt. %, from about 1.9 wt. %: 98.1 wt. %, from about 2.0 wt. %: 98.0 wt. %, from about 3.0 wt. %: 97.0 wt. %, from about 4.0 wt. %: 96.0 wt. %, from about 5.0 wt. %: 95.0 wt. %, from about 6.0 wt. %: 94.0 wt. %, from about 7.0 wt. %: 93.0 wt. %, from about 8.0 wt. %: 92.0 wt. %, from about 9.0 wt. %: 91.0 wt. %, from about 10 wt. %: 90 wt. %, from about 11 wt. %: 89 wt. %, from about 12 wt. %: 88 wt. %, from about 13 wt. %: 87 wt. %, from about 14 wt. %: 86 wt. %, from about 15 wt. %: 85 wt. %, from about 16 wt. %: 84 wt. %, from about 17 wt. %: 83 wt. %, from about 18 wt. %: 82 wt. %, from about 19 wt. %: 81 wt. %, from about 20 wt. %: 80 wt. %, from about 21 wt. %: 79 wt. %, from about 22 wt. %: 78 wt. %, from about 23 wt. %: 77 wt. %, from about 24 wt. %: 76 wt. %, from about 25 wt. %: 75 wt. %, from about 26 wt. %: 74 wt. %, from about 27 wt. %: 73 wt. %, from about 28 wt. %: 72 wt. %, from about 29 wt. %: 71 wt. %, from about 30 wt. %: 70 wt. %, from about 35 wt. %: 65 wt. %, from about 40 wt. %: 60 wt. %, from about 45 wt. %: 55 wt. %, from about 50 wt. %: 50 wt. %, from about 55 wt. %: 45 wt. %, from about 60 wt. %: 40 wt. %, from about 65 wt. %: 35 wt. %, from about 70 wt. %: 30 wt. %, from about 75 wt. %: 25 wt. %, from about 80 wt. %: 20 wt. %, from about 85 wt. %: 15 wt. %, from about 90 wt. %: 10 wt. %, or from about 95 wt. %: 5 wt.,,any combination thereof is to about 20.0 wt. %: 80.0 wt. %. In some embodiments,a weight % (wt. %) ratio, , any combination thereof isto about 0.2 wt. %: 99.8 wt. %, to about 0.3 wt. %: 99.7 wt. %, to about 0.4 wt. %: 99.6 wt. %, to about 0.5 wt. %: 99.5 wt. %, to about 0.6 wt. %: 99.4 wt. %, to about 0.7 wt. %: 99.3 wt. %, to about 0.8 wt. %: 99.2 wt. %, to about 0.9 wt. %: 99.1 wt. %, to about 1.0 wt. %: 99.0 wt. %, to about 1.1 wt. %: 98.9 wt. %, to about 1.2 wt. %: 98.8 wt. %, to about 1.3 wt. %: 98.7 wt. %, to about 1.4 wt. %: 98.6 wt. %, to about 1.5 wt. %: 98.5 wt. %, to about 1.6 wt. %: 98.4 wt. %, to about 1.7 wt. %: 98.3 wt. %, to about 1.8 wt. %: 98.2 wt. %, to about 1.9 wt. %: 98.1 wt. %, toWSGR Docket No.: 56017-733.601 about 2.0 wt. %: 98.0 wt. %, to about 3.0 wt. %: 97.0 wt. %, to about 4.0 wt. %: 96.0 wt. %, to about 5.0 wt. %: 95.0 wt. %, to about 6.0 wt. %: 94.0 wt. %, to about 7.0 wt. %: 93.0 wt. %, to about 8.0 wt. %: 92.0 wt. %, to about 9.0 wt. %: 91.0 wt. %, to about 10 wt. %: 90 wt. %, to about 11 wt. %: 89 wt. %, to about 12 wt. %: 88 wt. %, to about 13 wt. %: 87 wt. %, to about 14 wt. %: 86 wt. %, to about 15 wt. %: 85 wt. %, to about 16 wt. %: 84 wt. %, to about 17 wt. %: 83 wt. %, to about 18 wt. %: 82 wt. %, to about 19 wt. %: 81 wt. %, to about 20 wt. %: 80 wt. %, to about 21 wt. %: 79 wt. %, to about 22 wt. %: 78 wt. %, to about 23 wt. %: 77 wt. %, to about 24 wt. %: 76 wt. %, to about 25 wt. %: 75 wt. %, to about 26 wt. %: 74 wt. %, to about 27 wt. %: 73 wt. %, to about 28 wt. %: 72 wt. %, to about 29 wt. %: 71 wt. %, to about 30 wt. %: 70 wt. %, to about 35 wt. %: 65 wt. %, to about 40 wt. %: 60 wt. %, to about 45 wt. %: 55 wt. %, to about 50 wt. %: 50 wt. %, to about 55 wt. %: 45 wt. %, to about 60 wt. %: 40 wt. %, to about 65 wt. %: 35 wt. %, to about 70 wt. %: 30 wt. %, to about 75 wt. %: 25 wt. %, to about 80 wt. %: 20 wt. %, to about 85 wt. %: 15 wt. %, to about 90 wt. %: 10 wt. %, or to about 95 wt. %: 5 wt. %.

[0292] In some embodiments, a weight % (wt. %) ratio of : ,,any combination thereof is from about 0.2 wt. %: 99.8 wt. % to about 95 wt. %: 5 wt. % , from about 0.3 wt. %: 99.7 wt. % to about 95 wt. %: 5 wt. %, from about 0.4 wt. %: 99.6 wt. % to about 95 wt. %: 5 wt. %, from about 0.5 wt. %: 99.5 wt. % to about 95 wt. %: 5 wt. %, from about 0.6 wt. %: 99.4 wt. % to about 95 wt. %: 5 wt. %, from about 0.7 wt. %: 99.3 wt. % to about 95 wt. %: 5 wt. %, from about 0.8 wt. %: 99.2 wt. % to about 95 wt. %: 5 wt. %, from about 0.9 wt. %: 99.1 wt. % to about 95 wt. %: 5 wt. %, from about 1.0 wt. %: 99.0 wt. % to about 95 wt. %: 5 wt. %, from about 1.1 wt. %: 98.9 wt. % to about 95 wt. %: 5 wt. %, from about 1.2 wt. %: 98.8 wt. % to about 95 wt. %: 5 wt. %, from about 1.3 wt. %: 98.7 wt. % to about 95 wt. %: 5 wt. %, from about 1.4 wt. %: 98.6 wt. % to about 95 wt. %: 5 wt. %, from about 1.5 wt. %: 98.5 wt. % to about 95 wt. %: 5 wt. %, from about 1.6 wt. %: 98.4 wt. % to about 95 wt. %: 5 wt. %, from about 1.7 wt. %: 98.3 wt. % to about 95 wt. %: 5 wt. %, from about 1.8 wt. %: 98.2 wt. % to about 95 wt. %: 5 wt. %, from about 1.9 wt. %: 98.1 wt. % to about 95 wt. %: 5 wt. %, from about 2.0 wt. %: 98.0 wt. % to about 95 wt. %: 5 wt. %, from about 3.0 wt. %: 97.0 wt. % to about 95 wt. %: 5 wt. %, from about 4.0 wt. %: 96.0 wt. % to about 95 wt. %: 5 wt. %, from about 5.0 wt. %: 95.0 wt. % to about 95 wt. %: 5 wt. %, from about 6.0 wt. %: 94.0 wt. % to about 95 wt.WSGR Docket No.: 56017-733.601 %: 5 wt. %, from about 7.0 wt. %: 93.0 wt. % to about 95 wt. %: 5 wt. %, from about 8.0 wt. %: 92.0 wt. % to about 95 wt. %: 5 wt. %, from about 9.0 wt. %: 91.0 wt. % to about 95 wt. %: 5 wt. %, from about 10 wt. %: 90 wt. % to about 95 wt. %: 5 wt. %, from about 11 wt. %: 89 wt. % to about 95 wt. %: 5 wt. %, from about 12 wt. %: 88 wt. % to about 95 wt. %: 5 wt. %, from about 13 wt. %: 87 wt. % to about 95 wt. %: 5 wt. %, from about 14 wt. %: 86 wt. % to about 95 wt. %: 5 wt. %, from about 15 wt. %: 85 wt. % to about 95 wt. %: 5 wt. %, from about 16 wt. %: 84 wt. % to about 95 wt. %: 5 wt. %, from about 17 wt. %: 83 wt. % to about 95 wt. %: 5 wt. %, from about 18 wt. %: 82 wt. % to about 95 wt. %: 5 wt. %, from about 19 wt. %: 81 wt. % to about 95 wt. %: 5 wt. %, from about 20 wt. %: 80 wt. % to about 95 wt. %: 5 wt. %, from about 21 wt. %: 79 wt. % to about 95 wt. %: 5 wt. %, from about 22 wt. %: 78 wt. % to about 95 wt. %: 5 wt. %, from about 23 wt. %: 77 wt. % to about 95 wt. %: 5 wt. %, from about 24 wt. %: 76 wt. % to about 95 wt. %: 5 wt. %, from about 25 wt. %: 75 wt. % to about 95 wt. %: 5 wt. %, from about 26 wt. %: 74 wt. % to about 95 wt. %: 5 wt. %, from about 27 wt. %: 73 wt. % to about 95 wt. %: 5 wt. %, from about 28 wt. %: 72 wt. % to about 95 wt. %: 5 wt. %, from about 29 wt. %: 71 wt. % to about 95 wt. %: 5 wt. %, from about 30 wt. %: 70 wt. % to about 95 wt. %: 5 wt. %, from about 35 wt. %: 65 wt. % to about 95 wt. %: 5 wt. %, from about 40 wt. %: 60 wt. % to about 95 wt. %: 5 wt. %, from about 45 wt. %: 55 wt. % to about 95 wt. %: 5 wt. %, from about 50 wt. %: 50 wt. % to about 95 wt. %: 5 wt. %, from about 55 wt. %: 45 wt. % to about 95 wt. %: 5 wt. %, from about 60 wt. %: 40 wt. % to about 95 wt. %: 5 wt. %, from about 65 wt. %: 35 wt. % to about 95 wt. %: 5 wt. %, from about 70 wt. %: 30 wt. % to about 95 wt. %: 5 wt. %, from about 75 wt. %: 25 wt. % to about 95 wt. %: 5 wt. %, from about 80 wt. %: 20 wt. % to about 95 wt. %: 5 wt. %, from about 85 wt. %: 15 wt. % to about 95 wt. %: 5 wt. %, or from about 90 wt. %: 10 wt. % to about 95 wt. %: 5 wt. %.

[0293] In some embodiments, a weight % (wt. %) ratio of :,,any combination thereof is from about 0.1 wt. %: 99.9 wt. % to about 0.2 wt. %: 99.8 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 0.3 wt. %: 99.7 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 0.4 wt. %: 99.6 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 0.5 wt. %: 99.5 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 0.6 wt. %: 99.4 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 0.7 wt. %: 99.3 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 0.8WSGR Docket No.: 56017-733.601 wt. %: 99.2 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 0.9 wt. %: 99.1 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.0 wt. %: 99.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.1 wt. %: 98.9 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.2 wt. %: 98.8 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.3 wt. %: 98.7 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.4 wt. %: 98.6 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.5 wt. %: 98.5 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.6 wt. %: 98.4 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.7 wt. %: 98.3 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.8 wt. %: 98.2 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 1.9 wt. %: 98.1 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 2.0 wt. %: 98.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 3.0 wt. %: 97.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 4.0 wt. %: 96.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 5.0 wt. %: 95.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 6.0 wt. %: 94.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 7.0 wt. %: 93.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 8.0 wt. %: 92.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 9.0 wt. %: 91.0 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 10 wt. %: 90 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 11 wt. %: 89 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 12 wt. %: 88 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 13 wt. %: 87 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 14 wt. %: 86 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 15 wt. %: 85 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 16 wt. %: 84 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 17 wt. %: 83 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 18 wt. %: 82 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 19 wt. %: 81 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 20 wt. %: 80 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 21 wt. %: 79 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 22 wt. %: 78 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 23 wt. %: 77 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 24 wt. %: 76 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 25 wt. %: 75 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 26 wt. %: 74 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 27 wt. %: 73 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 28 wt. %: 72 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 29 wt. %: 71 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 30 wt. %: 70 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 35 wt. %: 65 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 40 wt. %: 60 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 45 wt. %: 55 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 50 wt. %: 50 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 55 wt. %: 45 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 60 wt. %: 40 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 65 wt. %: 35 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 70 wt. %: 30 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 75 wt. %: 25 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 80 wt. %: 20 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 85 wt. %: 15 wt. %, from about 0.1 wt. %: 99.9 wt. % to about 90 wt. %: 10 wt. %, or fromWSGR Docket No.: 56017-733.601 about 0.1 wt. %: 99.9 wt. % to about 95 wt. %: 5 wt. %.

[0294] In some embodiments, a weight % (wt. %) ratio of :,,any combination thereof is from about 0.1 wt. %: 99.9 wt. % to about 95 wt. %: 5 wt. %, from about 0.2 wt. %: 99.8 wt. % to about 90 wt. %: 10 wt. %, from about 0.3 wt. %: 99.7 wt. % to about 85 wt. %: 15 wt. %, from about 0.4 wt. %: 99.6 wt. % to about 80 wt. %: 20 wt. %, from about 0.5 wt. %: 99.5 wt. % to about 75 wt. %: 25 wt. %, from about 0.6 wt. %: 99.4 wt. % to about 70 wt. %: 30 wt. %, from about 0.7 wt. %: 99.3 wt. % to about 65 wt. %: 35 wt. %, from about 0.8 wt. %: 99.2 wt. % to about 60 wt. %: 40 wt. %, from about 0.9 wt. %: 99.1 wt. % to about 55 wt. %: 45 wt. %, from about 1.0 wt. %: 99.0 wt. % to about 50 wt. %: 50 wt. %, from about 1.1 wt. %: 98.9 wt. % to about 45 wt. %: 55 wt. %, from about 1.2 wt. %: 98.8 wt. % to about 40 wt. %: 60 wt. %, from about 1.3 wt. %: 98.7 wt. % to about 35 wt. %: 65 wt. %, from about 1.4 wt. %: 98.6 wt. % to about 30 wt. %: 70 wt. %, from about 1.5 wt. %: 98.5 wt. % to about 29 wt. %: 71 wt. %, from about 1.6 wt. %: 98.4 wt. % to about 28 wt. %: 72 wt. %, from about 1.7 wt. %: 98.3 wt. % to about 27 wt. %: 73 wt. %, from about 1.8 wt. %: 98.2 wt. % to about 26 wt. %: 74 wt. %, from about 1.9 wt. %: 98.1 wt. % to about 25 wt. %: 75 wt. %, from about 2.0 wt. %: 98.0 wt. % to about 24 wt. %: 76 wt. %, from about 3.0 wt. %: 97.0 wt. % to about 23 wt. %: 77 wt. %, from about 4.0 wt. %: 96.0 wt. % to about 22 wt. %: 78 wt. %, from about 5.0 wt. %: 95.0 wt. % to about 21 wt. %: 79 wt. %, from about 6.0 wt. %: 94.0 wt. % to about 20 wt. %: 80 wt. %, from about 7.0 wt. %: 93.0 wt. % to about 19 wt. %: 81 wt. %, from about 8.0 wt. %: 92.0 wt. % to about 18 wt. %: 82 wt. %, from about 9.0 wt. %: 91.0 wt. % to about 17 wt. %: 83 wt. %, from about 10 wt. %: 90 wt. % to about 16 wt. %: 84 wt. %, from about 11 wt. %: 89 wt. % to about 15 wt. %: 85 wt. %, or from about 12 wt. %: 88 wt. % to about 14 wt. %: 86 wt. %.

[0295] In some embodiments, a weight % (wt. %) ratio of :,,WSGR Docket No.: 56017-733.601any combination thereof is about 0.1 wt. %: 99.9 wt. %, about 0.2 wt. %: 99.8 wt. %, about 0.3 wt. %: 99.7 wt. %, about 0.4 wt. %: 99.6 wt. %, about 0.5 wt. %: 99.5 wt. %, about 0.6 wt. %: 99.4 wt. %, about 0.7 wt. %: 99.3 wt. %, about 0.8 wt. %: 99.2 wt. %, about 0.9 wt. %: 99.1 wt. %, about 1.0 wt. %: 99.0 wt. %, about 1.1 wt. %: 98.9 wt. %, about 1.2 wt. %: 98.8 wt. %, about 1.3 wt. %: 98.7 wt. %, about 1.4 wt. %: 98.6 wt. %, about 1.5 wt. %: 98.5 wt. %, about 1.6 wt. %: 98.4 wt. %, about 1.7 wt. %: 98.3 wt. %, about 1.8 wt. %: 98.2 wt. %, about 1.9 wt. %: 98.1 wt. %, about 2.0 wt. %: 98.0 wt. %, about 3.0 wt. %: 97.0 wt. %, about 4.0 wt. %: 96.0 wt. %, about 5.0 wt. %: 95.0 wt. %, about 6.0 wt. %: 94.0 wt. %, about 7.0 wt. %: 93.0 wt. %, about 8.0 wt. %: 92.0 wt. %, about 9.0 wt. %: 91.0 wt. %, about 10 wt. %: 90 wt. %, about 11 wt. %: 89 wt. %, about 12 wt. %: 88 wt. %, about 13 wt. %: 87 wt. %, about 14 wt. %: 86 wt. %, about 15 wt. %: 85 wt. %, about 16 wt. %: 84 wt. %, about 17 wt. %: 83 wt. %, about 18 wt. %: 82 wt. %, about 19 wt. %: 81 wt. %, about 20 wt. %: 80 wt. %, about 21 wt. %: 79 wt. %, about 22 wt. %: 78 wt. %, about 23 wt. %: 77 wt. %, about 24 wt. %: 76 wt. %, about 25 wt. %: 75 wt. %, about 26 wt. %: 74 wt. %, about 27 wt. %: 73 wt. %, about 28 wt. %: 72 wt. %, about 29 wt. %: 71 wt. %, about 30 wt. %: 70 wt. %, about 35 wt. %: 65 wt. %, about 40 wt. %: 60 wt. %, about 45 wt. %: 55 wt. %, about 50 wt. %: 50 wt. %, about 55 wt. %: 45 wt. %, about 60 wt. %: 40 wt. %, about 65 wt. %: 35 wt. %, about 70 wt. %: 30 wt. %, about 75 wt. %: 25 wt. %, about 80 wt. %: 20 wt. %, about 85 wt. %: 15 wt. %, about 90 wt. %: 10 wt. %, or about 95 wt. %: 5 wt. %

[0296] In some embodiments, a molar ratio of : is from about 2:1 to about 10:1, or any ratio between any two of these values. In some embodiments, a molar ratio of : is from about 2:1 to about 7:1, or any ratio between any two of these values. In some embodiments, a molar ratio of : is from about 3:1 to about 7:1, or any ratio between any two of these values. In some embodiments, a molar ratio of : is from about 3:1 to about 7:1, or any ratio between any two of these values.

[0297] In some embodiments, a molar ratio of : is from about 1:1, from about 1:2, from about 1:3, from about 1:4, from about 1:5, from about 1:6, from about 1:7, from about 1:8, from about 1:9, from about 1:10, from about 1:11, from about 1:12, from about 1:13, from aboutWSGR Docket No.: 56017-733.601 1:14, from about 1:15, from about 1:16, from about 1:17, from about 1:18, from about 1:19, from about 1:20, from about 1:21, from about 1:22, from about 1:23, from about 1:24, from about 1:25, from about 1:26, from about 1:27, from about 1:28, from about 1:29, or from about 1:30, or any ratio between any two of these values.

[0298] In some embodiments, a molar ratio of : is from about 1:1, from about 2:1, from about 3:1, from about 4:1, from about 5:1, from about 6:1, from about 7:1, from about 8:1, from about 9:1, from about 10:1, from about 11:1, from about 12:1, from about 13:1, from about 14:1, from about 15:1, from about 16:1, from about 17:1, from about 18:1, from about 19:1, from about 20:1, from about 21:1, from about 22:1, from about 23:1, from about 24:1, from about 25:1, from about 26:1, from about 27:1, from about 28:1, from about 29:1, or from about 30:1, or any ratio between any two of these values.

[0299] In some embodiments, a molar ratio of : is to about 1:2, to about 1:3, to about 1:4, to about 1:5, to about 1:6, to about 1:7, to about 1:8, to about 1:9, to about 1:10, to about 1:11, to about 1:12, to about 1:13, to about 1:14, to about 1:15, to about 1:16, to about 1:17, to about 1:18, to about 1:19, to about 1:20, to about 1:21, to about 1:22, to about 1:23, to about 1:24, to about 1:25, to about 1:26, to about 1:27, to about 1:28, to about 1:29, or to about 1:30, or any ratio between any two of these values.

[0300] In some embodiments, a molar ratio of : is to about 1:1, to about 2:1, to about 3:1, to about 4:1, to about 5:1, to about 6:1, to about 7:1, to about 8:1, to about 9:1, to about 10:1, to about 11:1, to about 12:1, to about 13:1, to about 14:1, to about 15:1, to about 16:1, to about 17:1, to about 18:1, to about 19:1, to about 20:1, to about 21:1, to about 22:1, to about 23:1, to about 24:1, to about 25:1, to about 26:1, to about 27:1, to about 28:1, to about 29:1, or to about 30:1, or any ratio between any two of these values.

[0301] In some embodiments, a molar ratio of : is from about 1:1 to about 1:2, from about 1:1 to about 1:3, from about 1:1 to about 1:4, from about 1:1 to about 1:5, from about 1:1 to about 1:6, from about 1:1 to about 1:7, from about 1:1 to about 1:8, from about 1:1 to about 1:9, from about 1:1 to about 1:10, from about 1:1 to about 1:11, from about 1:1 to about 1:12, from about 1:1 to about 1:13, from about 1:1 to about 1:14, from about 1:1 to about 1:15, from about 1:1 to about 1:16, from about 1:1 to about 1:17, from about 1:1 to about 1:18, from about 1:1 to about 1:19, from about 1:1 to about 1:20, from about 1:1 to about 1:21, from about 1:1 toWSGR Docket No.: 56017-733.601 about 1:22, from about 1:1 to about 1:23, from about 1:1 to about 1:24, from about 1:1 to about 1:25, from about 1:1 to about 1:26, from about 1:1 to about 1:27, from about 1:1 to about 1:28, from about 1:1 to about 1:29, or from about 1:1 to about 1:30, or any ratio between any two of these values.

[0302] In some embodiments, a molar ratio of : is from about 1:1 to about 1:30, from about 1:2 to about 1:30, from about 1:3 to about 1:30, from about 1:4 to about 1:30, from about 1:5 to about 1:30, from about 1:6 to about 1:30, from about 1:7 to about 1:30, from about 1:8 to about 1:30, from about 1:9 to about 1:30, from about 1:10 to about 1:30, from about 1:11 to about 1:30, from about 1:12 to about 1:30, from about 1:13 to about 1:30, from about 1:14 to about 1:30, from about 1:15 to about 1:30, from about 1:16 to about 1:30, from about 1:17 to about 1:30, from about 1:18 to about 1:30, from about 1:19 to about 1:30, from about 1:20 to about 1:30, from about 1:21 to about 1:30, from about 1:22 to about 1:30, from about 1:23 to about 1:30, from about 1:24 to about 1:30, from about 1:25 to about 1:30, from about 1:26 to about 1:30, from about 1:27 to about 1:30, from about 1:28 to about 1:30, or from about 1:29 to about 1:30, or any ratio between any two of these values.

[0303] In some embodiments, a molar ratio of : is from about 1:1 to about 2:1, from about 1:1 to about 3:1, from about 1:1 to about 4:1, from about 1:1 to about 5:1, from about 1:1 to about 6:1, from about 1:1 to about 7:1, from about 1:1 to about 8:1, from about 1:1 to about 9:1, from about 1:1 to about 10:1, from about 1:1 to about 11:1, from about 1:1 to about 12:1, from about 1:1 to about 13:1, from about 1:1 to about 14:1, from about 1:1 to about 15:1, from about 1:1 to about 16:1, from about 1:1 to about 17:1, from about 1:1 to about 18:1, from about 1:1 to about 19:1, from about 1:1 to about 20:1, from about 1:1 to about 21:1, from about 1:1 to about 22:1, from about 1:1 to about 23:1, from about 1:1 to about 24:1, from about 1:1 to about 25:1, from about 1:1 to about 26:1, from about 1:1 to about 27:1, from about 1:1 to about 28:1, from about 1:1 to about 29:1, or from about 1:1 to about 30:1, or any ratio between any two of these values.

[0304] In some embodiments, a molar ratio of : is from about 1:1 to about 30:1, from about 2:1 to about 30:1, from about 3:1 to about 30:1, from about 4:1 to about 30:1, from about 5:1 to about 30:1, from about 6:1 to about 30:1, from about 7:1 to about 30:1, from about 8:1 to about 30:1, from about 9:1 to about 30:1, from about 10:1 to about 30:1, from about 11:1 to about 30:1, from about 12:1 to about 30:1, from about 13:1 to about 30:1, from about 14:1 to about 30:1,WSGR Docket No.: 56017-733.601 from about 15:1 to about 30:1, from about 16:1 to about 30:1, from about 17:1 to about 30:1, from about 18:1 to about 30:1, from about 19:1 to about 30:1, from about 20:1 to about 30:1, from about 21:1 to about 30:1, from about 22:1 to about 30:1, from about 23:1 to about 30:1, from about 24:1 to about 30:1, from about 25:1 to about 30:1, from about 26:1 to about 30:1, from about 27:1 to about 30:1, from about 28:1 to about 30:1, or from about 29:1 to about 30:1, or any ratio between any two of these values.

[0305] In some embodiments, a molar ratio of : is from about 1:1 to about 10:1, from about 2:1 to about 10:1, from about 3:1 to about 10:1, from about 4:1 to about 10:1, from about 5:1 to about 10:1, from about 6:1 to about 10:1, from about 7:1 to about 10:1, from about 8:1 to about 10:1, or from about 9:1 to about 10:1, or any ratio between any two of these values. In some embodiments, a molar ratio of : is from about 1:1 to about 10:1, from about 1:1 to about 9:1, from about 1:1 to about 8:1, from about 1:1 to about 7:1, from about 1:1 to about 6:1, from about 1:1 to about 5:1, from about 1:1 to about 4:1, from about 1:1 to about 3:1, or from about 1:1 to about 2:1, or any ratio between any two of these values.

[0306] In some embodiments, a molar ratio of : is from about 1:1 to about 7:1, from about 2:1 to about 7:1, from about 3:1 to about 7:1, from about 4:1 to about 7:1, from about 5:1 to about 7:1, or from about 6:1 to about 7:1, or any ratio between any two of these values. In some embodiments, a molar ratio of : is from about 1:1 to about 7:1, from about 1:1 to about 6:1, from about 1:1 to about 5:1, from about 1:1 to about 4:1, from about 1:1 to about 3:1, or from about 1:1 to about 2:1, or any ratio between any two of these values.

[0307] In some embodiments, a molar ratio of : is about 1:1 , about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:11, about 1:12, about 1:13, about 1:14, about 1:15, about 1:16, about 1:17, about 1:18, about 1:19, about 1:20, about 1:21, about 1:22, about 1:23, about 1:24, about 1:25, about 1:26, about 1:27, about 1:28, about 1:29, or about 1:30, or any ratio between any two of these values.

[0308] In some embodiments, a molar ratio of : is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 11:1, about 12:1, about 13:1, about 14:1, about 15:1, about 16:1, about 17:1, about 18:1, about 19:1, about 20:1,WSGR Docket No.: 56017-733.601 about 21:1, about 22:1, about 23:1, about 24:1, about 25:1, about 26:1, about 27:1, about 28:1, about 29:1, or about 30:1, or any ratio between any two of these values.

[0309] In some embodiments, a molar ratio of : is from about 1:1 to about 1:3. In some embodiments, a molar ratio of : is from about 1:1 to about 1:2. In some embodiments, a molar ratio of : is from about 1:2 to about 1:3. In some embodiments, a molar ratio of : is about 1:1. In some embodiments, a molar ratio of : is about 1:2. In some embodiments, a molar ratio of : is about 1:3.

[0310] In some embodiments, a molar ratio, , anycombination thereof is from about 2:1 to about 10:1. In some embodiments, a molar ratio of :, , , or any combination thereof is from about 2:1 to about 7:1. Insome embodiments, a molar ratio, ,thereof is from about 3:1 to about 7:1. In some embodiments, a molar ratio of : ,, any combination thereof is from about 4:1 to about 7:1. In someWSGR Docket No.: 56017-733.601embodiments, a molar ratio, , any combination thereofis about 4:1.

[0311] In some embodiments, a molar ratio, , anycombination thereof is from about 1:1, from about 1:2, from about 1:3, from about 1:4, from about 1:5, from about 1:6, from about 1:7, from about 1:8, from about 1:9, from about 1:10, from about 1:11, from about 1:12, from about 1:13, from about 1:14, from about 1:15, from about 1:16, from about 1:17, from about 1:18, from about 1:19, from about 1:20, from about 1:21, from about 1:22, from about 1:23, from about 1:24, from about 1:25, from about 1:26, from about 1:27, from about 1:28, from about 1:29, or from about 1:30, or any ratio between any two of these values.

[0312] In some embodiments, a molar ratio, ,combination thereof is from about 1:1, from about 2:1, from about 3:1, from about 4:1, from about 5:1, from about 6:1, from about 7:1, from about 8:1, from about 9:1, from about 10:1, from about 11:1, from about 12:1, from about 13:1, from about 14:1, from about 15:1, from about 16:1, from about 17:1, from about 18:1, from about 19:1, from about 20:1, from about 21:1, from about 22:1, from about 23:1, from about 24:1, from about 25:1, from about 26:1, from about 27:1, from about 28:1, or from about 29:1, from about 30:1, or any ratio between any two of these values.

[0313] In some embodiments, a molar ratio, ,combination thereof is to about 1:2, to about 1:3, to about 1:4, to about 1:5, to about 1:6, to about 1:7, to about 1:8, to about 1:9, to about 1:10, to about 1:11, to about 1:12, to about 1:13, to about 1:14, to about 1:15, to about 1:16, to about 1:17, to about 1:18, to about 1:19, to about 1:20, to about 1:21, to about 1:22, to about 1:23, to about 1:24, to about 1:25, to about 1:26, to about 1:27, to about 1:28, to about 1:29, or to about 1:30, or any ratio between any two of these values.WSGR Docket No.: 56017-733.601

[0314] In some embodiments, a molar ratio, , anycombination thereof is to about 1:1, to about 2:1, to about 3:1, to about 4:1, to about 5:1, to about 6:1, to about 7:1, to about 8:1, to about 9:1, to about 10:1, to about 11:1, to about 12:1, to about 13:1, to about 14:1, to about 15:1, to about 16:1, to about 17:1, to about 18:1, to about 19:1, to about 20:1, to about 21:1, to about 22:1, to about 23:1, to about 24:1, to about 25:1, to about 26:1, to about 27:1, to about 28:1, to about 29:1, or to about 30:1, or any ratio between any two of these values.

[0315] In some embodiments, a molar ratio, ,combination thereof is from about 1:1 to about 1:2, from about 1:1 to about 1:3, from about 1:1 to about 1:4, from about 1:1 to about 1:5, from about 1:1 to about 1:6, from about 1:1 to about 1:7, from about 1:1 to about 1:8, from about 1:1 to about 1:9, from about 1:1 to about 1:10, from about 1:1 to about 1:11, from about 1:1 to about 1:12, from about 1:1 to about 1:13, from about 1:1 to about 1:14, from about 1:1 to about 1:15, from about 1:1 to about 1:16, from about 1:1 to about 1:17, from about 1:1 to about 1:18, from about 1:1 to about 1:19, from about 1:1 to about 1:20, from about 1:1 to about 1:21, from about 1:1 to about 1:22, from about 1:1 to about 1:23, from about 1:1 to about 1:24, from about 1:1 to about 1:25, from about 1:1 to about 1:26, from about 1:1 to about 1:27, from about 1:1 to about 1:28, from about 1:1 to about 1:29, or from about 1:1 to about 1:30.

[0316] In some embodiments, a molar ratio, ,combination thereof is from about 1:1 to about 1:30, from about 1:2 to about 1:30, from about 1:3 to about 1:30, from about 1:4 to about 1:30, from about 1:5 to about 1:30, from about 1:6 to about 1:30, from about 1:7 to about 1:30, from about 1:8 to about 1:30, from about 1:9 to about 1:30, from about 1:10 to about 1:30, from about 1:11 to about 1:30, from about 1:12 to about 1:30, from about 1:13 to about 1:30, from about 1:14 to about 1:30, from about 1:15 to about 1:30, from about 1:16 to about 1:30, from about 1:17 to about 1:30, from about 1:18 to about 1:30, from about 1:19WSGR Docket No.: 56017-733.601 to about 1:30, from about 1:20 to about 1:30, from about 1:21 to about 1:30, from about 1:22 to about 1:30, from about 1:23 to about 1:30, from about 1:24 to about 1:30, from about 1:25 to about 1:30, from about 1:26 to about 1:30, from about 1:27 to about 1:30, from about 1:28 to about 1:30, or from about 1:29 to about 1:30.

[0317] In some embodiments, a molar ratio, , anycombination thereof is from about 1:1 to about 2:1, from about 1:1 to about 3:1, from about 1:1 to about 4:1, from about 1:1 to about 5:1, from about 1:1 to about 6:1, from about 1:1 to about 7:1, from about 1:1 to about 8:1, from about 1:1 to about 9:1, from about 1:1 to about 10:1, from about 1:1 to about 11:1, from about 1:1 to about 12:1, from about 1:1 to about 13:1, from about 1:1 to about 14:1, from about 1:1 to about 15:1, from about 1:1 to about 16:1, from about 1:1 to about 17:1, from about 1:1 to about 18:1, from about 1:1 to about 19:1, from about 1:1 to about 20:1, from about 1:1 to about 21:1, from about 1:1 to about 22:1, from about 1:1 to about 23:1, from about 1:1 to about 24:1, from about 1:1 to about 25:1, from about 1:1 to about 26:1, from about 1:1 to about 27:1, from about 1:1 to about 28:1, from about 1:1 to about 29:1, or from about 1:1 to about 30:1.

[0318] In some embodiments, a molar ratio, ,combination thereof is from about 1:1 to about 30:1, from about 2:1 to about 30:1, from about 3:1 to about 30:1, from about 4:1 to about 30:1, from about 5:1 to about 30:1, from about 6:1 to about 30:1, from about 7:1 to about 30:1, from about 8:1 to about 30:1, from about 9:1 to about 30:1, from about 10:1 to about 30:1, from about 11:1 to about 30:1, from about 12:1 to about 30:1, from about 13:1 to about 30:1, from about 14:1 to about 30:1, from about 15:1 to about 30:1, from about 16:1 to about 30:1, from about 17:1 to about 30:1, from about 18:1 to about 30:1, from about 19:1 to about 30:1, from about 20:1 to about 30:1, from about 21:1 to about 30:1, from about 22:1 to about 30:1, from about 23:1 to about 30:1, from about 24:1 to about 30:1, from about 25:1 to about 30:1, from about 26:1 to about 30:1, from about 27:1 to about 30:1, from about 28:1 to about 30:1, or from about 29:1 to about 30:1.WSGR Docket No.: 56017-733.601

[0319] In some embodiments, a molar ratio, , anycombination thereof is from about 1:1 to about 10:1, from about 2:1 to about 10:1, from about 3:1 to about 10:1, from about 4:1 to about 10:1, from about 5:1 to about 10:1, from about 6:1 to about 10:1, from about 7:1 to about 10:1, from about 8:1 to about 10:1, or from about 9:1 to about 10:1.In some embodiments, a molar ratio, , any combinationthereof is from about 1:1 to about 10:1, from about 1:1 to about 9:1, from about 1:1 to about 8:1, from about 1:1 to about 7:1, from about 1:1 to about 6:1, from about 1:1 to about 5:1, from about 1:1 to about 4:1, from about 1:1 to about 3:1, or from about 1:1 to about 2:1.

[0320] In some embodiments, a molar ratio, ,combination thereof is from about 1:1 to about 7:1, from about 2:1 to about 7:1, from about 3:1 to about 7:1, from about 4:1 to about 7:1, from about 5:1 to about 7:1, or from about 6:1 to about7:1. In some embodiments, a molar ratio of, ,combination thereof is from about 1:1 to about 7:1, from about 1:1 to about 6:1, from about 1:1 to about 5:1, from about 1:1 to about 4:1, from about 1:1 to about 3:1, or from about 1:1 to about 2:1.

[0321] In some embodiments, a molar ratio, ,combination thereof is about 1:1 , about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:11, about 1:12, about 1:13, about 1:14, about 1:15, aboutWSGR Docket No.: 56017-733.601 1:16, about 1:17, about 1:18, about 1:19, about 1:20, about 1:21, about 1:22, about 1:23, about 1:24, about 1:25, about 1:26, about 1:27, about 1:28, about 1:29, or about 1:30, or any ratio between any two of these values.

[0322] In some embodiments, a molar ratio, ,combination thereof is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 11:1, about 12:1, about 13:1, about 14:1, about 15:1, about 16:1, about 17:1, about 18:1, about 19:1, about 20:1, about 21:1, about 22:1, about 23:1, about 24:1, about 25:1, about 26:1, about 27:1, about 28:1, about 29:1, or about 30:1, or any ratio between any two of these values.

[0323] In some embodiments, a molar ratio of , , , or anycombination thereof: is about 1:1 to about 1:4. In some embodiments, a molar ratio of ,some a , , , or anythereof: is from about 1:3 to about 1:4. In some embodiments, a molar ratio of,,, is from about 1:1 to about 1:3. InWSGR Docket No.: 56017-733.601some embodiments, a molar ratio of , , , or any combinationthereof: is from about 1:1 to about 1:2. In some embodiments, a molar ratio of ,some a , , , or anythereof: is from about 1:2 to about 1:3.In some embodiments, a molar ratio of ,some a , , , or anythereof: is about 1:1. In some embodiments, a molar ratio of,,,or any combination thereof: is about 1:2. In some embodiments, a molar ratio ofWSGR Docket No.: 56017-733.601, , , is about 1:3. In someembodiments, a molar ratio, , , any combination thereof:is about 1:4. Amylin analogs

[0324] In some embodiments, the therapeutic agent is an amylin analog or a functional variant thereof. In some embodiments, the amylin analog is a polypeptide having an amino acid sequence similar to human amylin. In some embodiments, the amylin analog comprises one or more chemical modifications that are different from endogenous human amylin. In some embodiments, the one or more chemical modifications render the amylin analog superior therapeutic effects compared with endogenous human amylin. In some embodiments, the amylin analog comprise a sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%.97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100% sequence identity to the endogenous human amylin sequence (e.g., SEQ ID NO: 1).

[0325] In some embodiments, the amylin analog or a functional variant thereof comprise a sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%.97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100% sequence identity to any one sequence selected from the group consisting of SEQ ID NOs:1-4. In some embodiments, the amylin analog or a functional variant thereof comprise any one sequence selected from the group consisting of SEQ ID NOs:1-4.

[0326] In some embodiments, the amylin analog or a functional variant thereof comprises a sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%.97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100% sequence identity to the sequence of SEQ ID NO: 5. In some embodiments, the amylin analog or a functional variant thereof comprises the sequence of SEQ ID NO: 5. In some embodiments, cagrilintide comprises the sequence of SEQ ID NO: 5. In some embodiments, Cys at the position 2 and Cys at the position 7 of SEQ ID NO: 5 forms a disulfide bond.WSGR Docket No.: 56017-733.601 Weight % Ratios of Cagrilintide:Counterion

[0327] In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.1 wt. % to 50.0 wt. % counterion relative to 99.9 wt. % to 50.0 wt. % an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.1 wt. % to 0.5 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.5 wt. % to 1.0 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.0 wt. % to 1.5 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.5 wt. % to 2.0 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.0 wt. % to 2.5 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.5 wt. % to 3.0 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.0 wt. % to 3.5 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.5 wt. % to 4.0 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.0 wt. % to 4.5 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g.,WSGR Docket No.: 56017-733.601 cagrilintide) or a functional variant thereof from 4.5 wt. % to 5.0 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.0 wt. % to 5.5 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.5 wt. % to 6.0 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.0 wt. % to 7.5 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.5 wt. % to 7.0 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.0 wt. % to 7.5 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.5 wt. % to 8.0 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.0 wt. % to 8.5 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.5 wt. % to 9.0 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.0 wt. % to 9.5 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.5 wt. % to 10.0 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 10.0 wt. % to 15.0 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylinWSGR Docket No.: 56017-733.601 analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 15.0 wt. % to 20.0 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 20.0 wt. % to 30.0 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 30.0 wt. % to 40.0 wt. % salt. In some embodiments, the compounds as provided herein, e.g., the salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of a counterion to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 40.0 wt. % to 50.0 wt. % salt. Exemplary Pharmaceutically Acceptable Salt Forms of Cagrilintide

[0328] In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof, comprises an aluminum salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof, comprises a sodium salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof, comprises a lithium salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof, comprises a potassium salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof, comprises a calcium salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof, comprises a magnesium salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof, comprises a zinc salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof, comprises an ammonium (i.e., NH4+) salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, the compound as provided herein, e.g., the saltWSGR Docket No.: 56017-733.601 form of an amylin analog (e.g., cagrilintide) or a functional variant thereof, comprises an NMe4+salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof, comprises an N(C1–4alkyl)4+salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof, comprises an amine cation salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof.

[0329] In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof comprises an aluminum salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof formulated in a wt. % ratio of from 0.1 wt. % to 50.0 wt. % aluminum cation relative to 99.9 wt. % to 50.0 wt. % an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.1 wt. % to 0.5 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.5 wt. % to 1.0 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.0 wt. % to 1.5 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.5 wt. % to 2.0 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.0 wt. % to 2.5 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.5 wt. % to 3.0 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.0 wt. % to 3.5 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios ofWSGR Docket No.: 56017-733.601 aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.5 wt. % to 4.0 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.0 wt. % to 4.5 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.5 wt. % to 5.0 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.0 wt. % to 5.5 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.5 wt. % to 6.0 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.0 wt. % to 7.5 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.5 wt. % to 7.0 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.0 wt. % to 7.5 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.5 wt. % to 8.0 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.0 wt. % to 8.5 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.5 wt. % to 9.0 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.0 wt. % to 9.5 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylinWSGR Docket No.: 56017-733.601 analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.5 wt. % to 10.0 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 10.0 wt. % to 15.0 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 15.0 wt. % to 20.0 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 20.0 wt. % to 30.0 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 30.0 wt. % to 40.0 wt. % aluminum salt. In some embodiments, certain aluminum salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of aluminum salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 40.0 wt. % to 50.0 wt. % aluminum salt.

[0330] In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof comprises a sodium salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof formulated in a wt. % ratio of from 0.1 wt. % to 50.0 wt. % sodium cation relative to 99.9 wt. % to 50.0 wt. % an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.1 wt. % to 0.5 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.5 wt. % to 1.0 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.0 wt. % to 1.5 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.5 wt. % to 2.0 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g.,WSGR Docket No.: 56017-733.601 cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.0 wt. % to 2.5 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.5 wt. % to 3.0 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.0 wt. % to 3.5 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.5 wt. % to 4.0 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.0 wt. % to 4.5 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.5 wt. % to 5.0 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.0 wt. % to 5.5 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.5 wt. % to 6.0 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.0 wt. % to 7.5 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.5 wt. % to 7.0 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.0 wt. % to 7.5 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.5 wt. % to 8.0 wt. %WSGR Docket No.: 56017-733.601 sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.0 wt. % to 8.5 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.5 wt. % to 9.0 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.0 wt. % to 9.5 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.5 wt. % to 10.0 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 10.0 wt. % to 15.0 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 15.0 wt. % to 20.0 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 20.0 wt. % to 30.0 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 30.0 wt. % to 40.0 wt. % sodium salt. In some embodiments, certain sodium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of sodium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 40.0 wt. % to 50.0 wt. % sodium salt.

[0331] In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof comprises a lithium salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof formulated in a wt. % ratio of from 0.1 wt. % to 50.0 wt. % lithium cation relative to 99.9 wt. % to 50.0 wt. % an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.1 wt.WSGR Docket No.: 56017-733.601 % to 0.5 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.5 wt. % to 1.0 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.0 wt. % to 1.5 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.5 wt. % to 2.0 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.0 wt. % to 2.5 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.5 wt. % to 3.0 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.0 wt. % to 3.5 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.5 wt. % to 4.0 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.0 wt. % to 4.5 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.5 wt. % to 5.0 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.0 wt. % to 5.5 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.5 wt. % to 6.0 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.0 wt. % to 7.5 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylinWSGR Docket No.: 56017-733.601 analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.5 wt. % to 7.0 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.0 wt. % to 7.5 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.5 wt. % to 8.0 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.0 wt. % to 8.5 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.5 wt. % to 9.0 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.0 wt. % to 9.5 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.5 wt. % to 10.0 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 10.0 wt. % to 15.0 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 15.0 wt. % to 20.0 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 20.0 wt. % to 30.0 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 30.0 wt. % to 40.0 wt. % lithium salt. In some embodiments, certain lithium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of lithium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 40.0 wt. % to 50.0 wt. % lithium salt.WSGR Docket No.: 56017-733.601

[0332] In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof comprises a potassium salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof formulated in a wt. % ratio of from 0.1 wt. % to 50.0 wt. % potassium cation relative to 99.9 wt. % to 50.0 wt. % an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.1 wt. % to 0.5 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.5 wt. % to 1.0 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.0 wt. % to 1.5 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.5 wt. % to 2.0 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.0 wt. % to 2.5 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.5 wt. % to 3.0 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.0 wt. % to 3.5 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.5 wt. % to 4.0 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.0 wt. % to 4.5 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.5 wt. % to 5.0 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylinWSGR Docket No.: 56017-733.601 analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.0 wt. % to 5.5 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.5 wt. % to 6.0 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.0 wt. % to 7.5 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.5 wt. % to 7.0 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.0 wt. % to 7.5 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.5 wt. % to 8.0 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.0 wt. % to 8.5 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.5 wt. % to 9.0 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.0 wt. % to 9.5 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.5 wt. % to 10.0 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 10.0 wt. % to 15.0 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 15.0 wt.WSGR Docket No.: 56017-733.601 % to 20.0 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 20.0 wt. % to 30.0 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 30.0 wt. % to 40.0 wt. % potassium salt. In some embodiments, certain potassium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of potassium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 40.0 wt. % to 50.0 wt. % potassium salt.

[0333] In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof comprises a calcium salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof formulated in a wt. % ratio of from 0.1 wt. % to 50.0 wt. % calcium cation relative to 99.9 wt. % to 50.0 wt. % an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.1 wt. % to 0.5 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.5 wt. % to 1.0 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.0 wt. % to 1.5 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.5 wt. % to 2.0 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.0 wt. % to 2.5 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.5 wt. % to 3.0 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.0 wt. % to 3.5 wt. %WSGR Docket No.: 56017-733.601 calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.5 wt. % to 4.0 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.0 wt. % to 4.5 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.5 wt. % to 5.0 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.0 wt. % to 5.5 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.5 wt. % to 6.0 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.0 wt. % to 7.5 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.5 wt. % to 7.0 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.0 wt. % to 7.5 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.5 wt. % to 8.0 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.0 wt. % to 8.5 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.5 wt. % to 9.0 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to anWSGR Docket No.: 56017-733.601 amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.0 wt. % to 9.5 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.5 wt. % to 10.0 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 10.0 wt. % to 15.0 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 15.0 wt. % to 20.0 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 20.0 wt. % to 30.0 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 30.0 wt. % to 40.0 wt. % calcium salt. In some embodiments, certain calcium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of calcium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 40.0 wt. % to 50.0 wt. % calcium salt.

[0334] In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof comprises a magnesium salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof formulated in a wt. % ratio of from 0.1 wt. % to 50.0 wt. % magnesium cation relative to 99.9 wt. % to 50.0 wt. % an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.1 wt. % to 0.5 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.5 wt. % to 1.0 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.0 wt. % to 1.5 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. %WSGR Docket No.: 56017-733.601 ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.5 wt. % to 2.0 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.0 wt. % to 2.5 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.5 wt. % to 3.0 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.0 wt. % to 3.5 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.5 wt. % to 4.0 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.0 wt. % to 4.5 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.5 wt. % to 5.0 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.0 wt. % to 5.5 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.5 wt. % to 6.0 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.0 wt. % to 7.5 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.5 wt. % to 7.0 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.0 wt. % to 7.5 wt. % magnesium salt. In some embodiments, certain magnesium salt formsWSGR Docket No.: 56017-733.601 of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.5 wt. % to 8.0 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.0 wt. % to 8.5 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.5 wt. % to 9.0 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.0 wt. % to 9.5 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.5 wt. % to 10.0 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 10.0 wt. % to 15.0 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 15.0 wt. % to 20.0 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 20.0 wt. % to 30.0 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 30.0 wt. % to 40.0 wt. % magnesium salt. In some embodiments, certain magnesium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of magnesium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 40.0 wt. % to 50.0 wt. % magnesium salt.

[0335] In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof comprises a zinc salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof formulated in a wt. % ratio of from 0.1 wt. % to 50.0 wt. % zinc cation relative to 99.9 wt. % to 50.0 wt. % an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, certain zinc salt forms of an amylin analogWSGR Docket No.: 56017-733.601 (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.1 wt. % to 0.5 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.5 wt. % to 1.0 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.0 wt. % to 1.5 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.5 wt. % to 2.0 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.0 wt. % to 2.5 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.5 wt. % to 3.0 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.0 wt. % to 3.5 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.5 wt. % to 4.0 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.0 wt. % to 4.5 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.5 wt. % to 5.0 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.0 wt. % to 5.5 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.5 wt. % to 6.0 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.0 wt. % toWSGR Docket No.: 56017-733.601 7.5 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.5 wt. % to 7.0 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.0 wt. % to 7.5 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.5 wt. % to 8.0 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.0 wt. % to 8.5 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.5 wt. % to 9.0 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.0 wt. % to 9.5 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.5 wt. % to 10.0 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 10.0 wt. % to 15.0 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 15.0 wt. % to 20.0 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 20.0 wt. % to 30.0 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 30.0 wt. % to 40.0 wt. % zinc salt. In some embodiments, certain zinc salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of zinc salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 40.0 wt. % to 50.0 wt. % zinc salt.

[0336] In some embodiments, the compound as provided herein, e.g., the salt form of an amylinWSGR Docket No.: 56017-733.601 analog (e.g., cagrilintide) or a functional variant thereof comprises an ammonium salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof formulated in a wt. % ratio of from 0.1 wt. % to 50.0 wt. % ammonium cation relative to 99.9 wt. % to 50.0 wt. % an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.1 wt. % to 0.5 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.5 wt. % to 1.0 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.0 wt. % to 1.5 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.5 wt. % to 2.0 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.0 wt. % to 2.5 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.5 wt. % to 3.0 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.0 wt. % to 3.5 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.5 wt. % to 4.0 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.0 wt. % to 4.5 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.5 wt. % to 5.0 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. %WSGR Docket No.: 56017-733.601 ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.0 wt. % to 5.5 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.5 wt. % to 6.0 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.0 wt. % to 7.5 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.5 wt. % to 7.0 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.0 wt. % to 7.5 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.5 wt. % to 8.0 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.0 wt. % to 8.5 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.5 wt. % to 9.0 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.0 wt. % to 9.5 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.5 wt. % to 10.0 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 10.0 wt. % to 15.0 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 15.0 wt. % to 20.0 wt. % ammonium salt. In some embodiments, certain ammonium saltWSGR Docket No.: 56017-733.601 forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 20.0 wt. % to 30.0 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 30.0 wt. % to 40.0 wt. % ammonium salt. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of ammonium salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 40.0 wt. % to 50.0 wt. % ammonium salt.

[0337] In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof comprises an NMe4+salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof formulated in a wt. % ratio of from 0.1 wt. % to 50.0 wt. % NMe4+cation relative to 99.9 wt. % to 50.0 wt. % an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, certain ammonium salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.1 wt. % to 0.5 wt. % NMe4+ salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.5 wt. % to 1.0 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.0 wt. % to 1.5 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.5 wt. % to 2.0 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.0 wt. % to 2.5 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.5 wt. % to 3.0 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.0 wt. % to 3.5 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+WSGR Docket No.: 56017-733.601 salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.5 wt. % to 4.0 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.0 wt. % to 4.5 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.5 wt. % to 5.0 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.0 wt. % to 5.5 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.5 wt. % to 6.0 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.0 wt. % to 7.5 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.5 wt. % to 7.0 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.0 wt. % to 7.5 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.5 wt. % to 8.0 wt. % NMe4+salt. In some embodiments, certain NMe4 salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.0 wt. % to 8.5 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.5 wt. % to 9.0 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.0 wt. % to 9.5 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 9.5 wt. % to 10.0WSGR Docket No.: 56017-733.601 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 10.0 wt. % to 15.0 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 15.0 wt. % to 20.0 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 20.0 wt. % to 30.0 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 30.0 wt. % to 40.0 wt. % NMe4+salt. In some embodiments, certain NMe4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of NMe4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 40.0 wt. % to 50.0 wt. % NMe4+salt.

[0338] In some embodiments, the compound as provided herein, e.g., the salt form of an amylin analog (e.g., cagrilintide) or a functional variant thereof comprises an N(C1–4alkyl)4+salt of an amylin analog (e.g., cagrilintide) or a functional variant thereof formulated in a wt. % ratio of from 0.1 wt. % to 50.0 wt. % N(C1–4alkyl)4+cation relative to 99.9 wt. % to 50.0 wt. % an amylin analog (e.g., cagrilintide) or a functional variant thereof. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1–4alkyl)4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.1 wt. % to 0.5 wt. % N(C1–4alkyl)4+salt. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1–4alkyl)4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 0.5 wt. % to 1.0 wt. % N(C1–4alkyl)4+salt. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1–4alkyl)4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.0 wt. % to 1.5 wt. % N(C1–4alkyl)4+salt. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1–4alkyl)4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 1.5 wt. % to 2.0 wt. % N(C1– 4alkyl)4+salt. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1–4alkyl)4+saltWSGR Docket No.: 56017-733.601 to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.0 wt. % to 2.5 wt. % N(C1–4alkyl)4+salt. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1–4alkyl)4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 2.5 wt. % to 3.0 wt. % N(C1–4alkyl)4+salt. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1– 4alkyl)4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.0 wt. % to 3.5 wt. % N(C1–4alkyl)4+salt. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1–4alkyl)4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 3.5 wt. % to 4.0 wt. % N(C1–4alkyl)4+salt. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1–4alkyl)4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.0 wt. % to 4.5 wt. % N(C1–4alkyl)4+salt. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1–4alkyl)4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 4.5 wt. % to 5.0 wt. % N(C1–4alkyl)4+salt. In some embodiments, certain N(C1– 4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1–4alkyl)4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.0 wt. % to 5.5 wt. % N(C1–4alkyl)4+salt. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1–4alkyl)4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 5.5 wt. % to 6.0 wt. % N(C1–4alkyl)4+salt. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1–4alkyl)4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.0 wt. % to 7.5 wt. % N(C1–4alkyl)4+salt. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1–4alkyl)4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 6.5 wt. % to 7.0 wt. % N(C1– 4alkyl)4+salt. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1–4alkyl)4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.0 wt. % to 7.5 wt. % N(C1–4alkyl)4+salt. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1–4alkyl)4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 7.5 wt. % to 8.0WSGR Docket No.: 56017-733.601 wt. % N(C1–4alkyl)4+salt. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1– 4alkyl)4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.0 wt. % to 8.5 wt. % N(C1–4alkyl)4+salt. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintide) or a functional variant thereof are formulated in wt. % ratios of N(C1–4alkyl)4+salt to an amylin analog (e.g., cagrilintide) or a functional variant thereof from 8.5 wt. % to 9.0 wt. % N(C1–4alkyl)4+salt. In some embodiments, certain N(C1–4alkyl)4+salt forms of an amylin analog (e.g., cagrilintid...

Claims

WSGR Docket No.: 56017-733.601 CLAIMS What is claimed is:

1. A compound comprising the structure of Formula I: Formula I, wherein: cagrilintide; andwherein does not have the structure, wherein R8, R9, and R10are independently C1-C5 alkyl, and R11is C2-C5 alkyl that is unsubstituted or substituted with 1 or more hydroxyl.

2. The compound of claim 1, wherein the anion of cagrilintide derives from the structure of the compound in Table 2.

3. The compound of claim 1 or 2, wherein the cationic component is selected from the group consisting of alkali metal, alkaline earth metal, a metal ion, ammonium (NH4+), a protonated or positively (+) charged ion from an aliphatic primary amine, secondary amine or tertiary amine, aralkyl amine, benzathine, benethamine, heterocyclic aromatic amine, quaternary ammonium, nontoxic quaternary ammonium, 1H-imidazole, substituted- imidazole, pyrrolidine, substituted pyrrolidine, piperidine or substituted piperidine, piperazine or substituted piperazine, morpholine, substituted morpholine, basic amino acid, aminoguanidine, guanidine derivatives, and an amine cation formed using a counterion.

4. The compound of claim 3, wherein: (i) a metal ion comprises aluminum, sodium, lithium, potassium, magnesium, calcium, or zinc; (ii) the aliphatic primary amine, secondary amine, or tertiary amine comprises 2- aminoethanol, tromethamine, dimethylamine, diethylamine, N-ethyl-glucamine, hydrabamine, trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, (2,2′,2″-nitrilotris(ethanol)), 2-WSGR Docket No.: 56017-733.601 diethylaminoethanol, procaine or substituted procaine, meglumine, carnitine, ethylenediamine, choline, or acetylcholine; (iii) aralkyl amine comprises Ν,Ν-dibenzylethylenediamine; (iv) heterocyclic aromatic amine comprises pyridine, pyrimidine, picoline, quinoline, or isoquinoline; (v) quaternary ammonium comprises NH4+or betaine; (vi) nontoxic quaternary ammonium comprises NMe4+, N+(C1–4alkyl)4,), tetramethylammonium, tetraethylammonium, benzyltrimethylammonium, benzyltriethylammonium, benzyltributylammonium, methyltrioctylammonium or tetrabutylammonium; (vii) substituted-imidazole comprises N-alkyl imidazole or N-methyl imidazole; (viii) substituted pyrrolidine comprises 1-alkyl pyrrolidine, 1-methyl pyrrolidine, or 1-(2- hydroxy-ethyl)-pyrrolidine); (ix) substituted piperidine comprises 1-alkyl piperidine or 1-methyl piperidine; (x) substituted piperazine comprises 1-alkyl piperazine, 1-methyl piperazine, 1,4-dialkyl piperazine, or 1,4-dimethyl piperazine; (xi) substituted morpholine comprises N-substituted morpholine, N-methyl morpholine ,or 4-(2-hydroxyethyl)-morpholine); (xii) basic amino acid comprises arginine, lysine, or histidine; (xiii) the amine cation is formed using a counterion selected from the group consisting of halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate; or (xiv) any combination thereof.

5. The compound of claim 4, wherein the substituted procaine comprises chloroprocaine.

6. The compound of claim 3, wherein the cationic component is betaine.

7. The compound of any one of claims 1-3, wherein the cationic component comprise the structure.

8. The compound of claim 1 or 2, wherein the cationic component is selected from the group consisting of those in Table 3.

9. The compound of claim 8, wherein any of the cationic components of Table 3 is provided in any of the molar ratios and weight ratios of Table 3 relative to one or more anions of cagrilintide.

10. The compound of claim 3, wherein the quaternary ammonium has the structure ofWSGR Docket No.: 56017-733.601 wherein: R8, R9, R10, and R11are each independently a substituted or unsubstituted group selected from C1-6 aliphatic, phenyl, cycloalkyl, 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

11. The compound of claim 3, wherein the quaternary ammonium has the structure of wherein: R8, R9, R10, and R11are each independently a substituted or unsubstituted C1-6aliphatic.

12. The compound of claim 3, wherein the quaternary ammonium has the structure of wherein: (i) R8, R9, R10, and R11are independently C1-C6 alkyl; (ii) R8, R9, R10, and R11are independently C1-C4alkyl; (iii) R8, R9, and R10are C2alkyl and R11is C1alkyl; (iv) R8, R9, and R10are C4 alkyl and R11is C1 alkyl; (v) all of R8, R9, R10, and R11are C1alkyl; (vi) all of R8, R9, R10, and R11are C2alkyl; (vii) all of R8, R9, R10, and R11are C3 alkyl; or (viii) all of R8, R9, R10, and R11are C4 alkyl.

13. The compound of claim 3, wherein the quaternary ammonium has the structure of.

14. The compound of claim 3, wherein the quaternary ammonium has the structure ofWSGR Docket No.: 56017-733.

601.

15. The compound of any one of claims 1-14, wherein the cationic component and anion of cagrilintide are provided in a molar ratio of anion of cagrilintide to cationic component that is selected from the group consisting of about 1:1, 1:2, and 1:

3.

16. The compound of any one of claims 1-14, wherein the cationic component and anion of cagrilintide are provided in a molar ratio of anion of cagrilintide to cationic component that is from about 1:2 to about 1:

3.

17. The compound of any one of claims 1-14, wherein the cationic component and anion of cagrilintide are provided in a molar ratio of anion of cagrilintide to cationic component that is selected from the group consisting of about 1:2 and about 1:

3.

18. The compound of any one of claims 1-14, wherein the cationic component and anion of cagrilintide are provided in a molar ratio of anion of cagrilintide to cationic component that is about 1:3.

19. The compound of any one of claims 1-14, wherein a molar ratio of : isselected from the group consisting of about 1:1, 1:2, and 1:3.

20. The compound of any one of claims 1-14, wherein a molar ratio of : isselected from the group consisting of from about 1:2 to about 1:3.

21. The compound of any one of claims 1-14, wherein a molar ratio of : isselected from the group consisting of about 1:2 and about 1:3.

22. The compound of any one of claims 1-14, wherein a molar ratio of : is about1:

3.

23. A compound comprising the structure of Formula IIa, Formula IIb, Formula IIc, or any combination thereof: Formula IIa,WSGR Docket No.: 56017-733.601Formula IIb,Formula IIc, wherein, , , any combination thereof is one or morecations of cagrilintide; andanionic component.

24. The compound of claim 23, wherein the one or more cations of cagrilintide derive from the structure of the compound in Table 2.

25. The compound of claim 23 or 24, wherein the anionic component is selected from the group consisting of besylate, mesylate, tosylate, sulfonate, sulfate, methylsulfate, camsylate, isethionate, edisylate, 1-hydroxy-2-naphthoate, 2,2-dichloroacetate, 2- hydroxyethanesulfonate, 2-oxoglutarate, 4-acetamidobenzoate, 4-aminosalicylate, acetate, adipate, ascorbate, aspartate, benzenesulfonate, benzoate, bromide, chloride, camphorate, camphor-10-sulfonate, caprate (decanoate), caproate (hexanoate), caprylate (octanoate), carbonate, cinnamate, citrate, cyclamate, dodecylsulfate, dodecylsulfurate, ethanesulfonate, ethane-1,2-disulfonate, ethanesulfonate, formate, fumarate, galactarate, gentisate, glucoheptonate, gluconate, glutantate, glucuronate, glutamate, glutarate, glycerophosphorate, glycine, glycolate, hippurate, hydrobromate, hydroiodide, hydrochlorate, isobutyrate, lactate, lactobionate, laurate, lysine, maleate, malate, malonate, mandelate, methanesulfonate , naphthalene-1,5-disulfonate, naphthalene-2-sulfonate, nicotinate, nitrate, oleate, orotate, oxalate, palmitate, pamoate, phosphorate, proprionate, pyroglutamate, salicylate, sebacate, stearate, succinate, sulfurate, tannate, tartarate, thiocyanate, toluenesulfonate, undecylenate, α-lipoate, 12-hydroxystearate, 2-(4- isobutylphenyl)propionate, 2-(4,4-dimethyl-2-pentanyl)-5,7,7-trimethyloctanoate, 2-WSGR Docket No.: 56017-733.601 aminoethanesulfonate, 2-hexyldecanoate, 2-hydroxyhippurate, 3-(4- hydroxyphenyl)propionate, 3-methylcrotonate, 3,3-diphenylpropionate, 3,4- dihydroxbenzoate, ,5-dihydroxybenzoate, 4-acetamido-benzoate, 3,7-dimethyloctanoate, 4-hydroxybenzenesulfonate, 4-hydroxybenzoate, 4-methylhexanoate, 4-methyloctanoate, valerate salts including 4-methylvalerate, 5-norbornene-2-carboxylate, 8-[(2- hydroxybenzoyl)amino]octanoate, abietate, acetylcysteine, aconitate, arachidonate, behenate, caffeate, chenodeoxycholate, citronellate, crotonate, galactonate, deoxycholate, dihydrocaffeate, 2-phenylpropionate (hydratropate), tropate, eicosanedioate, eicosapentanoate (EPA), elaidate, ellagate, erucate, ethylenediaminetetraacetate (EDTA), geranate, heptanoate, hydrocinnamate (3-phenylpropionate), isovalerate, glutathione reduced, lactate, laurate, levulinate, linoleate, linolenate, lithocholate, mesaconate, nonanoate, oxalate, coumarate, palmitate, perillate, pimelate, 3–phenylpropionate, pivalate, propionate, pyruvate, ricinoleate, salicylate, 2-hydroxybenzoate, sinapinate (3,5- dimethoxy-4-hydroxycinnamate), sorbate, syringate, tiglate, 2-decenoate, 2-hexenoate, 2- octenoate, 3-octenoate, 7-octenoate, ferulate, undecanoate, valerate, vanillate, perchlorate, alginate, bisulfate, borate, butyrate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, glycerophosphate, hemisulfate, hydroiodide, lauryl sulfate, 2–naphthalenesulfonate, pectinate, persulfate, phosphate, tartrate, o-(4- hydroxybenzoyl)benzoate, 1,2,-ethanedisulfonate, chlorobenzenesulfonate, 4- methylbicyclo[2.2.2]oct-2-ene-carboxylate, 4.4’-methylenebis(3-hydroxy-2- ene-1- carboxylate), trimethylacetate, tertiary butylacetate, lauryl sulfurate, hydroxynaphthoate, muconate, α-ketoglutarate, p-toluenesulfonate, p-coumarate, and p- chlorobenzenesulfonate.

26. The compound of claim 23 or 24, wherein the anionic component is selected from the group consisting of those in Table 4.

27. The compound of claim 26, wherein any of the anionic components of Table 4 is provided in any of the molar ratios and weight ratios of Table 4 relative to one or more cations of cagrilintide.

28. The compound of any one of claims 23-27, wherein the anionic component and cation of cagrilintide are provided in a molar ratio of cation of cagrilintide to anionic component that is selected from the group consisting of about 1:1, 1:2, 1:3, and 1:

4.

29. The compound of any one of claims 23-27, wherein the anionic component and cation of cagrilintide are provided in a molar ratio of cation of cagrilintide to anionic component that is from about 1:2 to about 1:

4.

30. The compound of any one of claims 23-27, wherein the anionic component and cation ofWSGR Docket No.: 56017-733.601 cagrilintide are provided in a molar ratio of cation of cagrilintide to anionic component that is about 1:

3.

31. The compound of any one of claims 23-27, wherein the anionic component and cation of cagrilintide are provided in a molar ratio of cation of cagrilintide to anionic component that is about 1:4.of any one of claims 23-27, wherein a molar ratio of ,,, or any combination thereof: is selected from the group consisting ofabout 1:1, 1:2, 1:3, and 1:4.of any one of claims 23-27, wherein a molar ratio of ,,, or any combination thereof: is selected from the group consisting ofabout 1:2, 1:3, and 1:4.of any one of claims 23-27, wherein a molar ratio of ,,, or any combination thereof: is about 1:4.

35. The compound of any one of claims 23-27, wherein a molar ratio of ,WSGR Docket No.: 56017-733.601,, or any combination thereof: is about 1:3.

36. The compound of any one of claims 1-35, wherein: (i) a weight % (wt. %) ratio of : is from about 0.1 wt. %: 99.9 wt. % to about 20.0 wt. %: 80.0 wt. %; or (ii) a weight % (wt. %) ratio, , , or any combination thereof is from about 0.1 wt. %: 99.9 wt. % to about 20.0 wt. %: 80.0 wt. %.

37. The compound of any one of claims 1-36, wherein: (i) a molar ratio of : is from about 2:1 to about 10:1; or(ii) a molar ratio of : , , , or any combination thereof is from about 2:1 to about 10:

1.

38. The compound of any one of claims 1-37, wherein: (i) a molar ratio of : is from about 2:1 to about 7:1; or(ii) a molar ratio of : , , , or any combination thereof is from about 2:1 to about 7:

1.

39. The compound of any one of claims 1-38, wherein: (i) a molar ratio of : is from about 3:1 to about 7:1; orWSGR Docket No.: 56017-733.601 (ii) a molar ratio, , , any combination thereof is from about 3:1 to about 7:

1.

40. The compound of any one of claims 1-39, wherein: (i) a molar ratio of : is from about 4:1 to about 7:1; or(ii) a molar ratio of : , , , or any combination thereof is from about 4:1 to about 7:

1.

41. The compound of any one of claims 1-39, wherein:(i) a molar ratio of : is from about 3:1 to about 7:1; or(ii) a molar ratio of : , , , or any combination thereof is about 4:

1.

42. A compound comprising the structure of Formula I: Formula I, wherein: is an anion of cagrilintide; and is a cationic component, wherein the cationic component is betaine.

43. The compound of claim 42, wherein the cationic component comprises the structure of.WSGR Docket No.: 56017-733.601 44. The compound of claim 42, wherein the compound has a molar ratio of anion of cagrilintide to betaine that is from about 1:1 to about 1:4 of anion of cagrilintide:betaine.

45. The compound of claim 42, wherein the compound has a molar ratio of anion of cagrilintide to betaine that is from about 1:1 to about 1:3 of anion of cagrilintide:betaine.

46. The compound of claim 42, wherein the compound has a molar ratio of anion of cagrilintide to betaine that is about 1:1 of anion of cagrilintide:betaine.

47. The compound of claim 42, wherein the compound has a molar ratio of anion of cagrilintide to betaine that is about 1:2 of anion of cagrilintide:betaine.

48. The compound of claim 42, wherein the compound has a molar ratio of anion of cagrilintide to betaine that is about 1:3 of anion of cagrilintide:betaine.

49. The compound of claim 42, wherein the compound has a molar ratio of anion of cagrilintide to betaine that is about 1:4 of anion of cagrilintide:betaine.

50. The compound of claim 42, wherein the compound has a molar ratio of to that is from about 1:1 to about 1:4 of : .

51. The compound of claim 42, wherein the compound has a molar ratio of to that is from about 1:1 to about.

52. The compound of claim 42, wherein the compound has a molar ratio of to that is about 1:1 of anion.

53. The compound of claim 42, wherein the compound has a molar ratio of to that is about 1:2 of anion of : .

54. The compound of claim 42, wherein the compound has a molar ratio of to that is about 1:3 of anion.WSGR Docket No.: 56017-733.601 55. The compound of claim 42, wherein the compound has a molar ratio of to that is about 1:4 of anion.

56. The compound of any one of claims 42-55, wherein the compound has a wt % of betaine of from about 1.0 wt % to about 12.0 wt %, relative to a wt % of anion of cagrilintide of from about 99.0 wt % to about 88.0 wt %.

57. The compound of claim 56, wherein the compound has a wt % of betaine of from about 2.6 wt % to about 8.0 wt %, relative to a wt % of anion of cagrilintide of from about 97.4 wt % to about 92.0 wt %.

58. The compound of claim 56, wherein the compound has a wt % of betaine of about 8.0 wt %, relative to a wt % of anion of cagrilintide of about 92.0 wt %.

59. A compound comprising the structure of Formula IIIa:Formula IIIa, or a pharmaceutically acceptable salt thereof, wherein: is a covalent derivative of one or more carboxyl groups of cagrilintide, or a pharmaceutically acceptable salt thereof; and R100is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, or pentyl, fluoromethyl, difluoromethyl, trifluoromethyl, CHCH3OC(O)OCH2CH, -CH3, -CH2CH3, -CH(CH3)2, CH2CH2CH2CH3, C(CH3)3, -CH2CH2N(CH3)3+,substituted C1-6aliphatic, unsubstituted C1-6aliphatic, substituted (C1-22)alkyl, unsubstituted (C1-22)alkyl, substituted (C1-22)alkenyl, unsubstituted (C1-22)alkenyl, substituted phenyl, unsubstituted phenyl, substituted -C(O)R, unsubstituted -C(O)R, substituted -C(O)OR, unsubstituted - C(O)OR, substituted -C(O)N(R)2, unsubstituted -C(O)N(R)2, (C2-C12)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1- (alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N- (alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-WSGR Docket No.: 56017-733.601 (alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4- crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(C1-C2)alkylamino(C2-C3)alkyl (such as β-dimethylaminoethyl), carbamoyl-(C1-C2)alkyl, N,N-di(C1-C2)alkylcarbamoyl-(C1- C2)alkyl, piperidino-, pyrrolidino- or morpholino(C2-C3)alkyl, C1-6 aliphatic, (C1-22)alkyl, (C1-22)alkenyl, -C(O)R, -C(O)OR, -C(O)N(R)2, phenyl, 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and each occurrence of R is independently hydrogen or an optionally substituted group selected from C1-6aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

60. The compound of claim 59, wherein the compound of Formula IIIa does not have the structureFormula II, wherein R8, R9, and R10are independently C1-C5alkyl.

61. A compound comprising the structure of Formula IIIb:Formula IIIb or a pharmaceutically acceptable salt thereof; wherein:is a covalent derivative of one or more hydroxyl groups of cagrilintide, or a pharmaceutically acceptable salt thereof; and wherein:WSGR Docket No.: 56017-733.601 R101is selected from the group consisting of -CH2R, -C(O)R, -C(O)OR, -C(O)N(R)2, - OP(O)OROR, wherein each occurrence of R is independently hydrogen or an optionally substituted group selected from C1-6aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R101is -CH2OCH2CH2OH, unsubstituted C(O)C1-6alkyl, substituted C(O)C1-6alkyl, substituted C(O)phenyl or unsubstituted C(O)phenyl, -(C1-C6)alkanoyloxymethyl, -1- ((C1-C6)alkanoyloxy)ethyl, -1-methyl-1-((C1-C6)alkanoyloxy)ethyl, -(C1- C6)alkoxycarbonyloxymethyl, -N-(C1-C6)alkoxycarbonylaminomethyl, -succinoyl, -(C1- C6)alkanoyl, -α-amino(C1-C4)alkanoyl, -arylacyl, -α-aminoacyl, or -α-aminoacyl-α- aminoacyl, optionally, wherein each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)2, -P(O)(O(C1-C6)alkyl)2 or glycosyl, and optionally, wherein the radical results from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate.

62. The compound of claim 61, wherein R101is the unsubstituted C(O)C1-6alkyl comprising COCH3, COCH2CH3, or COCH(CH3)2), or R101is the substituted C(O)C1-6alkyl comprising COCF3, COCHCF2, or -COCH2CF.

63. The compound of claim 61, wherein R101is -C(O)R selected from the group consisting of -C(O)CH3 and -C(O)H, -C(O)OR that is -C(O)OH2), -C(O)N(R)2 selected from the group consisting of -C(O)NH2 and -C(O)N(CH3)2), or -OP(O)OROR that is - OP(O)OHOH.

64. The compound of claim 61, wherein R101is -CHCH3OC(O)OCH2CH3.

65. A compound comprising the structure of Formula IIIc and / or Formula IIId:and / orWSGR Docket No.: 56017-733.601 Formula IIIc Formula IIId or a pharmaceutically acceptable salt of each thereof; wherein:is each a covalent derivative of one or more amino or imidazole groups of cagrilintide, or a pharmaceutically acceptable salt thereof; and wherein: each of R102and R103is independently selected from the group consisting of -CH2R, - C(O)R, -C(O)OR, -C(O)N(R)2, -OP(O)OROR, wherein each occurrence of R is independently hydrogen or an optionally substituted group selected from C1-6aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each R102and R103is independently C(O)R, C(O)OR, C(O)R’, or C(O)NR’R”, where R’ and R” are each independently (C1-C10)alkyl, (C3-C7)cycloalkyl, benzyl, or each R102and R103is a natural α-aminoacyl or natural α-aminoacyl-natural α- aminoacyl, -C(OH)C(O)OY1, wherein Y1is H, (C1-C6)alkyl or benzyl, -C(OY2)Y3, wherein Y2is (C1-C4) alkyl and Y3is (C1-C6)alkyl, carboxy(C1-C6)alkyl, amino(C1- C4)alkyl or mono-N-or di-N,N-(C1-C6)alkylaminoalkyl, -C(Y4)Y5, wherein Y4is H or methyl and Y5is mono-N- or di-N,N-( C1-C6)alkylamino, morpholino, piperidin-1-yl or pyrrolidin-1-yl.

66. The compound of claim 65, wherein each R102and R103is independently - CH2OCH2CH2OH or unsubstituted C(O)C1-6alkyl.

67. The compound of claim 65, wherein R102is substituted C(O)C1-6alkyl comprising COCF3, COCHCF2, or -COCH2CF.

68. The compound of claim 65, wherein R102is substituted C(O)phenyl or unsubstituted C(O)phenyl.WSGR Docket No.: 56017-733.601 69. The compound of claim 65, wherein R102is CHCH3OC(O)OCH2CH3.

70. A compound comprising the structure of Formula IIIe: Formula IIIe, or a pharmaceutically acceptable salt thereof; wherein: is a covalent derivative of one or more thiol groups of cagrilintide, or a pharmaceutically acceptable salt thereof; and wherein: R104is -CH2OCH2CH2OH, unsubstituted C(O)C1-6alkyl, substituted C(O)C1-6alkyl, substituted C(O)phenyl or unsubstituted C(O)phenyl, -(C1-C6)alkanoyloxymethyl, -1- ((C1-C6)alkanoyloxy)ethyl, -1-methyl-1-((C1-C6)alkanoyloxy)ethyl, -(C1- C6)alkoxycarbonyloxymethyl, -N-(C1-C6)alkoxycarbonylaminomethyl, -succinoyl, -(C1- C6)alkanoyl, -α-amino(C1-C4)alkanoyl, -arylacyl and -α-aminoacyl, or -α-aminoacyl-α- aminoacyl, wherein each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)2, -P(O)(O(C1-C6)alkyl)2or glycosyl, wherein the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate; R104is selected from an optionally substituted group consisting of -CH2R; or R104is C(O)R, -C(O)OR, -C(O)N(R)2, or -OP(O)OROR, wherein each occurrence of R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

71. The compound of claim 70, wherein R104is -C(O)R comprising -C(O)CH3or -C(O)H), - C(O)OR comprising -C(O)OH2), -C(O)N(R)2 comprising -C(O)NH2 or -C(O)N(CH3)2), - OP(O)OROR comprising -OP(O)OHOH), or C(O)C1-6alkyl comprising COCH3, COCH2CH3, or COCH(CH3)2).

72. The compound of claim 70, wherein R104is substituted C(O)C1-6alkyl comprising COCF3, COCHCF2, or -COCH2CF).WSGR Docket No.: 56017-733.601 73. The compound of claim 70, wherein R104is CHCH3OC(O)OCH2CH3.

74. The compound of claim 70, wherein the compound of Formula IIIe is formed from the side chain thiol moiety of one or more of the Cys residues of cagrilintide.

75. The compound of claim 70, wherein the compound of Formula IIIe is formed from the side chain thiol moiety of one of the Cys residues of cagrilintide.

76. The compound of claim 70, wherein the compound of Formula IIIe is formed from the side chain thiol moiety of one of the Cys residues of cagrilintide.

77. A pharmaceutical composition comprising the compound of any one of claims 1-76, and a pharmaceutically acceptable excipient.

78. The pharmaceutical composition of claim 77, wherein the pharmaceutical composition is formulated for parenteral administration, oral administration, or implantable administration.

79. The pharmaceutical composition of claim 77 or 78, wherein the pharmaceutical composition is formulated for subcutaneous administration or intravenous administration.

80. A drug delivery device comprising the compound of any one of claims 1-76, or the pharmaceutical composition of any one of claims 77-79.

81. The drug delivery device of claim 80, wherein the drug delivery device is a syringe, a single-dose pen with an injection needle, or an autoinjector with an injection needle.

82. The drug delivery device of claim 80, wherein the drug delivery device is an implantable osmotic drug delivery device.

83. A kit comprising the compound of any one of claims 1-76, the pharmaceutical composition of any one of claims 77-79, or the drug delivery device of any one of claims 80-82.

84. The kit of claim 83, further comprising an instruction for use.

85. A method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of any one of claims 1-76, or the pharmaceutical composition of any one of claims 77-79, wherein the administering is effective to treat the disease or disorder in the subject.

86. The method of claim 85, wherein the compound or the pharmaceutical composition is administered to the subject using the drug delivery device of any one of claims 80-82.

87. The method of claim 85 or 86, wherein the disease or disorder is a metabolic disease or disorder, a cardiovascular disease or disorder, chronic kidney disease, or a neurological disease or disorder.WSGR Docket No.: 56017-733.601 88. The method of any one of claims 85-87, wherein the disease or disorder is selected from the group consisting of type 1 diabetes, type 2 diabetes, obesity, overweight, metabolic dysfunction–associated fatty liver disease (MAFLD), metabolic dysfunction-associated steatohepatitis (MASH), and nonalcoholic steatohepatitis (NASH).

89. The method of any one of claims 85-87, wherein the disease or disorder is selected from the group consisting of arrhythmia, coronary artery disease, heart failure, valve disease, aortic disease, congenital heart disease, heart attack, angina, cardiomyopathy, peripheral arterial disease, atherosclerosis, cardiac dysrhythmias, pericarditis, pulmonary hypertension, stroke, cerebrovascular disease, rheumatic heart disease, atrial fibrillation, Brugada syndrome, aortic stenosis, bradycardia, endocarditis, high cholesterol, and long QT syndrome.

90. The method of any one of claims 85-87, wherein the disease or disorder is Parkinson’s disease or Alzheimer disease.

91. The method of any one of claims 85-90, wherein the subject is human.

92. The method of any one of claims 85-91, wherein the compound or the pharmaceutical composition is administered to the subject via parenteral administration, oral administration, or implantable administration.

93. The method of any one of claims 85-92, wherein the compound or the pharmaceutical composition is administered to the subject via subcutaneous administration or intravenous administration.

94. A method of reducing weight in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of any one of claims 1-76 or the pharmaceutical composition of any one of claims 77-79, wherein the administering is effective to reduce weight in the subject.

95. The method of claim 94, wherein the compound or the pharmaceutical composition is administered to the subject using the drug delivery device of any one of claims 80-82.

96. The method of claim 94 or 95, wherein the subject is human.

97. The method of any one of claims 94-96, wherein the subject has obesity or is overweight.

98. The method of any one of claims 94-97, wherein the compound or the pharmaceutical composition is administered to the subject via parenteral administration, oral administration, or implantable administration.

99. The method of any one of claims 94-98, wherein the compound or the pharmaceutical composition is administered to the subject via subcutaneous administration or intravenous administration.

Images